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Osteosarcoma (OS) is the most common malignant bone tumor in children and 
adolescents. Although the survival for OS patients increased remarkably over the past decades 
due to novel surgical techniques and multi-agent neoadjuvant chemotherapy, patients with 
metastatic disease, however, remain to have a poor 5-year survival rate of approximately 30 
%. Unfortunately, the aggressive chemotherapeutic treatment of OS is associated with severe 
side effects and chemoresistance. Consequently, there is an urgent need for a better 
understanding of the mechanisms of OS progression for the development of novel more 
effective therapies that improve the survival and the quality of life of OS patients. The bone 
microenvironment was shown to have a crucial role in OS development and metastasis. 
Therefore, in this thesis, we studied, on one hand, the potential benefit of the inhibition of a 
key regulator of bone remodeling on OS progression and, on the other hand, a low toxic 
therapeutic approach using photodynamic therapy (PDT). 
Bone affecting tumors are supposed to elicit a `vicious cycle` of bone remodeling by 
stimulating the bone microenvironment to provide a fertile soil for tumor growth. Bone 
remodeling is normally strictly regulated, but in patients with cancer affecting the bone, these 
processes get out of balance and promote tumor progression. For tumors metastasizing to the 
bone, such as multiple myeloma, breast or prostate cancer, activin A has been identified as an 
important regulator of this vicious cycle. Activin A inhibition exhibited therapeutic potential 
by suppressing tumor-associated bone remodeling and disease progression in those cancers, 
however, the role of activin A in OS and its bone microenvironment remains to be unraveled.  
Therefore, the first aim of this thesis was to investigate the therapeutic potential of activin A 
inhibition in OS by using two different inhibitors (FST315∆HBS-hFC and ActRIIA-mFC). 
Effects of activin A and its inhibitors in combination with the gold-standard inhibitor of 
pathological bone remodeling, zoledronic acid, on OS progression, bone remodeling and 
metastatic burden were investigated here. The experimental systems included in vitro OS cell 
lines and osteoclasts and in vivo a highly metastatic intratibial OS mouse model. Although 
both activin A inhibitors showed no inhibitory effects on OS cell viability and migration in 
vitro, they effectively inhibited intratibial tumor growth and associated bone remodeling in 
vivo, via the uncoupling of osteoclastogenesis and the effects of key factors involved in 
osteoblast activity. In addition, the combination of activin A inhibitors with zoledronic acid 
further reduced OS progression and suggests a promising combinational therapeutic approach. 
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In the second aim we evaluated the OS suppressive efficacy of PDT in vitro and in vivo in 
intratibial metastasizing OS mouse models in immune-deficient and immune-competent mice. 
PDT is a locally applied, low-toxic therapy, reported to be effective in a variety of tumor 
types. One of the most potent photosensitizers, 10,15,20-tetrakis (meta-hydroxyphenyl) 
chlorine (mTHPC, Foscan), was used for this study, in addition with two novel mTHPC 
formulation; a liposomal formulation (Foslip) and lipid nanoparticles (LNP). In vitro results 
showed an efficient cellular uptake and effective photo-toxicity of all formulations in different 
OS cell lines. In view of these promising results, mTHPC uptake and PDT efficacy was 
determined in two highly metastatic orthotopic OS mouse models, using both 
immunocompromised and immunocompetent mice. In vivo measurements revealed a 
significantly higher uptake of the different mTHPC formulations by tumor than by healthy 
tissue, with a significant higher uptake of Foslip and of LNP than of Foscan. Upon these 
promising results, the treatment efficacy was determined for Foscan, Foslip and LNP in vivo. 
Foslip-based PDT was most effective in inhibiting OS tumor growth in immunocompromised 
mice, whereas the LNP-based PDT, unexpectedly, showed no treatment effect. In the 
immunocompetent OS mouse model, a more pronounced tumor- and lung metastasis-
suppressive effect than in immunocompromised mice was observed in response to PDT with 
both Foscan and Foslip. 
In conclusion, a more detailed understanding of the role of the bone microenvironment on OS 
progression, revealing novel treatment modalities with bone remodeling inhibitors such as 
activin A inhibitors and bisphosphonates, and the application of low toxicity PDT turned out 
to be promising strategies for the development of novel effective OS treatment modalities, 




Osteosarkome (OS) sind aggressive Knochentumore, welche vor allem bei Kindern 
und Jugendlichen auftreten. Die stetige Verbesserung der chirurgischen Techniken zur 
Entfernung des Primärtumors und die Optimierung neoadjuvanter Chemotherapie hat die 5-
Jahre Überlebensrate von Patienten mit einem lokal begrenzten Tumor stark erhöht. Im 
Unterschied dazu haben sich die Überlebenschancen von OS Patienten mit Metastasen in den 
letzten Jahrzehnten nicht verbessert und die 5-Jahre Überlebensrate liegt nach wie vor bei ca. 
30 %. Zudem werden bei der Osteosarkomtherapie leider oft auch schwerwiegende 
Nebenwirkungen und Therapieresistenzen beobachtet. Oberstes Ziel der OS Forschung ist es 
deshalb, neue Therapien zu entwickeln, die auch die Lebensqualität und die Lebenserwartung 
von Patienten mit metastasierendem OS wesentlich verbessern. Voraussetzung dafür ist ein 
wesentlich verbessertes Verständnis der molekularen, pathophysiologischen Mechanismen, 
die bei der Pathogenese und Metastasierung des OS von zentraler Bedeutung sind. 
Entsprechend wurde der Interaktion der Mikroumgebung mit dem Primärtumor im Knochen 
in letzter Zeit immer mehr Beachtung geschenkt. Zudem werden intensiv neue, möglichst 
tumorselektive Therapieansätze gesucht und entwickelt, um toxische Nebenwirkungen in 
gesundem Gewebe zu verhindern. In dieser Dissertation wurde daher die Wirkung der 
Hemmung eines wichtigen Faktors in der Regulation des tumorassoziierten Knochenumbaus 
auf das Osteosarcomwachstum in einem experimentellen intratibialen OS Mausmodell 
untersucht. In vergleichbaren Modellen in immundefekten und immunkompetenten Mäusen 
wurden zudem die Tumor- und Metastasierung-hemmenden Effekte einer lokalen, 
tumorselektiven Behandlung von intratibialen OS mittels photodynamischer Therapie (PDT) 
untersucht.  
In den letzten Jahren wurde nachgewiesen, dass in Krebsarten, die den Knochen 
befallen, die Interaktionen zwischen dem Tumor und der pathologisch umgebauten 
Knochenumgebung im sogenannten „Vicious Cycle“, wesentlich zur Entwicklung der 
Tumore beitragen. Der in gesundem Knochen strikt regulierte Knochenumbau gerät in 
Knochentumorpatienten in ein Ungleichgewicht zu Gunsten eines erhöhten Tumorwachstums. 
Bei Tumoren, die in den Knochen metastasieren, wie z.B. das multiple Myelom, oder bei 
Brust- und Prostatatumoren, wurde Activin A als zentraler Effektor im „Vicious Cycle“ 
identifiziert. Präklinische Studien haben gezeigt, dass die gezielte Hemmung von Activin A 
den tumorinduzierten Knochenabbau und das Fortschreiten der Tumorerkrankung 
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unterdrückt. Erstaunlicherweise sind die genauen Funktionen und das therapeutische Potential 
von Activin A beim OS noch weitgehend nicht untersucht. Daher war es das erste Ziel dieser 
Arbeit, das tumorhemmende Potential verschiedener Activin A-Inhibitoren (FST315∆HBS-
hFC und ActRIIA-mFC) zu untersuchen. Zusätzlich wurde die Wirkung einer Kombination 
von Activin A-Inhibitoren mit dem Bisphosphonat Zoledronsäure auf das Tumorwachstum 
und die Tumormetastasierung analysiert. Die Wirksamkeit der Activin A Inhibitoren und der 
Zoledronsäure wurde sowohl in vitro in OS- und Knochenzellen, als auch in vivo in einem 
intratibialen, Maus Osteosarkommodell erforscht. Obwohl in vitro kein direkter Effekt auf das 
Überleben und die Migrationsrate der Osteosarkomzellen beobachtet wurde, konnte in vivo 
das Wachstum des intratibialen Tumors und der damit assoziierte Knochenumbau effizient 
gehemmt werden. Zudem war die Kombination von Activin A-Inhibitoren und Zoledronsäure 
am wirksamsten. 
Im zweiten Projekt wurden die Tumor- und Metastasen-hemmende Wirkung der PDT 
in vitro und in intratibialen OS Modellen in immundefekten und immunkompetenten Mäusen 
untersucht. PDT erwies sich als effiziente Therapie in verschiedenen Arten von Tumoren, und 
sie hat den Vorteil einer lokalen Anwendung mit geringen, systemischen Nebeneffekten. 
Einer der aktuell potentesten Photosensitizer, 0,15,20-tetrakis (meta-hydroxyphenyl) chlorine 
(mTHPC, Foscan) wurde für diese Studie verwendet. Zusätzlich wurden zwei Träger für 
mTHPC getestet, eine liposomale Formulierung (Foslip) und lipid-Nanopartikel (LNP). Die in 
vitro-Resultate zeigten eine hohe Aufnahme und Phototoxizität aller mTHPC-Formulierungen 
in verschiedenen Osteosarkomzellen. Basierend auf diesen vielversprechenden Resultaten 
wurde die PDT-Wirksamkeit aller mTHPC-Formulierungen in den zwei stark 
metastasierenden, intratibialen OS Modellen in immundefekten und immunkompetenten 
Mäusen untersucht. Foscan und Foslip-basierende PDT zeigte eine signifikante Hemmung des 
Wachstums der intratibialen Primärtumoren, wobei unerwartet, die LNP-basierende PDT 
keinen therapeutischen Effekt zeigte. In den immunokompetenten Mäusen war der Tumor-
hemmende Effekt noch ausgeprägter als in immundefektien Mäusen und zudem wurde 
ebenfalls die Bildung von Lungenmetastasen gehemmt. 
Die Ergebnisse der in dieser Dissertation gemachten Untersuchungen können wie folgt 
zusammengefasst werden: die Hemmung der biologischen Effekte von ActivinA in der 
Osteosarkommikroumgebung mittels Activin A Inhibitoren und Bisphosphonaten sowie die 
Primärtumor-selektive lokale PDT mit zusätzlich Metastasen-hemmender Wirkung in 
immunkompetenten Mäusen erwiesen sich in den hier verwendeten klinisch relevanten OS 
Modellen als vielversprechende Strategien für eine wirksame Therapie des metastasierenden 
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ACE-011   activin receptor type II and human IgG fusion protein 
ActRIIA  activin receptor type II 
ALP    alkaline phosphatase23 
APR   acute phase response 
BMP   bone morphogenetic protein 
BP   bisphosphonate 
CatK   cathepsin K 
CXCR4  C-X-C chemokine receptor type 4 
DAMP   damage associated molecular patterns 
Fc   fragment crystallizable region 
FST    follistatin 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
∆HBS   heparin binding site deletion 
IgG   immunoglobulin G 
IL   interleukin 
I-Smad  inhibitory Smad  
i.t.    intratibial 
i.v.    intravenous 
LED   light emitting diodes 
LNP   lipid nanoparticles 
MAPK  ,itogen-activated protein kinases 
MH   mad homology 
m-CSF  macrophage colony-stimulating factor 
MDM2  mouse double minute 2 homolog (E2 ubiquitin-protein ligase) 
MM   multiple myeloma  
MMP   matrix metalloproteinase 
mTHPC   m-tetrahydroxyphenylchlorin 
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NES    nuclear export signals 
NIR   near infrared 
OS   osteosarcoma 
PBMC   peripheral blood mononuclear cells 
PBS   phosphate-buffered saline 
PDT    photodynamic therapy  
PS    photosensitizer 
PTHrP    parathyroid hormone-related protein 
RANKL  receptor activator nuclear factor κB ligand 
ROS    reactive oxygen species 
s.c.   subcutaneously 
SCID   severe combined immunodeficiency 
Smad     small mothers against decapentaplegic 
Smurf   smad-ubiquitination-regulatory factor 
TCI   tumor cell injection 
TGF   transforming growth factor 
TRAP   tartrate resistant acid phosphatase 
WHO     World Health Organisation 










 Epidemiology and clinical characteristics 4.1.1
Osteosarcoma (OS) is a high grade primary bone neoplasm and one of the deadliest 
cancers in children and young adolescents (Ward, DeSantis et al. 2014). OS accounts for 35 
% of all primary bone cancers, followed by chondrosarcoma (25%), Ewing Sarcoma (16%), 
Chordoma (8%) and undifferentiated pleomorphic sarcoma (5%). 
The overall incidence is 8 - 11 patients per 1`000`000 adolescents between 15-19 
years of age, and an overall incidence of 3 per 1`000`000 people per year. OS has a bimodal 
age distribution with a first peak in the second decade of life and a smaller peak between 60 
and 80 years of age (Hogendoorn, Athanasou et al. 2010; Ritter and Bielack 2010). Males are 
more frequently affected than females with a ratio of 1.43 to 1, with, however, earlier peaks in 
female than in male subjects (Geller and Gorlick 2010).  
Typical symptoms reported for OS patients are local pain and swelling in the affected 
region, lasting often for several months before diagnosis (Marina, Gebhardt et al. 2004). OS is 
commonly located in close proximity to the metaphyseal growth plates of long bones, most 
frequently in the femur (43 %), followed by the tibia (19 %), the humerus (10-11 % ) and it 
rarely occurs in the axial skeleton such as the skull, and pelvis (Longhi, Errani et al. 2006; 
Ottaviani and Jaffe 2009).  
Approximately 15-20 % of the OS patients have detectable metastases at the time of 
diagnosis, and 80 % present with microscopic metastases. The most common site for 
metastatic spread is the lungs followed by other bones.  
Characteristic bone lesions detected by radiography include osteoblastic, osteolytic 
and mixed lesions. Typical characteristics for OS are the so called `sunburst` pattern, showing 
radial ossification in the soft tissue around the bone or the `Codman triangle`, which shows 
periosteal new bone formation and lifting of the cortex and mostly the mixed osteolytic-















Figure 1 Radio graphical appearance of osteosarcoma. (A) Codman triangle showing the elevated periosteum (large white 
arrows). (B) Proximal femur, with radial (sunburst) with periosteal reaction. (C) Mixed osteoblastic (small black arrow) 
/osteolytic (long black arrows) osteosarcoma with a Codman triangle (large white arrows)adapted from (Miller 2008). 
 Types of Osteosarcoma  4.1.2
Form the cellular aspect, OS is thought to be of mesenchymal origin, but proof for pre-
osteoblasts as precursor cells is still missing (Klein and Siegal 2006). OS has a wide variety of 
histological appearances and, according to the world health organization (WHO), OS is 
classified into different subgroups. Conventional OS is the most common histological 
subtype; The tumor cells have a spindle or polyhedral shape and produce extracellular matrix 
(osseous, cartilaginous or fibrous), and according to the cellular predominance, three main 
subtypes are distinguished: osteoblastic, chondroblastic, and fibroblastic, which 
radiographically show extremely variable appearances with lytic, osteoblastic or mixed 
lesions. Telangiectatic OS is characterized by lytic destruction with large blood filled empty 
spaces and has similar histological features as an aneurysmal bone cyst. It is a rare subtype, 
accounting for less than 4% of all OS, with prognostic factors similar to conventional OS. 
Small cell OS only represents around 1.5 % of all OS, characterized by small cells with a 
round, hyperchromatic nuclei with low nuclear pleomorphism. Additional rare OS subtypes 
are low grade central (< 1%), parosteal and periosteal surface (~ 2 - 4 %) OS. Last, secondary 
OS arises in bones with preexistent aberrations such as radiation or Paget disease. High grade 
OS predominate, with a better 5-year survival rate in patients with extremity (68.2 %) 
compared to axial OS (27.3 %) (Klein and Siegal 2006; Fletcher C.D.M. Lyon 2002). 
4.1.2.1 Staging 
Different staging for sarcomas and carcinomas, first described by Enneking et al., is 
nowadays widely accepted (Wolf and Enneking 1996; Fletcher C.D.M. Lyon 2002). Staging 
depends on the histological grading, the primary tumor size and distant metastasis. However, 
A B C 
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because patients with metastasis fare so much worse than those without metastasis, it is not 
that widely used or useful.  
 Metastasis 4.1.3
Metastases remain the main cause of death in OS patients. A hallmark of malignant 
tumors, such as OS, is their ability to metastasize to other organs via a multi-step process. 
This process includes local invasion of the surrounding tissue, intravasation, survival in the 
circulation, transport to the target organ, extravasation into parenchyma, and colonization of 
the target organ (Chambers, Groom et al. 2002). Preceding this process is the preparation of 
the tumors to metastasize, including angiogenesis for sufficient nutrient supply and access to a 
transportation system for metastasizing tumor cells. Equally important is the preparation of a 
`pre-metastatic` niche in the target organ, which also defines the sites for metastatic spread, 
e.g. the lungs and other bones in OS. Stephen Paget published this theory in 1889 and called it 
the `seed and soil` hypothesis, a proposal that metastatic spread depends on a cross-talk 
between the cancer cells (seeds) and the specific organ microenvironment (soil) (Paget 1989). 
A few years later, James Ewing added also the anatomical architecture of the vascular system 
as an important determinant of organ-specific metastasis, explaining the metastatic spread into 
the lungs but not the high propensity for bone metastases (Ewing 1928). Although not yet 
well understood, also organ-specific metastatic traits in primary tumors play an important role 
in priming tumor cells to metastasize into specific organs. A study performed by Zhang, et. 
al., reported that the mesenchymal signals CXCL12 and IGF, within the primary tumor 
stroma, prime breast cancer cells for the bone metastatic microenvironment (Zhang, Jin et al. 
2013).  
Additionally, intrinsic features of cancer cells play an important role in the process of 
metastases formation. Several classes of genes involved in metastases initiation, progressions 
and virulence have been identified. Genes involved in the initiation of metastases regulate key 
processes such as the epithelial-mesenchymal transition (EMT), degradation of extracellular 
matrix, angiogenesis, intravasation (Nguyen, Bos et al. 2009; Valastyan and Weinberg 2011). 
For the progression of the metastasis, genes that promote survival during circulation, 
extravasation of the circulating tumor cell and proliferation in the new microenvironment, 
such as MMPs, angiopoietin-like 4 or COX2, are essential (Minn, Gupta et al. 2005). 
Virulence genes on the other hand, do not participate in the growth of the primary tumor, but 
are essential only at the metastatic site, such as interleukin 11 (IL11) and parathyroid 
hormone-related protein (PTHRP) facilitated bone metastasis (Mundy 2002). 
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Furthermore, cells within the tumor microenvironment, such as osteoclasts and 
macrophages, induce progression and metastasis development in OS. Cells in the tumor 
stroma can release growth factors and induce inflammation, angiogenesis and tissue 
remodeling, promoting metastatic spread (Endo-Munoz, Evdokiou et al. 2012). Receptor 
activator nuclear factor κB ligand (RANKL), an important regulatory factor in 
osteoclastogenesis, is expressed on a variety of cells in the bone microenvironment 
(osteoblasts, osteocytes, bone marrow stromal cells) and high RANKL expression in bone 
metastases was shown to correlate with poor survival of OS patients (Lee, Jung et al. 2011; 
Nakashima and Takayanagi 2011). The expression of RANKL is also associated with 
increased cell mobility and anchorage-independent growth, important processes in metastatic 
spread (Beristain, Narala et al. 2012). Denosumab, a human monoclonal RANKL antibody, is 
currently under investigation for the treatment of metastatic OS (Cathomas, Rothermundt et 
al. 2015). A vicious cycle between the primary tumor and the bone microenvironment is 
thought to drive OS progression, and is described in more detail in the next chapter 
(Lamoureux, Richard et al. 2007; Endo-Munoz, Evdokiou et al. 2012).  
All in all, the metastatic process in OS is complex and dependent on intrinsic 
characteristics of the tumor cells and on a complex interplay between the tumor, its 
microenvironment and the target tissue.  
 Etiology 4.1.4
Despite progress in OS treatment regimens, the etiology of OS remains largely 
obscure. Proven risk factors for the development of OS are the exposure to radiation, with a 
risk of 0.03 - 0.8 % in an irradiated bone, but only account for 2 % of all OS (Fletcher C.D.M. 
Lyon 2002). A number of inherited genetic predispositions are associated with a high risk for 
OS. These include: heritable germline mutations in the retinoblastoma gene (RB1), a tumor 
suppressor gene and negative regulator of cell cycle progression, lead to an up to 1000 times 
higher risk for OS than that observed in the normal population; the Li- Fraumeni syndrome, a 
rare autosomal dominant disorder caused by germline mutations of the tumor suppressor and 
guardian of the genome, TP53; autosomal recessive syndromes caused by a mutation in the 
RecQ DNA helicase family, which are essential for DNA repair and genomic stability. The 
Rothmund-Thompson syndrome is caused by a germline-line mutation in the helicase RecQ 
protein –like 4 (RECQL4) and up to 32 % of affected persons develop OS. Werner’s 
syndrome is caused by a mutation in the WRN helicase RECQL2 causing an abnormal 
telomere length and chromosomal alterations (~10 % of the affected persons develop OS). 
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Blooms syndrome is caused by mutation in the BLM DNA helicase causing striking genomic 
instability and OS in 2 % of the affected individuals (Fuchs and Pritchard 2002; Martin, 
Squire et al. 2012; Kansara, Teng et al. 2014). Also Paget`s disease, a bone disease 
characterized by disordered bone metabolism, causing an excessive bone remodeling; with 
abnormal osteoclast function can cause OS formation. The incidence is less than 1 % and 
occurs usually in individuals older than 50 years (Hansen, Seton et al. 2006). 
Chromosomal abnormalities and genomic instability are common in OS. 
Chromothripsis, a massive genomic rearrangement is shown in approximately a third of 
primary OS tumors, causing a considerable diversity of genetic alterations. Chromothripsis is 
particularly high in bone cancer (approx. 25%) compared to other cancers (2-3 %) (Stephens, 
Greenman et al. 2011). 
Somatic mutations of the RB1 gene and TP53 are detected in 35 % and 80 %, 
respectively, of examined OS tumors and also overexpression of oncogenes, such as the p53 
tumor suppressor negative regulator MDM2 or cyclin dependent kinase 4 (CDK4) are 
observed. In addition, alterations in the glutamate signaling, regulating normal bone 
physiology, and changes in the glutamate receptor metabotropic 4 (GRM4) expression have 
been attributed to OS tumorigenesis (Kansara, Teng et al. 2014). 
  Prognosis and Treatment 4.1.5
Complete surgical resection of the primary tumor is important, and advanced novel 
surgical techniques allows limb-salvage procedures in many patients (Bacci, Ferrari et al. 
2002). Despite the importance of surgery, before the introduction of chemotherapy, the 6-year 
survival rate was 11 % compared to 61% after the introduction of adjuvant chemotherapy 
(Link, Goorin et al. 1991). Current state-of-the art OS therapy includes therefore a multi-agent 
chemotherapeutic approach, including neoadjuvant (before surgery), surgery and adjuvant 
chemotherapy. This treatment yields cure rates of approx. 90 % for patients who are good-
responders to the neoadjuvant chemotherapy (> 90 % of necrosis), but patients with a poor 
histological response have a cure rate of 50 - 60 % (Isakoff, Bielack et al. 2015).  
Although rare, patients with pathological fractures at diagnosis show a lower 5- year 
survival (34%) than patients with no fractures (58%), thus fractures are apparently a sign for 
more aggressive tumors (Bramer, Abudu et al. 2007). 
Likewise the anatomical location is an important factor for the prognosis. Tumors in 
the distal femur, proximal tibia, humerus and the radius have a better prognosis. A worse 
prognosis have patients with OS in the pelvis, with 27 - 47 % 5 year-survival rate and those 
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with tumors in the spine with a medium survival rate of only 1- 2 years (Bielack, Kempf-
Bielack et al. 2002; Clark, Dass et al. 2008). The most reliable prognostic finding is the 
detection of metastatic spread at time of diagnosis, reducing long-term outcome to less than 
20 %. Lung metastases are the most frequent metastases followed by other bone metastases 
and skip metastases. Patients with bone metastases have a worse survival than those with lung 
metastases. Skip metastases are rare, but lead to a patients overall survival of only 27.2 
months from diagnosis (Clark, Dass et al. 2008).  
The most effective chemotherapeutic drugs used so far include doxorubicin, cisplatin 
and high-dose methotrexate (MAP). Treatment usually starts by the administration of the 
multi-agent chemotherapeutics for 10 weeks, followed by surgery and another 29 weeks of 
adjuvant chemotherapy. To improve current therapy, especially for patients with a poor 
histological response after neoadjuvant chemotherapy (<90% necrosis), effects of ifosfamide 
and etoposide were studied in the very recent international randomized EUROAMOS-1 study. 
Patients with a respectable tumor received the MAP regimen as a neo-adjuvant therapy. Poor 
responders received in addition post-operatively ifosfamide and etoposide, whereas good 
responders received MAP with or without interferon α. The molecular mechanism behind the 
different treatment regimens are shown in Table 1. Because OS is a rare disease, international 
collaboration is crucial and current published data from the EURAMOS study show the 
feasibility of such a collaboration and reports on the patient data, side effects and its 
successful execution. Unfortunately, the results did not support adding interferon to the 
standard treatment for OS patients, but treatment benefits for the addition of ifosfamide and 
etoposide for poor responders are still awaited (Whelan, Bielack et al. 2015). 
4.1.5.1 Treatment induced Side Effects and Chemoresistance 
Although standard OS therapy considerably increased patient survival, severe side 
effects are common and affect the quality of life over years. In addition to mild reported side 
effects such as skin rashes, emesis, alopecia, gastrointestinal problems, also severe toxicities 
with permanent damage are regularly reported and range from inflammation, neutropenia, 
cardiotoxicity, nephrotoxicity, neurotoxicity, infertility and even death (Table 1) (Janeway 
and Grier 2010; Whelan, Bielack et al. 2015). 
Drug Mechanism of action Side effect 
Doxorubicin 
DNA and RNA intercalating 
agents. 
Emesis, alopecia, myelosuppression, 
cardiotoxicity, infection of the bowel, 
chemotherapy-induced acral erythema 
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 Table 1 Chemotherapeutic drugs used in osteosarcoma treatment, their mechanism of action and side effects. 
OS patients are often under 20 years of age and effects on the development and long 
term adverse outcome of OS patients have to be carefully considered. Patients who were 
treated with multi-agent chemotherapy are nowadays in middle age, making it possible to 
assess the treatment-induced long term side effects. Subsequent primary neoplasms are 
reported to cause 34.7 % of all deaths in OS patients (Figure 2), showing a significant 
difference to the expected number of deaths in the general population at the age of 72 (Fidler, 
Frobisher et al. 2015). Reported second primary neoplasms were most frequently breast 
cancer, gliomas, leukemia, bladder and digestive cancer, leiomyosarcoma, fibrosarcoma. OS 
survivors are also reported to have more severe limitations in health status, especially physical 
function and pain than healthy persons (Aung, Gorlick et al. 2002; Klein, Michaelis et al. 





Figure 2: Recurrence and second primary neoplasms in osteosarcoma survivors (adapted from Fidler, Frobisher et al. 2015). 
Chemoresistance is also one of the major reasons of failure in OS therapy. Up to 35 - 
45% of patients become nonresponsive to chemotherapeutic agents during treatment (Luetke, 
Meyers et al. 2014). The molecular mechanism inducing chemoresistance are not yet 
completely known. Mechanisms that play a role include decreased intracellular drug 
Cisplatin 
Binding to DNA, causing 
crosslinking of DNA strands 
Nephrotoxicity, ototoxicity, emesis, 
myelosuppression, hemolytic anemia, 
infertility 
Methotrexate 
Antimetabolite, inhibits synthesis of 
purine and thymidine by inhibiting 






Binding to DNA, causing 
crosslinking of DNA strands 
Emesis, hemorrhagic cystitis, 
nephrotoxicity, neurotoxicity 
Etoposide Topoisomerase inhibitor 
Hypotension, emesis, skin reactions, 




accumulation (e.g. upregulation of efflux pump P-glycoprotein), drug inactivation (e.g. 
overexpression of glutathione S-transferase P1), enhanced DNA repair (e.g. overexpression of 
apurinic endonuclease 1, excision repair, cross-complementing proteins), changes in cell cycle 
related gene expression (e.g. downregulation of Rb and p53, overexpression of CDK4), 
inhibition of apoptosis (e.g. upregulation of anti-apoptotic proteins e.g. Bcl-2, downregulation 
of pro-apoptotic protein e.g. Bax, Bak, Bad), and abnormal regulation of signaling 
transduction pathways (e.g. activation of MAPK, PI3K) (He, Ni et al. 2014).  
Despite the aggressive treatment regimens, survival rates of OS patients have 
plateaued or remain still very low in patients with recurrent and metastatic disease. Numerous 




4.2 The Vicious cycle of Bone Remodeling in Osteosarcoma and the 
Role of Activin 
Bone is a dynamic tissue, which is constantly remodeled and tightly controlled to 
maintain its structural integrity. The bone microenvironment plays an important role in 
primary bone tumors such as OS, chondrosarcoma or Ewing’s sarcoma (David, Blanchard et 
al. 2011; Alfranca, Martinez-Cruzado et al. 2015; Redini and Heymann 2015). The bone is 
also the most common organ affected by metastatic spread of many other tumor types with 
prostate, breast, and lung cancer having the highest prevalence for metastatic spread to the 
bone (Li, Peng et al. 2012). Primary bone tumors and bone metastases are both associated 
with a high morbidity (Coleman 2006) . 
Tumor cells and bone interact with each other in a `vicious cycle`, causing 
pathological tumor-driven bone remodeling (Figure 3). Tumors are reported to produce a 
variety of factors such as PTHrP, IL-1, IL-6, IL-8, IL-11, TGFβ that stimulate pathological 
bone remodeling through interaction with osteoblasts and osteoclasts (Guise 2002; Akiyama, 
Dass et al. 2008). Osteoclasts play an important pro-tumorigenic role in cancer metastasizing 
to the bone, by generating skeletal lesions. Upon the resorption of the bone, the tumor gains 
access to these stored growth factors, calcium and phosphate within the bone, which promote 
the growth of tumor cells (Hauschka, Mavrakos et al. 1986; Mundy 2002; Yoneda and Hiraga 
2005). 
A recent study performed by Garimella R. et al., described the bone microenvironment 
as a central part in OS-associated bone remodeling. Extracellular membrane vesicles from OS 
cells were shown to be mediators of communication between the tumor cells and the bone. 
These extracellular membrane vesicles contain osteoclastogenic cargo, inducing a 
dysregulated bone remodeling in OS (Garimella, Washington et al. 2014). Another study by 
Avent S. et al., pointed out the interdependence of OS lesions and the bone by demonstrating 
that osteoclast activity is associated with the aggressiveness of the tumor (Avnet, Longhi et al. 
2008). Therefore the finding of novel agents blocking the vicious cycle is an attracting field of 




Figure 3: The vicious cycle of tumor and bone interaction (apapted from Ferrari S, Webinar: Mechanisms of Bone 
Remodeling as Therapeutic Targets, BoneKey Webinar, 14 April 2012) 
 The Balance of Bone Remodeling  4.2.1
Bone remodeling is regulated by the activity of specialized cells; osteoblasts, the bone 
forming cells that produce the bone matrix and induce its mineralization, and the bone-
resorbing osteoclasts, which resorb bone and degrade its extracellular matrix. Osteocytes, a 
third type of bone cells, derived from osteoblast, are embedded in the bone matrix and 
regulate mineralization (Bonewald 2011) and bone lining cells coordinate remodeling 
processes (Everts, Delaisse et al. 2002).  
Osteoclasts are huge multinucleated cells from mononuclear precursors of the 
hematopoietic lineage. Osteoclastogenesis is dependent on the hematopoietic factors, such as 
the receptor activator of nuclear factor kappa-B ligand (RANKL) and the colony-stimulating 
factor (m-CSF). RANKL and m-CSF induce signaling regulating genes important for 
osteoclastogenesis that mediate activation of the precursor cells and cell fusion. Functional 
osteoclasts polarize, and form a resorption pit (Howship`s lacunae), a sealed compartment 
between the cell membrane and the bone surface RANKL and m-CSF also stimulate the 
expression of e.g. cathepsin K (CatK) and tartrate resistant acid phosphatase (TRAP). CatK 
and TRAP are enzymes secreted into the resorption pit that acidify the resorption area for 
resorption of the underlying bone (reviewed in (Boyle, Simonet et al. 2003)).  
Osteoblast are cells of mesenchymal origin that promote hydroxyapatite crystal 
formation and delivery to the bone surface via membrane matrix vesicles forming new bone 
(osteoid) (Anderson 1995). Osteoblastogenesis is tightly regulated by transcription factors, 
including runt-related transcription factor 2 (Runx2) and distal-less homeobox 5 (DLX5), 
which induce the production of the key enzyme alkaline phosphatase (ALP) and the secretion 
of collagen І. The exact function of ALP is not known, but it’s assumed that ALP removes 
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pyrophosphate, an inhibitor of hydroxyapatite crystallization, from the bone 
microenvironment, (Hessle, Johnson et al. 2002). Osteoblast differentiation is also regulated 
by bone morphogenetic protein (BMP), another member of the TGFβ family, which controls 
local bone formation tightly coupled to bone resorption (Cao and Chen 2005) 
Osteoblasts and osteoclasts communicate via different mechanism. Both cell types can 
secrete paracrine factors but also make direct contact allowing membrane ligands and 
receptors to interact with each other or form gap junctions to allow interaction between the 
two cell types. As an example, osteoblasts express RANKL on their surface, which interacts 
with its receptor RANK on osteoclast, and thereby induce osteoclastogenesis (Karsenty, 
Kronenberg et al. 2009). Likewise the release of growth factors by osteoclast-mediated bone 
matrix resorption is important for the activation of osteoblastic bone formation (reviewed in 
(Matsuo and Irie 2008)). Other factors affecting bone remodeling include physical activity 
triggering mechanical signals, hormones (calcitonin, PTH, vitamin D3 (1,25 Vit D3) and 
oestrogen) and, as outlined above, tumor-driven processes. 
Altogether, bone remodeling is regulated on many levels and a more detailed 
description is beyond the scope for this introduction. 
 Therapeutics targeting Tumor-Associated Bone Remodeling  4.2.2
Standard therapeutics for the inhibition of excessive bone remodeling are bisphosphonates 
(BP). BP have structural similarities to pyrophosphate enabling them to accumulate in the 
bone by binding to hydroxyapatite. There are two types of BP, the non-nitrogen and nitrogen 
containing BP, with the nitrogen-containing compounds having a higher bone resorption 
inhibiting potency than the non-nitrogen containing BP. Third-generation BP such as 
zoledronic acid or risedronate have additionally two heterocyclic nitrogen ring as a side chain, 
which increases their affinity for bone compared to the other BP (De Rosa, Misso et al. 2013). 
Third-generation BP`s promote osteoclast apoptosis by inhibiting farnesyl pyrophosphate 
synthase, a key enzyme in the mevalonate pathway, which is important for protein prenylation 
and the production of isoprenoids (e.g. cholesterol, vitamin K) (Luckman, Hughes et al. 
1998). Central for osteoclast activity is the process of membrane polarization via vesicular 
trafficking, regulated by small GTPase, like Rho, Rab, Rac. These proteins require post-
translational isoprenylation by the mevalonate pathway to induce stress fiber assembly, 
membrane ruffling and osteoclast survival (Coxon and Taylor 2008). Thus, third generation 
BP inhibit these processes.  
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BP are most commonly used to treat osteoporosis (Black, Delmas et al. 2007; Drake, Clarke 
et al. 2008), but BP do not only induce osteoclast apoptosis, they also revealed anti-tumor 
efficacy via different mechanisms (Figure 4). Zoledronic acid was shown to reduce bone pain 
and skeletal related events in breast cancer, prostate cancer and multiple myeloma (MM) 
patients (Berenson, Rosen et al. 2001; Rosen, Gordon et al. 2004; Saad, Gleason et al. 2004). 
Numerous preclinical studies in animal models including MM, breast cancer and prostate 
cancer demonstrate tumor-suppressing effects of ZOL (Green 2004).  
The efficacy of BP in breast cancer patients to reduce tumor burden is still under 
discussion. The ZO-FAST study, in which postmenopausal woman with early breast cancer 
received letrozole and zoledronic acid, revealed a reduced risk for local and distant 
recurrences (-34%) in patients treated from the beginning of the study with zoledronic acid 
compared to patients obtaining the treatment only upon the appearance of clinical symptoms 
(Coleman, de Boer et al. 2013). On the other side, a study in early-stage breast cancer patients 
didn’t support the use of ZOL in adjuvant therapy (Coleman, Marshall et al. 2011). A clinical 
trial in multiple myeloma patients (MM) reported improved progression-free survival and 
overall survival in patients undergoing high-dose chemotherapy and stem-cell transplantation 
together with ZOL treatment of MM (Aviles, Neri et al. 2013). 
In addition to its ability to inhibit tumor-associated bone resorption, ZOL showed 
direct effects on SaOS-2 OS cell viability, invasion and differentiation (Dass and Choong 
2007). ZOL is also reported to induce cell cycle arrest in POS-1 OS cells (Ory, Heymann et 
al. 2005), and a study with the OS cell lines HOS, MG-63, SAOS-2, and U2OS showed 
significant cytotoxicity mediated by the blocking of DNA synthesis and by provoking cell 
cycle arrest, microfilament breakdown and apoptosis (Kubista, Trieb et al. 2006). Preclinical 
studies in OS mouse models reported an inhibition of tumor growth, metastatic spread and 
prolonged overall survival (Ory, Heymann et al. 2005; Dass and Choong 2007). As mentioned 
above, chemoresistance in OS treatment is p53, Rb and caspase dependent; cytotoxic ZOL 
effects were shown to be independent of these key genes in several OS cell lines (Ory, 
Blanchard et al. 2007). 
ZOL is commonly well tolerated with mild adverse effects; only rarely, severe side 
effects such as osteonecrosis of the jaw, pathologic fractures mainly in the proximal femur, 
and an increased incidence of atrial fibrillation are reported (Berenson, Rosen et al. 2001; 




Figure 4: Mechanism of action of zoledronic acid on osteoclasts and OS tumor growth 
 
The demonstration of anti-tumor efficacy by bone remodeling inhibiting agents 
opened up a novel direction in the pursuit of therapies against OS. A rather novel agent 
investigated in the context of bone remodeling is activin A, a member of the TGFβ 
superfamily, influencing osteoclastogenesis, osteoblastogenesis and tumorigenesis. 
 Activin A and its Role in Bone Remodeling 4.2.3
Activin is the most abundant member of the TGFβ superfamily in the bone and it is 
secreted by different types of cells in the bone microenvironment, such as bone marrow 
stromal cells, osteoblast and osteoclasts (Ogawa, Schmidt et al. 1992; Vallet, Mukherjee et al. 
2010). Bone tissue contains high levels of activin A (Eijken, Swagemakers et al. 2007). 
Activin A knockout mice die within 24 hours due to craniofacial defects, indicating its 
important role in the bone remodeling (Matzuk, Kumar et al. 1995). Activin A is a known 
inducer of osteoclastogenesis. In vitro studies revealed an enhanced osteoclast formation in 
bone marrow cell cultures incubated with activin A, without any effect on osteoclast 
activation (Sakai, Eto et al. 1993). Later on, activin A was discovered as an essential co-factor 
for RANKL in osteoclast differentiation, increasing the induction of osteoclast-like cells from 
precursor cells (Fuller, Bayley et al. 2000).  
The role of activin A in bone formation is more controversial. Matrix mineralization in 
human osteoblast cultures was shown to be inhibited by activin A, by changing matrix 
composition to reduced mineralizing capacity (Eijken, Swagemakers et al. 2007). Another 
study confirmed the inhibitory effects of activin A on osteoblast-mediated mineralization by 
decreasing ALP activity (Alves, Eijken et al. 2013). Mice overexpressing inhibin A (an 
activin A inhibitor) showed increased bone formation (Perrien, Akel et al. 2007). In contrast 
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several studies state stimulatory effects of activin A on osteoblast differentiation and bone 
mineralization. Osteoblast differentiation is enhanced by activin A in bone marrow cultures 
(Gaddy-Kurten, Coker et al. 2002) and local administration of activin in bone induced bone 
formation and fracture healing (Sakai, Miwa et al. 1999). 
These different observations might in the end just reflect the complexity of activin A 
signaling and species-dependent differences.  
 Activin A and its Role in the Vicious Cycle 4.2.4
In recent years the focus in cancer research was on TGFβ and its involvement in 
tumorigenesis. TGFβ was shown to have important tumor suppressive characteristics, but it 
was also shown to induce tumor formation and progression (Massague 2008). Although 
activin A and TGFβ show structural similarity and share some downstream signaling 
mechanisms, there are distinct differences in their function (Loomans and Andl 2014). 
Activin A is involved in the regulation of tissue repair (Antsiferova and Werner 2012) and 
inflammation (Werner and Alzheimer 2006), processes closely related to cancer (Schafer and 
Werner 2008; Trinchieri 2012), implying a role of activin A in cancer. Activin A, like TGFβ, 
has also a dual role in cancer biology. Different studies over the last years revealed a tumor 
inhibiting function of activin A in a variety of tumours. Activin is shown to have growth 
inhibitory effects e.g. on liver, prostate and pancreatic cancer cells (Risbridger, Schmitt et al. 
2001; Antsiferova and Werner 2012). In contrast, Activin A has also been shown to have 
direct effects on tumor cells, inducing tumorigenesis. 
Different researchers in recent years described activin A as an important regulator in 
the `vicious cycle` of tumor and bone microenvironment interaction. Activin A is involved in 
the growth and progression of tumors metastasizing into the bone, such as breast cancer, lung 
cancer, prostate cancer and MM. Activin A enhances prostate cancer cell migration and it is 
overexpressed in metastatic prostate cancer (Kang, Huang et al. 2009). In breast cancer, 
activin A signaling induces epithelial-mesenchymal transition, invasion and metastatic growth 
(Bashir, Damineni et al. 2015). In a MM mouse model, activin A inhibition exerts anti-tumor 
effects by inhibition of tumor-associated bone remodeling (Vallet, Mukherjee et al. 2010). 
The overexpression of the activin A inhibitor Follistatin (FST) reduces tumor progression in 
small cell lung cancer by inhibiting angiogenesis (Ogino, Yano et al. 2008). 
Several studies in patients relate activin A to cancer progression. Circulating levels of 
activin A were shown to correlate with advanced stage disease, inferior survival and increased 
bone involvement in patients with advanced MM (Terpos, Kastritis et al. 2012). Patients with 
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breast or prostate cancers showed increased activin A serum concentration. Activin A levels 
were also higher in patients with bone metastases and correlated with the Gleason score in 
prostate cancer patients. (Leto, Incorvaia et al. 2006) 
These findings implicate the importance of activin A in the pathogenesis of bone 
cancers and make it an interesting target for OS research.   
 Activin A and its Signaling 4.2.5
Activin A is a glycoprotein and a member of the TGF beta superfamily, characterized 
by six conserved cysteine residues (Lander, Linton et al. 2001). First discovered in 1980, it 
was purified from gonadal fluids and shown to stimulate the follicle stimulating hormone 
(FSH) release from the pituitary gonadotropes (Vale, Rivier et al. 1986). Its more detailed 
characterization lead to the discovery of diverse regulatory functions, including cell 
proliferation and differentiation, wound repair, inflammation, glucose metabolism and 
immune response (Yu, Shao et al. 1987; Florio, Luisi et al. 2000; Werner and Alzheimer 
2006; Kreidl, Ozturk et al. 2009; Xia and Schneyer 2009). 
Members of the TGF beta superfamily include additionally activins, inhibins, TGFβ, 
bone morphogenetic proteins (BMPs), growth and differentiation factor (GDF), Nodal, 
myostatin and others. Activins are dimers of two β subunits linked with a single covalent 
disulfide bond. Four different genes INHBA, INHBB, INHBC, INHBE code for different 
hetero- and homodimers such as activin A, activin AB, activin B, activin C, activin AC, 
activin AE, activin CE, and activin BC, where only the first 3 are characterized in their 
function (Burger and Igarashi 1988; Mason, Berkemeier et al. 1989; Massague 1998).   
Activin A is made of to two βA subunits (each around 13kDa) giving rise to a 26 kDa 
dimeric protein. The βA subunit is produced from a precursor molecule with 425 amino acids. 
The pro-βA domain is separated from the mature βA subunit via a polyarginine cleavage site, 
giving rise to a 116 amino acid protein. The pro-βA domain is important for activin folding, 
dimerization and secretion (Gray and Mason 1990). The monomers are linked via a disulfide 
bridge between two highly conserved cysteine residues located in the C-terminus of the tow 
monomers, known as the cysteine knot (Sun and Davies 1995; Makanji, Zhu et al. 2014). 
Crystallization of activin A alone was not yet achieved. Recent activin structural studies 
revealed highly flexible conformations, depending on the binding partner of activin. The 
structure of Activin A contains β-sheets forming a finger domain and an α-helical wrist 
domain (Thompson, Lerch et al. 2005; Harrington, Morris-Triggs et al. 2006).  
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There are twelve members of TGFβ receptors in humans, seven type 1 (also called 
ALKs) and five type 2 receptors and all of them have serine/threonine kinase activity in the 
cytoplasm (Manning, Whyte et al. 2002). Similar to other TGFβ superfamily members, 
activin A signals via two types of transmembrane receptors, activin receptor type 1 and 2 with 
serine/threonine kinase activity. Activin A receptors have a short extracellular domain, a 
single transmembrane region and a large intracellular domain with N-glycosylation sites and 
the serine/threonine kinase domain. Type 2 receptors ActRІІA and ActRІІB are constitutively 
active kinases and act as the primary activin binding receptors. 
Crystal structure analyses with binding partners revealed that activin A differs from 
other TGFβ ligand structures and has a compact folded-back conformation. It binds to its 
receptors with the outer finger region (Thompson, Woodruff et al. 2003). Upon ligand 
binding, activin receptor type 1 (ALK4) heterodimerizes with type 2 receptors. Type 2 
receptors then phosphorylate type 1 receptors in their juxtamembrane glycine- and serine-rich 
(GS)-domain. Type 1 receptors contain a conserved GS domain, shown to be important for 
signal transduction (Franzen, Heldin et al. 1995) and additionally a nine-amino acid sequence, 
called the L45 loop, shown to be a critical regulator of interactions with Smad isoforms 
(Persson, Izumi et al. 1998). Phosphorylation of the GS domain of the type 1 receptor by the 
type 2 receptor in type 1/activin A/type 2 receptor heterodimers activates the kinase domain in 
the type 1 receptor, which then activates intracellular signaling through the phosphorylation of 
intracellular mediators, known as the Smad proteins (reviewed in (Abe, Minegishi et al. 2004; 
Weiss and Attisano 2013)). 
4.2.5.1 Smad-dependent Signaling 
Smad proteins are transcription factors classified into three groups; receptor regulated Smads 
(R-Smads, Smad1, 2, 3, 5, 8), common mediator Smads (co-Smads, Smad4) and inhibitory 
Smads (I-Smads, Smad6, 7) (reviewed in (Shi and Massague 2003; Abe, Minegishi et al. 
2004)). Smad2 and Smad3 are mainly activated by activins and TGFβ, whereas Smad1, 
Smad5 and Smad8 are activated by BMPs. R-Smads and Co-Smads have similar structural 
domains, the conserved N-terminal Mad homology 1 (MH1) domain and the C-terminal MH2 
domain. The interaction of the L3 MH2 domain of the Smad2/3 proteins with the L45 loop 
within the kinase domain of the Activin type 1 receptor regulate binding specificity. Smad6 
and -7 contain MH2 domains, but lack many other homologies with R-Smad and Co-Smad. 
(Abe, Minegishi et al. 2004) 
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Type 1 receptors activate R-Smad (e.g. Smad 2 and Smad 3) by phosphorylation of 
distal serines (SSXS motif) in the C-terminal domain. Co-Smads contain also a conserved 
MH2 domain but miss the SSXS motif. Upon their activation, R-Smad form a heterodimeric 
complex with Smad 4, via their L3 loop region, and the heterodimers are then translocated 
into the nucleus. In the inactive state Smads are constantly shuttling between the nucleus and 
the cytoplasm. R-Smads are localized mostly in the cytoplasm while Smad4 can be found in 
the cytoplasm and the nucleus. R-Smad/Smad4 complexes need a nuclear import and export 
system, which is regulated by importins (into the nucleus), exportins (out of the nucleus), and 
nucleoporins (part of the nuclear pore complex) (Fornerod, Ohno et al. 1997; Hill 2009). 
Smads contain in their MH1 domain a conserved nuclear localization sequence (NLS). Smad1 
and Smad3 were shown to use the NLS sequence for the classical importin pathway (Chai, 
Wu et al. 2003). Smad2, on the other hand, has intrinsic shuttling activity in its MH2 domain, 
binding directly to the nuclear pore complex (Xu, Kang et al. 2002). Nuclear export is guided 
be nuclear export signals (NES), which are localized in the MH2 domain of the R-Smads or 
the linker domain of Co-Smads (Smad4) (Hill 2009). 
In the nucleus, activated Smads bind to consensus DNA sequences and other binding 
partners to activate transcription. The Smads (despite Smad2) have a DNA binding sequence 
in their MH1 domain which binds to the Smad binding element (SBE) (Zawel, Dai et al. 
1998). However, the affinity of the Smads for their SBE is weak and co-factors are therefore 
needed to increase the DNA binding affinity (Schmierer and Hill 2007). 
The R-Smad/Smad4 complex interacts with sequence specific transcription factors that 
bind to their cognate DNA sequences and thereby induce transcription of numerous target 
genes (Massague, Seoane et al. 2005). 
4.2.5.2 Smad independent Signaling 
Although activin A signaling is mainly mediated by Smad-dependent signaling, non-
Smad dependent pathways are also activated that amplify the biological effects of the TGFβ 
superfamily. 
Activin A ligand binding was shown to activate the p38-mitogen-activated protein 
kinase (p38MAPK), ERK and JNK pathways, which regulate cell proliferation, migration and 
differentiation (Cocolakis, Lemay et al. 2001; Bao, Tsuchida et al. 2005; Vallet, Mukherjee et 
al. 2010). Activation and abnormalities in the signaling by the MAPK pathway play important 
roles in the development and progression of cancer. In OS, MAPK signaling induces cell 
proliferation, invasion, metastases in preclinical OS models, and inhibitors for different MAP 
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kinases demonstrated clinical benefit in OS patients (Sasaki, Hitora et al. 2011; 
Chandhanayingyong, Kim et al. 2012). 
Another non-canonical pathway activates phosphatidylinositol-3-kinase (PI3K), which 
acts via the phosphorylation of Akt. (Zhang 2009). Phosphorylated Akt acts on mammalian 
target of rapamycin (mTOR), which regulates protein synthesis via phosphorylation of S6 
kinase. The PI3K/Akt signaling is involved in OS tumorigenesis by increasing proliferation 
and invasion (Zhang, Yu et al. 2015). 
 Regulation of Activin Signaling 4.2.6
Activin A signaling is regulated at different levels; on the nuclear, cytoplasmic, membrane 
and extracellular level (Figure 5). Its regulation is a dynamic process, broadening the field of 
action for activin A.  
 
Figure 5: Activin A signaling pathway (adapted from Hedger M.P. Vitam Horm. 2011;85:255-97. doi: 10.1016/B978-0-12-
385961-7.00013-5. (Hedger, Winnall et al. 2011)) 
4.2.6.1 Follistatin 
Follistatin (FST) is a soluble extracellular glycoprotein expressed in a wide range of 
tissues, including the bone microenvironment. FST binds activin with high affinity and with 
lower affinity it binds to myostatin, inhibin and BMPs (Welt, Sidis et al. 2002; Uhlen, 
Fagerberg et al. 2015). 
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FST was first isolated form follicular fluid, shown to inhibit FSH secretion. Located 
on chromosome 5, the FST gene consists of 6 exons, which, upon alternative splicing, form 
transcripts encoding the three FST isoforms, FST288, FST315 and a gonadal isoform 
FST303. FST is made up of five domains, an N-terminal domain, three FST modules (FS1, 
FS2, FS3) and an FST-isoform dependent C-terminal domain. Two FST molecules bind one 
activin molecule, building a ternary complex that shield both type1 and type2 receptor 
binding sites and thereby block receptor binding (Thompson, Lerch et al. 2005). The N-
terminal domain and FS domains of FST is associated with the binding to the wrist region of 
activin (Harrington, Morris-Triggs et al. 2006). Both FST288 and FST315 were shown to 
have almost identical activin A binding affinities, whereas the C-terminal truncated form 
FST288 shows much higher affinity for heparin sulfate proteoglycans (Sugino, Kurosawa et 
al. 1993). FST315 is thought to be the predominant circulating isoform, whereas the FST288 
is bound to cell surface proteins. The binding site for heparin sulfate is located in both 
isoforms in the FS1 domain (Gajos-Michniewicz, Piastowska et al. 2010). FST288/activin A 
complexes are taken up by cells with the help of cell surface glycoproteins and are degraded 
by lysosomes. FST315 gains glycoprotein binding affinities after activin A binding, thereby 
promoting activing A degradation (Lerch, Shimasaki et al. 2007). FST knockout mice die 
during embryonic development, due to growth retardation, musculoskeletal defects, failure of 
breathing (Lin, Craythorn et al. 2008).  
Follistatin-related protein (FSTL/FSRP) is a homolog of Follistatin, encoded by the 
FLRG gene: FLRG is an additional regulator of activin with a lower affinity for activin and 
BMPs than for Follistatin. FLRG possesses only two FST domains, but shares a conserved 
key residue (R192) with FST, important for activin binding (Tortoriello, Sidis et al. 2001). 
4.2.6.2 Additional Regulatory Mechanisms of Activin A Signaling  
As outlined above, activin A signaling is regulated on different levels, ranging from 
intracellular, membranous and extracellular regulatory mechanisms. 
Like activin, inhibins are dimeric proteins belonging to the TGFβ superfamily. They 
consist of βA or βB subunit and a inhibinα subunit linked by a disulfide bond (Risbridger, 
Schmitt et al. 2001). Inhibin antagonizes activin signaling via the availability of α-subunits  
which preferentially assembly of αβ heterodimers (inhibins) over ββ dimers (activins) and by 
competition with activin type І receptor binding. Type ІІІ receptor (Betaglycan), a co-receptor 
and a known binding partner of inhibin, potentiates its binding activity to activin receptors 
(Makanji, Zhu et al. 2014).  
28 
 
Other regulators of activin signaling are the membrane bound BMP and activin 
receptor membrane bound inhibitor (BAMBI) and Cripto (glycosylphosphatidylinositol 
membrane-anchored receptor) (Figure 5). BAMBI is transmembrane glycoprotein with 
sequence similarities to activin A type I receptors, but without a functional intracellular kinase 
domain (Onichtchouk, Chen et al. 1999), while Cripto forms a complex with activin type ІІ 
receptors, that blocks activin signaling (Gray, Harrison et al. 2003). 
Intracellular regulators are Smad anchor for receptor activation (SARA) binding to 
Smad2 and Smad3 proteins. The resulting complex facilitates their recruitment to activin 
receptor type І, and thereby activates activin A signaling. Activin receptor activity is 
furthermore regulated intracellularly by I-Smads, such as Smad7 and Smad6 (Smad 6 is 
favorably involved in BMP signaling). Ubiquitin guided proteasome degradation also controls 
activin receptor and R-Smad levels in the cytoplasm and the nucleus via the E3 ubiquitin 
ligases called Smurf proteins (Zhang, Chang et al. 2001; Murakami, Watabe et al. 2003).  
 Activin in Osteosarcoma 4.2.7
Surprisingly, research unravelling activin A inhibition in OS is still in its very infancy. 
20 years ago, a follistatin-like protein with activin binding activity, called mac25, was shown 
to suppress growth of OS cells via cell cycle arrest (Kato, Sato et al. 1996; Kato 2000). A few 
years later, Matsuyama et al. reported that the inhibitor SB-431542 of the activin type І 
receptor (ALK4) suppressed proliferation of the OS cell line MG63 (Matsuyama, Iwadate et 
al. 2003). A recent study investigated the effect of knock-down and overexpression of activin 
A in MG63 cells. Activin A overexpression activated and activing A depletion suppressed 
proliferation, invasion and migration (Zhu, Liu et al. 2015).  
For tumors metastasizing to the bone, a tumorigenic role of activin A in bone 
metastasis was described (Chapter 4.2.4). In vitro data and preclinical studies revealed activin 
A as a crucial regulator of the `vicious cycle` between tumor growth and associated 
pathological bone remodeling in the tumor microenvironment. Activin A inhibition exhibited 
therapeutic potential by suppressing tumor-associated bone remodeling and disease 
progression in tumors metastasizing to the bone. The common ground of primary bone 
tumors, such as OS, and tumors metastasizing to the bone, is their bone microenvironment, 
the disruption of the bone homeostasis and the associated tumor growth. Preliminary results 
of the above mentioned in vitro studies in OS strengthen the involvement of activin A in 
osteosarcomagenesis. Therefore, the role of activin A and a potential therapeutic benefit of 
targeting activing A in OS needs to be further investigated.   
29 
 
 Activin A Inhibition as a Therapeutic Approach 4.2.8
Based on the novel knowledge on the biological role of activin A and its function in 
bone remodeling, tumor development and progression, blocking its signaling with antagonists 
has great potential for the development of new strategies for the treatment of OS, even more 
so since existing inhibitors of activin A revealed promising therapeutic effects in other 
cancers affecting the bone. 
There are several clinical studies investigating ACE-011 for the treatment of different 
types of cancers. ACE-011 (Sotatercept, Acceleron Pharma Inc, Cambridge USA, Celgeme 
Corporation, Summit USA) is a soluble activin receptor type ІІA IgG-Fc fusion protein (A 
murine analogue is called RAP-011) (Ruckle, Jacobs et al. 2009). A completed phase ІІA 
study examined safety, tolerability and efficacy of ACE-011 in osteolytic lesions of multiple 
myeloma (ClinicalTrials.gov Identifier: NCT00747123). Results displayed higher bone 
mineral density, increase in bone formation as well as anti-tumor efficacy in treated patients. 
ACE-011 displayed high tolerability and safety (Abdulkadyrov, Salogub et al. 2014). 
Currently two additional clinical studies are ongoing in multiple myeloma patients. The first 
phase ІІA study investigates its effect on bone mass and turnover (ClinicalTrials.gov 
Identifier: NCT02230917). The second phase І study examines the combination of 
lenalidomide, dexamethasone with ACE 011 with the purpose to reduce or prevent the growth 
of cancer cells along with improving anemia and bone lesions (ClinicalTrials.gov Identifier: 
NCT01562405). 
Due to the tight regulation of the activin signaling, different approaches are promising 




4.3 Photodynamic Therapy, an Introduction 
Photodynamic therapy (PDT) and its medical application dates back to ancient times 
in Egypt, Greece and India, where plant extracts were applied on the skin that, upon exposure 
to the sun, caused skin reactions and changes of pigmentation (Castano, Demidova et al. 
2005). PDT became in the last decades a new treatment option for a variety of neoplastic 
diseases. It involves the uptake of a so called photosensitizer (PS) in a tissue, followed by 
illumination, of the area of interest with laser light of a specific wavelength. Upon 
illumination the PS, in the presence of oxygen, generates cytotoxic reactive oxygen species 
(ROS) in the tissue. PDT is an attractive treatment modality, since neither the PS, light and 
oxygen are toxic on their own; only in combination they elicit toxicity. In addition, PDT has 
high tissue selectivity, because the laser light can be applied locally.  
PDT is a multi-staged process; relevant aspects are the way of light absorption and the 
production of cytotoxic molecules (Figure 6). The PS is normally in a low energetic state. 
Following light absorption, the PS is transformed into a higher energetic state. Usually this 
energetic state is short-lived, but via intersystem crossing, changing the spin of the electrons, 
the PS enters a more stable triple-state. The PS then transfers excess energy on tissue-
molecules producing radicals, which further react with oxygen producing ROS in a so called 
type 1 reaction. In a type 2 reaction the excited PS transfers its energy directly on ground-state 
oxygen, giving rise to ROS. Both processes are occurring during PDT, with the type 2 
reaction being assumed to be the predominant one. The PS has a short lifetime, reacting with 
molecules only in its proximity, and the produced ROS have a diffusion capacity of up to 300 
nm, limiting the area of ROS production (Castano, Demidova et al. 2004; Josefsen and Boyle 
2008; Robertson, Evans et al. 2009). Consequently, PDT can be applied locally, limiting its 
effect on surrounding healthy tissue and overall side effects. This may offer PDT an 
advantage over other therapies such as chemotherapy, where not only the tumor is a target but 
the drug is distributed through the entire body, often causing severe side effects. This 
specificity of PDT, on the other hand, has also disadvantages, because many OS patients are 




Figure 6: Photodynamic Therapy and its mechanisms of action 
 
 Photosensitizer  4.3.1
PS are small non-toxic compounds with a specific pattern of absorption and emission 
wavelength. Most PS are based on a tetrapyrrole structure (Figure 7), such as porphyrin 
derivates, chlorins, phtalocyonine and porphycenes. Their close structural resemblance to 
tetrapyrrole in the body such as hemoglobin is probably a reason of the low toxicity of the PS. 
A perfect PS should have the following features: pure chemical properties, negligible dark-
toxicity, high chemical and physical stability, higher uptake in tumor than in normal tissue, 
rapid clearance from the body, appropriate photophysical attributes, strong absorption in the 
near infrared region (650-850nm) and suitable solubility for its administration  (Josefsen and 
Boyle 2008; Agostinis, Berg et al. 2011).  
 
Figure 7: Tetrapyrole structure 
 
 The Optical Window of PS and Laser Light Applications 4.3.2
Although PS are taken up by most cells of the body, the limiting factors of PDT are 
tissue absorbance and limited tissue penetration of the applied light. Light is both scattered 
and absorbed by different chromophores in the tissue, such as hemoglobin, melanin, 
cytochromes, water and lipids, giving rise to a so-called optical window of PDT between 650-
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1200 nm, where the absorption of the light by those chromophores is the lowest (Plaetzer, 
Krammer et al. 2009). Tissue penetrance is dependent on the absorption/excitation spectrum 
of the PS, with the highest tissue penetration in the red and near infrared spectrum (Figure 8). 
Despite an increase in tissue penetration with increasing wavelength, an optimal therapeutic 
window for PDT is limited due to absorption of water and lipids and due insufficient energy 
to produce singlet oxygen (Castano, Demidova et al. 2004). 
 
 
Because tissue penetration is limited in PDT, optimal light application is fundamental. 
The development of lasers or light emitting diodes (LED) and the appropriate devices for the 
light delivery was crucial for effective application of PDT. Although PDT is mostly applied 
for superficial tumors (e.g. head and neck area, skin, bladder), its application expanded also 
on tumors not so easily accessible, such as brain tumors, using fiber optic devices (Quirk, 
Brandal et al. 2015).  
 Generations of Photosensitizers 4.3.3
One of the first PS is Photofrin. It is a chemical derivate of hematoporphyrin, 
composed of a mixture of compounds with an absorption peak at 630nm, limiting the 
penetration depth to only 3-5mm in different tissues (Wang, Zhu et al. 2005). Photofrin is 
nowadays used for esophageal and endobronchial cancers, high grade dysplasia in Barrett’s 
esophagus, a variety of cutaneous lesions, breast and bladder cancer (O'Connor, Gallagher et 
al. 2009). First generation PSs are associated with several disadvantages; high dosage 
(Photofrin 1.5 – 2 mg/kg, approx. 100-200 J/cm2) and long-lasting photosensitivity in the skin 
(around 30 – 90 days). Approved worldwide, Photofrin is the most frequently used PS in 
PDT, although it is far from being a perfect PS. Due to the drawbacks of the first generation, 
second generation PSs were developed such as Foscan, Levulan, Visudyne, Tookad and 
652nm 
Figure 8: Penetration depth of light of 400 - 2000 nm wavelength into the skin (adapted from (Bashkatov AN, 
J. Phys. D: Appl. Phys. 38 (2005) 2543–2555, 2005). 
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Lutrex. All of these second generation PS have a faster biodistribution, an absorption peak at 
higher wavelengths and a higher quantum yield of singlet oxygen formation. 
Foscan (5,10,15,20-tetrakis(meta-hydroxyphenyl)chlorine (mTHPC), Temoporfin) is a 
chlorin PS approved in Europe since 2001 and is used for a variety of skin lesions, head and 
neck, pulmonary and esophageal cancers (Allison, Downie et al. 2004). Photophysical 
properties were investigated demonstrating a high quantum yield of singlet oxygen formation, 
longer lifetime of singlet state and lower dosage compared to first generation PS (0.1 mg/kg, 
approx. 5-10 J/cm2). Foscan with its near-infrared absorbance peak at 652nm allows deeper 
penetration of the laser light than that achieved with Photofrin at 630 nm. In a preclinical PDT 
study in mice, tumor necrosis was observed at a depth of approximately 10 mm, making 
Foscan an attractive PS for PDT treatment of not so easy accessible tumors (Bown, Rogowska 
et al. 2002).  
Another clinically approved second generation PS is Levulan (δ-aminolevulinic acid 
(ALA)), a biosynthetic porphyrin precursor with an absorption spectrum of 635nm. Levulan 
can be applied topically and is currently used worldwide for skin, bladder brain and 
esophagus cancer types. Another clinically approved PS is Visudyne (Verteporfin), a 
benzoporphyrin with an absorption peak at 690 nm. Verteporfin is approved in the U.S. for 
ophthalmic, pancreatic and skin cancer (Allison, Downie et al. 2004; Josefsen and Boyle 
2008).  
While second generation PS improved PDT applications remarkably, the development 
of third generation PS is in progress to improve the solubility (important for the route of 
administration) and to achieve higher tumor/healthy tissue ratios than those observed for 
second generation PS.  
A number of different carriers have been developed for PS, such as oil-water 
emulsions, liposomes or nanoparticles. Liposomes became during the last years valuable 
carriers for PS, because they allow the delivery of a high payload of PS. In addition, 
liposomes can carry PS with different chemical properties, such as hydrophobic PS (e.g 
mTHPC), which normally form aggregates in aqueous solution, reducing the photo-activity 
(Derycke and de Witte 2004). A number of studies demonstrated a significantly higher 
accumulation of liposomal formulations in tumor tissue than of standard PS formulations 
(Johansson, Svensson et al. 2007). 
One promising liposomal PS formulation of mTHPC is Foslip (Foscan, Bioltec AG, 
Jena, Germany). It has a unilamellar liposomal structure of dipalmitoylphosophatidylcholine 
(DPPC), dipalmitoylphosphatidylglycerol (DPPG), glucose and water. In vivo studies in 
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different preclinical models revealed a faster plasma distribution, a faster tumor accumulation 
and a lower accumulation in the skin compared to Foscan (Buchholz, Kaser-Hotz et al. 2005; 
Lassalle, Dumas et al. 2009). Foslip shows high PDT efficacy, shown in a study with feline 
cutaneous squamous cell carcinoma with a complete response rate of 75% after 1-year follow-
up (Buchholz, Wergin et al. 2007). Another study in a subcutaneous colon adenocarcinoma 
mouse model, revealed a significant longer survival upon treatment with Foslip (44.4 days 
instead of 22.7 days in the control group treated with Foscan).  
Furthermore other PS carriers such as lipid nanoparticles, based on a water/oil 
nanoemulsion, are additional promising carriers for PS (Navarro, Creusat et al. 2014). 
4.3.3.1 Targeted Photosensitizers  
A next step in PDT is the targeted PS delivery to the tumor. Different strategies can be used to 
couple PS to targeting moieties, such as covalent conjugates that bind via PEG-ylated 
liposomes or also non-covalent binding mediated by avidin or streptavidin and biotin.   
The effective targeting is of course dependent on the coupling properties but also on 
an attractive target. Many tumors, such as OS, lack a common target, making targeted PDT 
challenging. Possible candidates may include EGFR or CXCR4, which have been reported to 
be expressed by multiple OS cell lines (Laverdiere, Hoang et al. 2005; Pahl, Ruslan et al. 
2012). 
 PS Tumor Localization 4.3.4
After administration of the PS into the blood stream, it has to bind to the vessel wall 
for extravasation and to reach the tumor parenchyma. Tetrapyroles are unlikely to be 
metabolized in other organs other than the liver. The tumor to healthy tissue ratio is important 
for PDT: the higher the ratio, the lower the toxic effect on surrounding healthy tissue. Upon 
injection into the blood, PS bind to serum proteins such as albumin, HDL, or LDL, 
influencing their cellular uptake. PS preferentially localize in the tumor, the exact 
mechanisms of uptake are not yet clear. A possible explanation is the anatomical difference 
between solid tumors and normal tissue, including differences in angiogenesis, vascular 
density, and lymphatic system. Solid tumors have a higher vascular density because of 
constant neovascularization due to the rapid growth of the tumor. Due to accelerated 
angiogenesis, the blood vessels are not fully matured, giving rise to an abnormal architecture 
with fenestrations between the endothelial cells, irregular alignment and a wider lumen 
compared to normal blood vessels, leading to enhanced leakiness of the vessels for 
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macromolecules. In addition, the lymphatic clearance is impaired in the tumor, due to the lack 
of a proper lymphatic system, causing a slower clearance of molecules in the tumor tissue. 
These anatomical changes in the tumor are causing a so-called enhanced permeability and 
retention effect (EPR effect). Due to a slower lymphatic drainage, molecules stay longer in 
the tumor tissue, causing also retention of the PS in the tumor tissue. Therefore, encapsulation 
of PS into particles such as liposomes like Foslip increases the molecular size and prolongs 
the half-life in the circulation and enhances the EPR effect. 
 PDT-Mechanisms of Action 4.3.5
PDT has multiple effects; it does not only induce direct cytotoxic effects, but it also 
affects the tumor vasculature, induces inflammatory processes and activates the immune 
system.  
4.3.5.1 Cytotoxicity 
The uptake of the PS by cells is crucial for PDT efficacy. As the produced singlet 
oxygen species have a very short half-life and a low diffusion range, cytotoxicity occurs only 
in the immediate environment of activated PS. PS can localize in different cellular organelles, 
but they do not accumulate in the nucleus. Porphyrins are for example more associated with 
lipid membranes, whereas mTHPC is reported to target mitochondria, the plasma membrane, 
the Golgi apparatus and the endoplasmatic reticulum (Agostinis, Berg et al. 2011). 
Cytotoxicity is observed already shortly after light exposure, manifested by swelling of the 
cell, membrane polarization, reduced activity of enzymes in the membrane, shedding of 
vesicles containing cytosolic and lysosomal enzymes and a rise in intracellular Ca2+. The 
produced ROS severely damage cellular membranes by oxidation of unsaturated fatty acids 
and cholesterol. Many pathways are involved in the direct PDT induced cytotoxicity; 
including MAPK signaling, or cellular adhesion protein receptor signaling. In addition, in 
vitro studies also showed an increase in intracellular Ca2+ levels in cancer cells, causing the 
release of arachidonic acid, which activates phospholipase A2 that generates superoxide 
radicals, which induce cell death (Luksiene 2003; Robertson, Evans et al. 2009).  
PDT induces all major cell death pathways, necrosis, apoptosis and autophagy. 
Apoptosis is thought to be the predominant cell death pathway activated by cells in response 
to PDT. Indicators of apoptosis are cell shrinkage and cell fragmentation into membrane 
enclosed vesicles, called apoptotic bodies, which are phagocytosed (Castano, Demidova et al. 
2004). Apoptosis is a programmed process, involving gene regulation, activation of 
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endonucleases and caspases. Due to an increase in permeability of the mitochondrial 
membrane, cytochrome c is released, forming a complex with Apaf-1 and ATP that binds to 
the initiator caspase 9, forming the apoptosome complex. Caspases are intracellular proteases 
grouped into initiator and effector caspases. Initiator caspases (e.g. caspase 9) cleave the 
inactive precursors of effector caspases (e.g. Caspase 3, 7), activating them for proteolytic 
cleavage of cellular components. Caspase 3/7 cleave poly (ADP-ribose) polymerase (PARP), 
which maintains cell viability by inducing DNA repair, into an 89 kDa fragment. The process 
eventually leads to nuclear disintegration (Elmore 2007).   
Necrosis, also provoked by PDT, is a violent destruction of cells, caused by cytoplasm 
swelling, disruption of the plasma membrane and release of cellular contents. Autophagy, also 
reported as a response to PDT, is characterized by the formation of autophagosomes, 
membrane-bound structures, which mediate degradation of cellular contents by fusion with 
lysosomes.  
4.3.5.2 Anti-Vascular Effects and Oxygen Consumption 
Neo-angiogenesis is an important process in tumor progression, because fast growing 
tumors are dependent on a sufficient oxygen supply (Bergers and Benjamin 2003). A wide 
range of vascular effects in response to PDT is reported. Endothelial cells as targets of PDT 
play a major role in the anti-vasculature effects. A study performed by West et al., in bovine 
aorta endothelial cells and colon adenocarcinoma cells, showed that exponentially growing 
endothelial cells were sensitive to PDT (Gomer, Rucker et al. 1988; Gomer, Rucker et al. 
1988; West, West et al. 1990). PDT is also known to induce platelet formation, 
microvasculature collapse, vascular leakage and vessel constriction (Star, Marijnissen et al. 
1986). A key study performed by Synder et al. revealed that PDT increases vessel 
permeability, which facilitated the accumulation of a liposomal formulation of doxorubicin in 
the tumor tissue (Snyder, Greco et al. 2003). Pointing out the importance of the vasculature 
effect, a study by Maugain et al., displayed that PDT efficacy was higher with a short (3h 
after injection) than with long drug-light intervals, even though tumor mTHPC accumulation 
was not at its maximum. PS levels in leukocytes at this time point were high, indicating an 
early vascular PDT response (Maugain, Sasnouski et al. 2004).  
The drug-light interval is a crucial factor in PDT. Interestingly, for Foscan, the 
concentration of PS in the tumor does not always correlate with PDT efficacy. The PDT 
response was maximal shortly after the injection of Foscan and not when the accumulation of 
the PS in the tumor was highest (Cramers, Ruevekamp et al. 2003). Despite these findings, 
37 
 
current standard protocols for Foscan recommend irradiation of the tumor 96 h after PS 
administration. 
Tumor oxygenation is crucial for PDT efficacy. Chen et al., demonstrated that the 
manipulation of tumor oxygenation (treatment under different atmospheric pressure) can alter 
PDT efficacy. Hyper-oxygenation of the tumor tissue lead a better treatment outcome (Chen, 
Huang et al. 2002). Lowering light irradiation especially the fluence rate causes slower 
oxygen consumption and therefore improves the tumor response. Different fluence rates (14 
and 112 mW/cm2) were applied in a subcutaneous Colo 26 murine tumor model, low fluence 
rates caused in 70- 80% of the mice tumor cures compared to 10-15 % tumor cures in the high 
fluence dose treated animals (Henderson, Gollnick et al. 2004). Therefore, optimal energy 
settings should be taken into consideration for optimal PDT. 
4.3.5.3 Inflammation and the Immune System 
PDT evokes a strong inflammatory response, recognized as a local swelling and 
formation of an edema. An acute inflammatory response is launched immediately after 
illumination. PDT rapidly induces the so called damage-associated molecular patterns 
(DAMPs). DAMPs are a variety of molecules normally located within the cells (tumor cells 
and vasculature), but, upon cell destruction, they are released in the surrounding area. DAMPs 
are recognized by the innate immune system, but they also stimulate the adaptive immune 
system. The cells that first arrive at the treated area are neutrophils. Photofrin- and mTHPC-
based PDT induced systemic neutrophilia mediated by the acute-phase response and the 
complement system, both key factors in the innate immune system. Neutrophils release a 
number of cytokines attracting monocytes/macrophages and mast cells and thereby initiate the 
removal of residual tumor cells and vasculature (Cecic, Parkins et al. 2001; Cecic, Stott et al. 
2006; Garg, Nowis et al. 2010).  
The acute phase response (APR) is a stress response that is activated to control the 
induced damage. APR is activated by the release of various cytokines (such as IL-6, IL-1, 
TNF) by cells of the innate immune system (neutrophils, macrophages, monocytes) APR 
induces a wide range of pathophysiological responses like hormone alterations via the 
adrenal/pituitary axes, changes in plasma protein levels, leukocytosis and neutrophilia (Jain, 
Gautam et al. 2011). The importance of neutrophils was demonstrated upon their depletion in 
host mice, which reduced long-term tumor cure (Korbelik and Cecic 1999). In addition, 
neutrophils are able to induce maturation of dendritic cell (DC) and lymphocytes, establishing 
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a link between the innate and the adaptive immune response (Yang, de la Rosa et al. 2009; 
Jaillon, Galdiero et al. 2013). 
Numerous studies have shown that PDT induces also the adaptive immune system, 
potentiating PDT efficacy. Subsequent studies in murine mouse model also showed that local 
PDT does not only induce anti-tumor immunity, it also suppressed a tumor re-challenge 
(Castano, Mroz et al. 2006). Phagocytosis of destroyed tumor cells by the innate immune 
system plays a vital role in presenting tumor associated antigens to cells of the adaptive 
immune system that results e.g. in the attraction of dendritic cells to the site of treatment and 
their maturation (Korbelik 2006). An adaptive immunity effect of PDT is supported by 
pioneer studies performed by Korbelik et al.. Mammary sarcoma cells (EMT6) were 
subcutaneously injected into nude, SCID and Balb/c mice. Nude mice lack T lymphocytes but 
have normal levels of natural killer (NK) and B lymphocytes, whereas SCID mice have no 
matured B and T lymphocytes, with normal NK cell and myeloid cell number. Photofrin-
mediated PDT revealed a long term cure in BALB/c mice, and a delayed PDT effect in SCID 
and nude mice with tumor regrowth and no long time cure. Adoptive T cell transfer from 
BALB/c to SCID mice delayed tumor regrowth and a transfer of bone marrow from BALB/c 
to SCID lead to an almost 100% long term tumor cure in SCID mice, whereas BALB/c mice 
with transplanted SCID bone marrow lost long term PDT cure (Korbelik, Krosl et al. 1996). 
These studies demonstrate the induction of the adaptive immune response with a subsequent 
immune memory. Although PDT is a local therapy, different studies report not only a local 
anti-tumor effect, but also a systemic immune effect against the tumor. This was supported by 
the detection of tumor-sensitized immune cells in tumor distant lymph nodes (Korbelik and 
Dougherty 1999). Furthermore, a clinical study in angiosarcoma patients, showed 
spontaneous remission of distant untreated tumor sites after PDT and high T-lymphocytic 
infiltration was observed in biopsies (Thong, Ong et al. 2007).   
Furthermore, it is important to note that PDT can also have direct cytotoxic effects in 
cells of the tumor microenvironment, such as tumor-supporting cells like various immune 
cells (e.g. macrophages, lymphocytes, DC). 
 PDT Applications 4.3.6
PDT has been used for cancer therapy since 1970s by Thomas Dougherty, who 
successfully treated skin cancer patients using a hematoporphyrin derivative (HPD) and red 
light. He observed a complete or partial response in 111 of 113 cutaneous or subcutaneous 
malignant lesions (Dougherty, Kaufman et al. 1978). At the same time J.F. Kelly 
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demonstrated anti-cancer efficacy of HPD in bladder cancer patients (Kelly and Snell 1976). 
Since these pioneer studies, a multitude of clinical studies has been performed and a number 
of PS tested and some of them were clinically approved; these include Foscan (mTHPC), 
Photofrin (HpD), Metvix (ALA), and Visudyne (Verteporfin). Most PS have been approved 
for different kinds of premalignant and malignant non-melanoma skin lesions and have been 
extensively studied with porfimer sodium and ALA. PDT using Photofrin has been shown to 
induce a complete response in 92% of patients with basal cell carcinoma (BCC) together with 
a reduced 4 year recurrence rate of only 10% (Zeitouni, Shieh et al. 2001). In potentially 
metastatic squamous cell carcinoma, on the other hand, the initial response rate ranged from 
54% to 100% and a recurrence rate of up to 69% was observed (Braathen, Szeimies et al. 
2007). 
In an mTHPC-mediated PDT study with 121 oral squamous cell carcinoma 85%, 
functional and cosmetic benefits were higher compared to patients treated with surgery or 
radiation (Hopper, Kubler et al. 2004). Furthermore in an mTHPC-based PDT study with 128 
patients for which conventional therapy had failed, 38% of the patients showed an overall 
tumor response and 16% a complete tumor response. Important to mention is also the 
improvement in quality of life in this study (D'Cruz, Robinson et al. 2004). Tumor 
suppressive effects were also shown for tumors of the digestive system and for intraperitoneal 
malignancies, prostate and bladder cancer, and are now subject to clinical investigations 
(Agostinis, Berg et al. 2011) (Table 1). 
 
 




Although PDT has been mostly applied for superficial tumors, several studies also 
investigated the feasibility and efficacy of PDT in a more inaccessible location as an 
intraoperative approach. Already in 1988, Nambisan et al. applied PDT to recurrent 
retroperitoneal sarcomas and achieved a complete tumor resection in 8 of 10 patients. In 
patients with mesothelioma, Foscan-based PDT was also shown to be a safe intraoperative 
treatment (Friedberg, Mick et al. 2003). Importantly, PDT application as an intraoperative 
approach or with fiber optics in combination with fluorescence guided tumor resection, 
making use of the fluorescence of PS and their higher accumulation in tumors than in healthy 
tissue, revealed promising results in different studies investigating brain tumors (Quirk, 
Brandal et al. 2015). 
Although PDT has a low systemic toxicity, frequent mild side effects of the therapy 
include local pain after illumination and cutaneous photosensitivity. 
 PDT in Osteosarcoma 4.3.7
Standard therapy for OS includes surgery and chemotherapy. Unfortunately 
chemotherapy is often associated with severe side effects and resistance, and certain tumors 
are located at delicate or hardly accessible locations (Chou and Gorlick 2006). PDT is a 
promising strategy for the treatment of metastasizing OS. Due to its local application and the 
per se non-toxic compounds, PDT induces low system toxicity. Compared to other therapies, 
e.g. chemotherapy or radiation, PDT can elicit an anti-tumor immunity, and therefore inhibit 
distant metastases through the activation of an immune response. Furthermore, an 
intraoperative combination of PDT with surgery could improve complete tumor eradication, 
and a combination with standard chemotherapy could potentially lower toxic doses of 
chemotherapeutics, thereby reducing recurrences, immediate and long-term side effects and 
consequently improve patient survival. Unfortunately, only a few studies have been published 
on these combinations. However, PDT has already been successfully applied in combination 
with chemotherapy and radiation (Agostinis, Berg et al. 2011). Interestingly, PDT, in 
combination with cisplatin, potentiated treatment efficacy in different OS mouse models 
(Nahabedian, Cohen et al. 1988; Canti, Nicolin et al. 1998). PDT was also shown to sensitize 
cancers cells to radiotherapy (Pogue, O'Hara et al. 2003), with an increase in anti-cancer 
effects (Luksiene 2003). 
Unfortunately only a few preclinical studies have been published until now using PDT 
for the treatment of OS. Kusuzaki et al. tested acridine orange- based PDT on multi-drug 
resistant OS cell lines and observed a strong cytotoxic effect, which is in line with other in 
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vitro data, which demonstrated ALA-based PDT toxicity in HOSM-1 and HOSM-2 cell lines 
(Kusuzaki, Minami et al. 2000; Yanase, Nomura et al. 2009). In preclinical studies in mice, 
Nomura et al. showed that subcutaneous OS tumors injected with HpD and treated with light 
exhibited reduced tumor growth (Nomura, Yanase et al. 2004) Unfortunately, this 
subcutaneous model has only minimal clinical relevance. A very recent study performed by 
Sun et al., using Hiporfin mediated PDT, showed tumor suppression in subcutaneous and 
tibial OS mouse models (Sun, Zhou et al. 2015), but their models lacked a proper immune 
system, which might explain the only slight reduction in tumor growth in response to PDT.  
A preclinical study in seven dogs with spontaneous OS used the PS Visudyne 
(Vetoporfin) intravenously. Upon injection the tumors were locally irradiated with light 
provided by a 0.94 mm fiber optic cable. Tissue staining and MRI after PDT showed 
remarkable tumor necrosis. Unfortunately the affected legs were amputated 48 h after the 
treatment and a systemic impact on potential metastases or long-term treatment effects were 
therefore not reported (Burch, London et al. 2009). 
OS mortality is mostly caused by metastatic spread; therefore, PDT may represent a 
promising treatment option due to a potential systemic effect on the immune system and the 
options for combined and repetitive treatment. In addition, PDT on metastatic lesions such as 
lung metastases might also be a novel treatment possibility, because in patients with lung 
cancer, PDT was shown to be an effective, preserving lung function (Usuda, Kato et al. 2006). 
Altogether, PDT is an interesting and promising novel option in OS therapy with minimal 
side effects and, if necessary, applicable in a repetitive manner. 
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5 Aims of the Thesis
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5.1 Aim 1 
Activin A is a member of the TGFβ superfamily and has been implicated in the 
`vicious cycle` between bone tumors and their microenvironment. It not only influences bone 
remodeling, including osteoclastogenesis and osteoblastogenesis, but was also shown to have 
a tumor promoting role in a variety of bone homing tumors, e.g. MM, breast, prostate and 
lung cancers. Similar to these bone homing tumors, a `vicious cycle` of pathological bone 
remodeling driving tumor progression is also assumed to be crucial in OS, therefore, the 
inhibition of activin A signaling, is a promising strategy for the treatment of OS. 
The aim of this study was to investigate the role of activin and its inhibition on OS 
growth. To achieve this, we used two engineered fusion-proteins inhibiting activin A; a 
soluble fusion protein acting as a decoy receptor for activin A, consisting of the extracellular 
domain of the ActRІІA receptor fused to the murine immunoglobulin G (IgG) Fc domain 
(ActRІІA-mFc); and an engineered analogue of follistatin (FST315), a natural occurring 
inhibitor of activin A with a heparin-binding site deletion (∆HBS), fused to an Fc of an human 
IgG (FST315∆HBS-hFc). (Figure 9 A, B). Additionally, we analyzed the effects of both 
activin A inhibition in combination with the bisphosphonate ZOL, a gold standard for the 
inhibition of cancer-associated bone remodeling with anti-tumor efficacy, on OS progression. 
As a first sub-aim, activin A inhibitors, as single compounds or in combination with 
ZOL, were studied in vitro on osteosarcoma cells and cells of the bone microenvironment, 
and levels of activin A in serum samples collected from osteosarcoma patients were assessed.  
As a second sub-aim, we studied the efficacies of the activin A inhibitors, with or 
without combination of ZOL, to disrupt tumor growth, tumor associated bone remodeling, as 










Figure 9: Engineered fusion proteins for the inhibition of activin A. (A) A soluble decoy receptor ActRIIA-
mFc (B) and a FST315 analogue FST315∆HBS-hFc. 
5.2 Aim 2 
Current osteosarcoma therapies cause severe treatment-related side effects and 
chemoresistance, and have low success rates. Thus, alternative treatment options are needed. 
PDT is associated with low systemic toxicity, local application, and anti-tumor immunity, and 
has been effective against a variety of tumors, such as skin and head and neck cancers. In this 
second part of the thesis, we therefore investigated PDT as a therapeutic approach against OS.  
To accomplish this aim, we performed in vitro and in vivo studies with one of the most 
powerful PS, mTHPC (Foscan) and two novel liposomal formulations, Foslip (biolitec, Jena, 
Germany) and lipid-based nanoparticles (LNP).  
The purposes of the in vitro experiments were to compare the uptake of Foscan, Foslip 
and LNP and their dark- and phototoxicity in the highly aggressive OS cell lines and to 
characterize the induced cell death pathways.  
The experiments in vivo were performed in intratibial human xenograft and syngeneic 
OS mouse models, both metastasizing to the lung. First, the uptake of Foscan, Foslip and LNP 
within the tumor tissue was compared. Subsequently, their tumor- and metastasis-suppressive 
potential in PDT applied in the xenograft and syngeneic intratibial OS mouse models was 
investigated. In addition, we studied the impact of PDT on the tumor tissue and vasculature in 
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Purpose: Osteosarcoma is thought to elicit a `vicious cycle` of bone remodeling to provide a 
fertile soil for tumor growth and progression. Activin A, a member of the TGFβ superfamily, 
may play a critical role in this cycle. We evaluated the impact of activin A inhibition in vitro 
and in vivo in osteosarcoma and its microenvironment. 
Experimental Design: The effects of an engineered follistatin analogue (FST315-∆HBS-hFc) 
and an engineered activin decoy receptor (ActrIIA-mFc) in combination with zoledronic acid 
(ZOL) were evaluated in vitro in osteosarcoma and bone cells. Using an orthotopic 143B 
osteosarcoma xenograft mouse model, the efficacy of activin A inhibitors (i.p. 10 mg/kg, 
biweekly) and ZOL (s.c. 100 µg/kg, biweekly) as single treatment or in combination on tumor 
growth, bone remodeling and metastases development was determined. 
Results: Despite a functional activin A signaling in 143B cells, activin A neutralization had 
no effect on cell viability or migration in vitro, whereas ZOL was cytotoxic. On the other 
hand, activin A-induced osteoclastogenesis was effectively inhibited using the two activin A 
inhibitors. Both activin A inhibitors successfully disrupted tumor growth and tumor-
associated bone remodeling. When combined with ZOL, tumor growth was further reduced 
and a decreased metastatic spread was observed in mice treated with ActrIIA-mFc and ZOL.  
Conclusions: This study shows that activin inhibitors, as single treatment or in combination 
with bisphosphonates, successfully disturbed the osteosarcoma microenvironment. Because 
both classes of compounds interfere with different pathways and were well tolerated, clinical 




Current therapies for osteosarcoma have not been able to overcome the currently 
plateaued patient survival curve. To overcome chemoresistance and the high diversity of 
osteosarcoma in phenotype, anatomical location and histology, novel interventions are 
needed. In recent years, a `vicious cycle` between the tumor and its bone microenvironment 
was proposed to play an important role in osteosarcoma development. Some bone cancers 
identified activin A as a novel component involved in this cycle. This study shows that activin 
inhibitors and zoledronic acid (ZOL), administered as single treatment or in combination, 
successfully disturb this microenvironment, leading to a significant reduction of osteosarcoma 
tumor growth, tumor associated bone remodeling and metastatic spread. The effects of ZOL 
against osteosarcoma are currently under clinical investigation, and our results suggest that a 
combination of this compound with activin A inhibitors may offer additional clinical benefit. 





Osteosarcoma is the most common malignant primary tumor of bone and the second 
leading cause of cancer-associated death in childhood and adolescence (1, 2). Since the 
introduction of multi-agent chemotherapy, 5-year survival rates in patients with localized 
disease increased above 60%, but in case of metastatic or recurrent disease, the survival rate 
remains poor with 20-30%. 
Tumor heterogeneity presents a real challenge in finding a therapeutic target to treat 
osteosarcoma. Further, osteosarcoma includes a number of different subtypes, which differ in 
their anatomical location, histology, phenotype and genetic profile (3). Therefore, this study 
concentrates on a common factor for all osteosarcoma subtypes: the bone and its 
microenvironment. Bone is a dynamic tissue, and physiological micro-damages within the 
bone matrix are being constantly absorbed by osteoclasts and rebuilt by osteoblasts. This bone 
remodeling is strictly regulated and in an equilibrium in healthy individuals (4). In patients 
with cancers affecting the bone, these processes become unbalanced, leading to excessive 
bone remodeling. This in turn offers the tumor access to growth factors stored within the bone 
matrix, which then allows it to grow and spread. Osteosarcoma cells are reported to directly 
cross-talk with bone cells, and thus play an important role in regulating bone remodeling (5). 
Consequently, researchers nowadays believe that a `vicious cycle` between the tumor and the 
bone microenvironment exists in osteosarcoma, as it was previously proposed for other 
tumors affecting bone, such as breast, prostate cancer, multiple myeloma, Ewing’s sarcoma 
and chondrosarcoma (6-10). 
In prostate and breast cancers and multiple myeloma, activin A was identified as a 
novel component involved in this `vicious cycle` (11-13). Activin A is a homodimeric protein 
belonging to the TGF-β superfamily, a known regulator of pituitary follicular stimulating 
hormone (FSH), cell proliferation and differentiation, immune response, wound healing and 
embryogenesis (14). Additionally, it is abundantly present in the bone microenvironment and 
acts as a regulator of bone remodeling. Activin A has been shown to be a cofactor for 
RANKL, a key cytokine for osteoclastogenesis (15). Although its effects on osteoblasts are 
more controversial, an inhibition in the mineralization capacity of osteoblast has been 
reported (16). Activin A is also involved in tumor growth and progression in osteosarcoma 
and tumors metastasizing to the bone (13, 17, 18). Serum levels of activin A were found to be 
elevated in patients with bone metastasis of breast and prostate cancers and multiple myeloma 
(13, 19) and in the latter, these serum levels inversely correlated with patient survival (20). 
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Finally, inhibition of activin A in preclinical in vivo models for multiple myeloma, lung, and 
breast cancer led to suppression of cancer associated bone remodeling (11, 13, 21) as well as 
an effective reduction of tumor progression (13, 22, 23).  However, in osteosarcoma, the role 
of activin A, its involvement in the tumor microenvironment and its potential as a therapeutic 
target is not well studied. Therefore, we investigated whether the inhibition of activin A is 
able to counteract osteosarcoma tumor growth both locally and systemically. To this end, we 
used two different types of inhibitors, a soluble engineered activin A receptor type 2A 
inhibitor fused with the fragment crystallizable region (Fc) of an IgG (ActRIIA-mFc) and an 
engineered analogue of follistatin (FST315), which has high affinity for activin A and lower 
affinity for myostatin and bone morphogenetic proteins, fused to an Fc of an IgG 
(FST315∆HBS-hFc). The FST protein carries additionally a heparin binding sulfate deletion 
(∆HBS) to prolong circulation (24). Moreover, we also combined activin A inhibitors with the 
bisphosphonate zoledronic acid (ZOL). ZOL has anti-tumor efficacy (25) and is currently 
being used as a gold standard for the inhibition of cancer-associated bone remodeling by 
inhibition of osteoclast differentiation and activity (26, 27). In this study, we analyzed the 
effects of both activin A inhibition and ZOL in vitro on osteosarcoma cells as well as cells of 
the bone microenvironment. We further assessed the levels of activin A in serum samples 
collected from osteosarcoma patients. In addition, we studied the efficacies of the activin A 
inhibitors and ZOL to disrupt tumor growth and associated bone remodeling as well as 
metastasis formation in an intratibial xenograft osteosarcoma model. Our studies revealed 
activin A as an important regulator of the osteosarcoma microenvironment and demonstrated 
therapeutic efficacy of ActRIIA-mFc and FST315∆HBS-hFc, with or without ZOL against 
osteosarcoma. 
 
Materials and Methods 
Cells and culture conditions 
Human 143B (CRL-8303), SaOS-2 (HTB-85), murine K7M2 (CRL-2836) and HEK293 
(CRL-3216) cells were obtained from the American Type Culture Collection. Cells were 
cultured in DMEM (4.5 g/l glucose)/HamF12 (1:1) tissue culture medium (Invitrogen, CA, 
USA), supplemented with 10% heat-inactivated FCS (GIBCO, Basel, Switzerland), at 37°C in 
a humidified atmosphere (5% CO2). 143B were transduced with the LacZ and mCherry gene 
as described before (143B/lacZ/mCherry) (28). 
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Cells were authenticated by multiplex PCR (Microsynth, Switzerland) using the 
PowerPlex®16HS system (Promega, Fitchburg, USA) and verified by comparison with the 
database at the Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, 
Germany).  
Peripheral blood mononuclear cells (PBMC) were obtained from the whole blood of 
healthy individuals (HI) and sorted for CD14-positive PBMC with a human CD14 Selection 
Kit (#18058, STEMCELL Technologies, Vancouver, Canada) following manufacturer’s 
instruction using the Manual EasySep® protocol with the Purple EasySep® Magnet (#18000, 
STEMCELL Technologies). Cells were cultured in MEM Alpha Medium (#22561.021, 
Gibco) supplemented with 15% heat-inactivated FCS. 
Activin A inhibitors and zoledronic acid  
FST-315∆HBS-hFc represents human follistatin (FST315), in which FST’s heparin 
binding sulfate is replaced (∆HBS) as described by Sidis et al. (29), and fused to the fragment 
crystallizable region (Fc) of a human IgG1. ActR‖A-mFc is a fusion protein of the human 
activin A receptor type 2A (ActRIIA) with the Fc of a murine IgG2a. FST315, FST315∆HBS-
hFc and ActR‖A-mFc were kindly provided by Arcarios (Rotterdam, Netherlands). Zoledronic 
acid (ZOL) was purchased from Novartis (Zometa, Switzerland). 
Activin A Elisa in human blood samples and osteosarcoma cell lines 
Human blood was collected in serum collection tubes (# 368774, BD, New Jersey, 
USA) from 19 osteosarcoma patients and 14 healthy individuals (HI). Tubes were centrifuged 
for 10 minutes at 3700 rpm at room temperature (RT). Blood serum was transferred to a new 
15 ml tube, aliquoted and stored at -20°C.  
Cells were cultured in 25 cm2 cell culture flasks under tissue culture conditions  until 
60% confluency, washed with PBS and starved for 24 hours with 2ml/well DMEM(4.5 g/l 
glucose)/HamF12 (1:1) without FCS. Supernatant was collected by centrifugation (2 minutes, 
1200 rpm), stored at -20°C and normalized to the number of cells. 
Activin A ELISA (ab113316, Abcam, Cambridge, UK) was performed following 
manufacturer’s instructions.  
Binding assay 
Activin A binding was quantified using a luciferase based bioassay. Briefly, HEK293 
cells containing a (CAGA) 12-luciferase reporter (as described in 30) were stimulated with 
0.2 nM activin A and co-treated with a concentration range of activin A inhibitors. After 24 
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hours cells were lysed and luciferase signal was measured in a microplate reader (Wallac 
1420 victor2, PerkinElmer, MA, USA). The corresponding dose-response curves were 
analyzed and the half maximal inhibitory concentration (IC50) calculated using GraphPad 
Prism v5.01 software (GraphPad PRISM, Inc, California Corporation, CA, USA). 
Western blot analysis 
Serum-starved 143B/lacZ/mCherry cells were pre-incubated under tissue culture 
conditions for 1 hour with or without FST315 (10 nM, 100 nM), FST315∆HBS-hFc (10 nM, 100 
nM) or ActR‖A-mFc (10 nM, 100 nM). Cells were then stimulated with 2 nM activin A (# 
338-AC, R&D systems, Minneapolis, MN, USA) for 15 minutes.  
CD14-positive PBMC were differentiated into pre-osteoclasts for 7 days in the 
presence of m-CSF (25 ng/ml, #216-MC, R&D Systems, MD, USA) and RANKL (60 ng/ml, 
#310-01, Peprotech Inc., Rocky Hill, USA) under tissue culture conditions. On day 7, pre-
osteoclasts were starved for 6 hours in tissue culture medium without FCS and then pre-
incubated for 1 hour with or without FST315 (100 nM), FST315∆HBS-hFc (100 nM) or 
ActRІІA-mFc (100 nM) and stimulated for 60 minutes with 2 nM activin A. 
The preparation of protein extracts and western blot analysis were performed as 
previously described (31). Phospho-Smad2 (1:1000, #3108, Cell Signaling, Boston, USA), 
total Smad2 and Smad3 (1:1000, #8685, Cell Signaling), GAPDH (1:3000, FL-335, Santa 
Cruz Biotechnologies, Dallas, Texas, USA) and HRP-conjugated secondary antibody (1:1000, 
sc-2054, Santa Cruz Biotechnologies) were used.  
Cell viability assay 
143B/lacZ/mCherry cells were seeded in 96-well plates (750 cells/well) and allowed 
to adhere overnight. The cells were then incubated in triplicates with activin A and/or FST315, 
FST315∆HBS-hFc, ActR‖A-mFc, ZOL and their combination FST315∆HBS-hFc/ZOL or 
ActR‖A-mFc/ZOL at indicated concentrations for 48 hours. Cell viability was measured with 
the WST-1 assay (#05015944001, Roche, Basel, Switzerland) according to the manufacturer’s 
protocol. 
Migration assay 
Cells were seeded into 6-well plates; when confluency reached 90%, cells were 
starved for 12 hours with tissue culture medium containing 1% FCS. On the confluent cells, 
tissue culture medium (containing 1% FCS) with or without activin A (0.5 nM or 2 nM activin 
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A) was added to the wells. Six wounds per well, in duplicate, were applied and the migration 
rate assessed as previously described (32). 
PBMC differentiation into TRAP-positive large multinucleated cells 
CD14-positive cells (60`000 cells/well in a 96 well plate) were differentiated with m-
CSF (25 ng/ml, #216-MC, R&D Systems, MD, USA) and soluble RANKL (60 ng/ml, #310-0, 
Peprotech Inc., Rocky Hill, USA) as described (33). From day 4 onwards, activin A (0.5 nM), 
FST315 (100 nM), FST315∆HBS-hFc (100 nM), ActR‖A-mFc (100 nM), ZOL (0.5 µM) and 
their combination FST315∆HBS-hFc and ZOL or ActR‖A-mFc and ZOL were added to the 
tissue culture medium.  
Following fixation, tartrate-resistant acid phosphatase (TRAP) histochemistry was performed 
by incubating the cells with 0.2 M acetate buffer for 20 minutes at RT. Cells were then 
incubated with 0.5 mg/ml naphtol AS-MX phosphate (#855, Sigma Aldrich) and 1.1 mg/ml 
Fast Red TR Salt (# F8764, Sigma Aldrich) in the presence of 50 mM sodium tartrate for 1 
hour at 37°C and then washed with PBS and stained with Hoechst (#H3570, Life 
Technologies, Carlsbad, USA, 1:10`000, 10 minutes, RT). Wells were photographed in 
quadruplicate and the number of TRAP-positive, huge multinucleated osteoclasts (approx. 
100-200 µm) were determined with ImageJ software (http://rsb.info.nih.gov/ij/).  
Osteoclast resorption activity  
Osteoclast resorption activity was measured using an OsteoLyse™ Assay Kit (#PA-
1500, Lonza, Basel, Switzerland). Osteoclast precursors (#2T-110, Lonza) were seeded 
following the manufacturer’s protocol at a density of 10’000 cells/well on an 96-well 
OsteoLyse™ cell culture plate coated with fluorophore-derivatized human bone matrix in 
differentiation medium (OCP BulletKit, #PT-8201, #PT-9501) and differentiated, following 
the manufacturer`s protocol. Precursors without RANKL served as undifferentiated controls. 
On day 6, the differentiation medium was replaced and activin A (0.5 nM), with or without 
FST315 (100 nM), FST315∆HBS-hFc (100 nM), ActR‖A-mFc (100 nM), ZOL (50 nM) or their 
combination FST315∆HBS-hFc and ZOL or ActR‖A-mFc and ZOL was added. On day 10 
resorption activity was measured following manufacturer`s instructions. Results were 
displayed as relative fluorescence unit (RFU). 
Intratibial human xenograft osteosarcoma mouse model 
All in vivo studies were conducted with approval of the Veterinary Office Kanton 
Zurich, Switzerland (animal application license 42/2013) and in accordance with the 
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guidelines of the Swiss Federal Veterinary Office. Eleven-week-old female SCID (C.B-17/lcr 
Prkdcscid/scid) mice were obtained from Charles River Laboratories (Sulzfeld, Germany) and 
kept for a 10 day acclimation period before tumor cell injection (TCI). For orthotopic TCIs, 
mice were intratibially (i.t) injected with 105 143B/lacZ/mCherry cells as previously 
described (34). Mice were randomized according to their weight into the following six 
experimental groups and injected one week after TCI with vehicle (KPO4, 100 µl, n=11), 
FST315∆HBS-hFc (biweekly, intraperitoneally (i.p.), 10 mg/kg, n=11), ActR‖A-mFc 
(biweekly, i.p., 10mg/kg, n=10), ZOL and KPO4  (biweekly, subcutaneously (s.c.), 100 µg/kg, 
n=11), FST315∆HBS-hFc (biweekly, i.p., 10 mg/kg) plus ZOL (biweekly, s.c., 100 µg/kg) 
(n=12) or ActR‖A-mFc (biweekly, i.p., 10 mg/kg) plus ZOL (biweekly, s.c., 100 µg/kg) 
(n=11).  
Tumor growth in all mice was monitored by caliper measurements as described (34). 
All mice were sacrificed 34 days after TCI, lungs were in situ perfused and lung surface 
metastasis counted as previously described (35). All major organs and the tumor tissue were 
dissected, snap-frozen in liquid nitrogen or placed into 4% paraformaldehyde/PBS until 
analysis. 
IVIS optical imaging 
In vivo fluorescence imaging was performed for the visualization of mCherry-
expressing 143B cells within the intratibial primary tumors. Mice were monitored weekly 
using the IVIS Lumina XR (PerkinElmer) under gas anaesthesia (2-5% isoflurane). Epi-
fluorescence (excitation 605 nm, emission 660, 680 and 700 nm,) was analyzed using Living 
Image v4.4 software (PerkinElmer). Epi-fluorescence is indicated as radiant efficiency 
(p/sec/cm2/sr)/(µW/cm2). 
Micro–computed tomography analysis 
Animals were anesthetized (2-5% isoflurane/O2). Hind limbs of mice were scanned in 
the Bruker/SkyScan-1176 in vivo X-ray micro–computed tomography (μCT) in supine 
position (Bruker, MA, USA). µCT scanning was commenced with a voxel size of 17 µm, 
source voltage of 50 kV, source current of 500 µA, exposure of 290 ms with a rotation step of 
0.8 degrees. Three-dimensional datasets were generated using Cone-Beam reconstruction 
(NRecon v1.6.9.18.SkyScan/Bruker). A region of interest (ROI) of the tibia was manually 
selected (CtAnalyser v1.13.11.0, Bruker/Skyscan), starting from the tibial plateau until the 
point in the distal tibia where the fibula and tibial bones converge. After segmentation of the 
ROI, the amount of bone volume (BV, in mm3) was calculated. 
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Alkaline Phosphatase (ALP) Assay 
ALP assay was performed using a fluorometric Alkaline Phosphatase Assay (ALP) Kit 
(ab83371, Abcam) following manufacturer’s instructions. Fluorescence (Ex/Em = 360/440 
nm) was measured in a Spectramax Gemini XS plate reader (Molecular Devices, Sunnyvale, 
CA). ALP activity was calculated using the following formula: ALP activity = A/T (mU/min), 
with A = amount of 4-methylumbelliferone (4-MU) generated, T = reaction time in minutes 
and normalized to the total protein concentration in the tissue lysates. 
Assessment of tumor necrosis 
Upon sacrifice, the tumor in the hind limb was cut in half along the longitudinal axis, 
fixed in 4% buffered paraformaldehyde for 2 days and decalcified for 2 weeks using 
Osteosoft (# 101728, Merck Millipore, Germany). After routine paraffin wax embedding, 
sections (3-5 µm thick) were stained with hematoxylin and eosin (HE) for histological 
examination. The amount of tumor necrosis was scored in the HE-stained, blindly labeled 
slides by a veterinary pathologist, as follows: Grade 0: no necrosis; Grade 1: necrosis below 
20% of the total tumor surface; Grade 2: necrosis greater than 20% but less than 40%; Grade 
3: necrosis greater than 40% but less than 60%; Grade 4: necrosis greater than 60% but less 
than 80%; and Grade 5: necrosis greater than 80%. 
Quantitative real-time PCR  
mRNA isolation from 143B cell line derived primary tumor tissue was performed with 
an RNeasy Plus Universal Mini Kit (#73404, Qiagen, Valencia, CA, USA, catalogue # 73404) 
following manufacturer`s guidelines. Purified mRNA was reverse-transcribed into cDNA 
using the high-capacity cDNA reverse transcription kit (# 4368814, Applied Biosystems, 
Foster City, CA, USA). Quantitative real-time PCR (qRT-PCR) was quantified as previously 
described (36). Primers used were; murine Cathepsin K forward: 5’-
GCACCCTTAGTCTTCCGCTC-3’, reverse: 5’-ACCCACATCCTGCTGTTGAG-3’; murine 
Gapdh forward: 5’-TTGTGCAGTGCCAGCCTCGT-3’, reverse: 5’-
TGCAAATGGCAGCCCTGGTGA-3’.  
Statistical analysis 
In vitro experiments show results of three independent experiments. Results are 
presented as mean ± standard error of the mean (SEM). All results were analyzed using 
GraphPad Prism v5.01 software (GraphPad PRISM, Inc, California Corporation). One-way 
ANOVA analysis was used when comparing a variable in three and more groups with 
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indicated post hoc analysis. Two-way repeated measures analysis was performed when 
comparing two categorical independent, repeatedly measured variables, with Bonferroni post 




Activin A serum levels  
In order to investigate the clinical significance of circulating activin A levels in 
osteosarcoma patients (OS), we compared their activing A serum levels to the levels of 
healthy individuals (HI). The overall comparison between HI and OS revealed a tendency for 
increased serum activin A levels (Fig. 1A). The clinical data of patients and healthy 
individuals are presented in Fig. 2B. 
Activin A and its inhibitors in osteosarcoma cells 
Activin A is secreted by cells within the osteosarcoma microenvironment, such as 
osteoblasts, osteoclasts and bone marrow stromal cells (13). Here, we demonstrated that 
osteosarcoma cell lines 143B, SaOS-2 and K7M2 also secrete significant amounts of activin 
A into their culture supernatant (Fig. 2A). 
To block activin A, the FST315, a FST315-based fusion protein FST315∆HBS-hFc and a 
soluble decoy receptor ActR‖A-mFc were used and their binding capacities shown using a 
luciferase reporter assay. The IC50 concentrations are displayed for all activin A inhibitors and 
show similar binding abilities within the pM range for activin A, without significant 
differences (Fig. 2B).  
Activin A induced intracellular Smad2 phosphorylation within 15 minutes in 143B 
osteosarcoma cells and upon pre-incubating for 1 hour with FST315, FST315∆HBS-hFc or 
ActR‖A-mFc, Smad2 phosphorylation was evidently inhibited (Fig. 2C). Nonetheless, 48 hour 
long treatment with activin A inhibitors had no effect on cell viability in 143B cells, whereas 
the incubation with ZOL resulted in a dose-related inhibition of cell viability (Fig. 2D). 
Similar data was obtained for K7M2 and SaOS-2 osteosarcoma cell lines (Supplementary Fig. 
S1A, B). Also, the cell migration of 143B was not affected by activin A stimulation (Fig. 2E). 
Collectively, functional binding efficacy for both activin A inhibitors was shown, with 
no direct effects on cell viability or migratory behavior of osteosarcoma cells. Therefore, the 
subsequent in vitro experiments consequently focused on the tumor microenvironment. 
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FST315∆HBS-hFc and ActR‖A-mFc inhibit osteoclast differentiation in vitro 
Because activin A has been reported to induce osteoclastogenesis (15), we investigated 
differentiation of human CD14-positive PBMC towards multinucleated TRAP-positive 
osteoclasts, in the presence or absence of activin A, and FST315, FST315∆HBS-hFc, ActR‖A-
mFc or ZOL. Activin A significantly (P < 0.001) increased the number of multinucleated 
TRAP-positive osteoclasts, whereas FST315, FST315∆HBS-hFc, ActR‖A-mFc reversed activin 
A induced osteoclastogenesis. Furthermore, the combination of ZOL with FST315∆HBS-hFc 
or ActR‖A-mFc additionally inhibited osteoclastogenesis, compared to the control condition 
(i.e., only RANKL and m-CSF) and not only in relation to the activin A-enhanced 
osteoclastogenesis (Fig. 3A, B). We next investigated the involvement of intracellular Smad 
signaling proteins in activin A induced osteoclastogenesis. Activin A induced Smad2 
phosphorylation in a time-dependent manner in pre-osteoclasts (Supplementary Fig. S2) and 
activin A inhibitors impeded the activin A induced Smad phosphorylated within pre-
osteoclasts (Fig. 3C). 
Resorption activity of osteoclasts, on the other side, measured on human collagen coated 
plates, remained unchanged upon activin A stimulation (Fig. 3D) and consequently, FST315, 
FST315∆HBS-hFc, ActR‖A-mFc had no effect on the resorption activity of the osteoclasts. 
Osteoclasts treated with ZOL showed a clear reduction in their collagen resorbing activity.  
In conclusion, activin A induced intracellular Smad2 phosphorylation in pre-
osteoclasts and promoted osteoclastogenesis without affecting osteoclast activity. The activin 
inhibitors with or without ZOL successfully inhibited osteoclastogenesis, but did not affect 
the resorptive activity of osteoclasts. 
Activin A inhibition and ZOL treatment reduces osteosarcoma tumor growth in an 
orthotopic osteosarcoma mouse model 
The impact of FST315∆HBS-hFc, ActR‖A-mFc, and ZOL treatment on the tumor and 
its microenvironment was investigated in a metastatic, orthotopic xenograft osteosarcoma 
mouse model. The highly metastatic human 143B/lacZ/mCherry cells were injected into the 
left tibia of SCID mice (Fig. 4A, left panel). IVIS imaging exposed that all mice developed a 
viable tumor one week after tumor cell injection (TCI) (Fig. 4A, right panel), therefore, 
treatment was started and mice were injected with either FST315∆HBS-hFc, ActR‖A-mFc, 
ZOL or their combination FST315∆HBS-hFc/ZOL, ActR‖A-mFc/ZOL according to the 
previously described treatment schedule. To verify stable serum levels over the treatment 
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period, FST315∆HBS-hFc and ActR‖A-mFc levels measured at day 5, 12 and 19 of the 
treatment revealed stable serum levels throughout the study (Supplementary Fig. S3A, B). 
After three weeks of treatment with activin A inhibitors and ZOL, significantly 
smaller tumors were observed both in the ZOL (-59.8%) treated and the combination treated 
groups FST315∆HBS-hFc/ZOL (-62%), ActR‖A-mFc/ZOL (-83.6%) compared to the control 
group (KPO4) set as 100%. Continuation of treatment considerably inhibited tumor growth in 
all treated groups (P < 0.001). At the end of the treatment, single compound treated mice 
showed significantly smaller tumor volumes compared to that of the KPO4 treated mice 
(FST315∆HBS-hFc -46%, ActR‖A-mFc -36.5%, ZOL -48%, P < 0.001). The single arm 
treatment efficiency was confirmed in a second in vivo study (data not shown). Mice injected 
with the combination of activin A inhibitor and ZOL displayed the smallest tumor volume 
compared to the control group (FST315∆HBS-hFc/ZOL -66.1%, ActR‖A-mFc/ZOL -77.5%). 
Furthermore, the ActRIIA-mFc/ZOL treated mice developed also a significantly smaller 
tumor volume compared to the single compound ActRIIA-mFC- and ZOL- treated mice (-
64%, resp. -56.8%, P < 0.01) (Fig. 4B).  
Taken together, activin A inhibitors alone had a significant impact on osteosarcoma 
tumor development, and the combination with ZOL further reduced tumor growth. 
The effect of activin A inhibition and ZOL treatment on pulmonary metastases 
Mice treated with FST315∆HBS-hFc and ActRIIA-mFc (with and without ZOL co-
treatment) showed a tendency for reduced pulmonary metastatic spread. However, a 
statistically significantly (Plower number of metastases was observed in the ZOL (56 ± 17, P 
< 0.05) and in the ActRIIA-mFC/ZOL (16.14 ± 4.9, P < 0.01) treated groups when compared 
to the KPO4 treated control group (269 ± 100.8) (Fig. 4C, D).  
The combination of activin A inhibition and ZOL treatment leads to tumor necrosis 
Microscopically, the primary tumor tissue consisted of large areas of bone and soft 
tissue effacement associated with infiltrating neoplastic osteosarcoma cells exhibiting 
numerous mitotic figures, prominent anisocytosis, cellular atypia and a variable amount of 
necrosis. This was represented either by multifocal scattered small groups of necrotic 
neoplastic cells or more discrete, confluent areas of necrosis, infiltrated by neutrophils. 
Histological responses to the combination (FST315∆HBS-hFc/ZOL and ActR‖A-
mFc/ZOL) and single ZOL treatments were characterized by higher amounts of necrosis 
within the primary tumors as compared to those observed in osteosarcomas exposed to the 
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activin inhibitors or the vehicle-controls (Fig. 5A, B), indicating a direct cytotoxic effect of 
ZOL.  
Activin A inhibition and ZOL impedes tumor-associated bone remodeling in an 
orthotopic osteosarcoma mouse model 
An intramedullary injection of 143B osteosarcoma cells results mainly in an osteolytic 
phenotype, however, both osteolytic and osteoblastic lesions are present. Representative µCT 
images of the tumor bearing hind limbs show the presence of these osteolytic lesions (Fig. 
6A).  
Following four weeks of treatment, all treated groups demonstrated a significantly 
higher bone volume compared to the vehicle treated KPO4 group (Fig. 6B). Extensive 
pathological bone remodeling in the vehicle treated groups was observed, with a 28% 
reduction of bone volume compared to the initiation of the treatment. The activin A inhibitors, 
ZOL or combination treated groups showed a diminished loss of bone volume (FST315∆HBS-
hFc -21%, ActR‖A-mFc -6%) or even an increase in the ZOL (+21%), FST315∆HBS-hFc/ZOL 
(+18%) and ActR‖A-mFc/ZOL (+21%) treated mice compared to the beginning of their 
treatment (Fig. 6B). 
Histological analysis revealed that in all groups the originally intramedullary tumor 
cells had infiltrated and effaced the cortical bone, expanding into the adjacent soft tissues. 
Localized or multifocal formation of new bone was evident at the periosteal, and, to a lesser 
extent, at the endosteal surface in all compound-treated groups (Fig. 6C), confirming the 
mixed bone phenotype of this model.  
To further confirm the increase of anabolic activity in the tumor-bone 
microenvironment, alkaline phosphatase (ALP) activity, an important indicator for bone 
mineralization (37), was determined in tissue extracts of tumor-bearing hind limbs. ALP 
levels had a propensity for higher activity in the single-compound treated groups 
(FST315∆HBS-hFc, ActR‖A-mFc and ZOL) with a significant increase in activity in the 
combination treated groups FST315∆HBS-hFc/ZOL and ActR‖A-mFc/ZOL (P < 0.01) (Fig. 
6D). Furthermore, comparative gene expression analysis of the primary tumor tissue showed a 
downregulation of the key enzyme for osteoclast function, cathepsin K, in all treated groups 
compared to the KPO4 treated group (Fig. 6E).  
Thus, in line with µCT bone volume analysis and histological observations, we found 
evidence for increased osteoblast activity and decreased osteoclast activity upon activin A 
inhibition or/and ZOL treatment.  
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Treatment induced side effects  
After four weeks of treatment, FST315∆HBS-hFc and FST315∆HBS-hFc/ZOL injected 
mice experienced a significant increase in body weight compared to all other treated mice (P 
< 0.001) (Supplementary Fig. S4A). Furthermore, to investigate whether the activin A-
inhibiting compounds or their combination with ZOL induced additional side effects, overall 
histological analysis of several major organs (heart, liver, spleen, lungs, and kidneys) was 
performed. Additionally, we observed an increase in extramedullary hematopoiesis (EMH) in 
the spleen in ActR‖A-mFc and ActR‖A-mFc/ZOL treated mice (Supplementary Fig. S4B, C). 
 These observations point towards a safe application of both activin A inhibitors and 
ZOL or their combination. 
 
Discussion 
Osteosarcoma is a highly aggressive cancer, associated with destruction of the bone, 
so called tumor-associated bone remodeling (5, 6). Illuminating the function of activin A in 
the interaction between the tumor, the bone and its `vicious cycle`, may give new insights in 
the cancerogenesis of osteosarcoma, as current understanding is still limited.  
In this study, we showed a tumor promoting role of activin A in osteosarcoma, through 
altering the `vicious cycle` between bone remodeling and osteosarcoma tumor growth. The 
effects of the activin A inhibitors FST315∆HBS-hFc, ActR‖A-mFc and the bisphosphonate 
ZOL were compared in vitro on osteosarcoma cells and osteoclasts, and in vivo as a potential 
novel therapeutic approach against osteosarcoma tumor growth in a clinically relevant model. 
Our data supports the importance of activin A in the osteosarcoma microenvironment, as its 
inhibition altered the osteolytic phenotype in our intratibial xenograft osteosarcoma mouse 
model and caused a significant reduction of tumor growth in vivo. Finally, we showed another 
benefit of a combination therapy of activin A inhibitors and ZOL, which exhibited the highest 
treatment efficacy. 
In contrast to the findings of elevated activin A serum levels in breast and prostate 
cancer patients with bone metastases, compared to patients without metastases (19), we could 
not detect statistical differences in activin A serum levels between osteosarcoma patients and 
healthy individuals. Due the rarity of this disease, with an incidence of three to five per 
million per year in the general population (1), the number of patients analyzed was low; 
nevertheless, a higher number of patients may turn the tendency into significance. 
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Both, the engineered FST analogue and a soluble decoy activin type 2 receptor were 
shown to effectively bind activin A and block intracellular phosphorylation of Smad2 in 
osteosarcoma cells in vitro. Nevertheless, the neutralization of activin A did not inhibit cell 
viability or migration in 143B cells, as opposed to a previous study, in which MG63 
osteosarcoma cells were depleted of activin A, leading to decreased cell proliferation and 
migration (18). However, our data confirmed results reporting direct cytotoxicity of ZOL 
(38). Furthermore, activin A has been reported to not only have tumor promoting 
characteristics (12, 13, 19), but also a tumor protective function in different cancers, such as 
liver and pancreatic cancers (39). Likewise, the effects of ZOL on tumor growth are still 
widely debated (26). Nonetheless, the here presented data demonstrate a tumor suppressive 
effect for both, activin A inhibition and ZOL treatment in osteosarcoma. 
Investigation of the microenvironment revealed imbalanced bone remodeling in our 
osteosarcoma mouse model. Osteosarcoma usually has a mixed osteolytic and osteoblastic 
phenotype (3, 6), with osteoclasts and osteoblasts activity playing a substantial part. Activin A 
is a known inducer of osteoclastogenesis, whereas ZOL induces osteoclast apoptosis by 
inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway 
important for osteoclast polarization (15, 27). Our results are in line with these data; activin A 
induced intracellular Smad phosphorylation and osteoclastogenesis, and the inhibition of 
activin A demonstrated inhibition of osteoclast differentiation with both engineered activin A 
inhibitors. These observations were confirmed by our in vivo study showing an inhibition of 
tumor-associated osteolysis, via inhibition of osteoclastogenesis. Although osteoclast 
resorptive activity was not observed in vitro, downregulation of cathepsin K gene expression, 
a key enzyme in osteoclast activity, was observed in vivo in the tumor microenvironment. 
These findings are concurrent with the described association of osteoclasts and increased 
tumor tissue cathepsin K levels, and osteosarcoma aggressiveness (40). 
The effects of activin A and ZOL on osteoblasts are more controversial, both 
osteoblast inhibition (41, 42) and activation (43, 44) were reported. We observed an increase 
in bone volume in the compound treated groups compared to the vehicle treated mice with 
evidence of local periosteal new bone formation. These observations are in agreement with 
the demonstrated increased activity of the ALP enzyme, important for osteoblast activity (37) 
and support reports of an inhibiting role of activin A and an activating role of ZOL on 
osteoblasts (41, 44). Although our model displays an osteolytic phenotype, both osteoblast 
and osteoclast are involved in the tumor associated bone remodeling. We therefore speculate 
that both activin A inhibitors and ZOL treatment would also exhibit anti-tumor effects in 
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predominantly osteoblastic osteosarcoma, which may be supported by a study of Labrinidis et 
al., who demonstrated that ZOL is effective in inhibiting both osteoclastic and osteoblastic 
lesions in osteosarcoma (45). 
Both activin A inhibition and ZOL acid treatments are reported to be well tolerated 
and safe (46). Nevertheless, treatment with the FST analogue led to an increase in 
bodyweight, possibly due to the affinity of FST to other members of the TGFβ superfamily, 
such as BMP and myostatin. Myostatin is known as a major negative regulator of skeletal 
muscle mass (47), therefore inhibition of myostatin by FST315∆HBS-hFc likely led to an 
increase in muscle mass, hence, to an increase in body weight (24). Also an increase in EMH 
was shown in soluble ActRIIA treated mice, which has been previously reported to induce 
erythropoiesis and red blood cell formation and to have beneficial outcome for anemic 
patients (48). The observed side effects are not undesirable, as osteosarcoma is associated 
with anemia and cancer cachexia, those patients might therefore additionally benefit from an 
activin A inhibition treatment (49, 50). 
In conclusion, this study supports the important role of the `vicious cycle` between 
osteosarcoma and its bone microenvironment, with activin A as one of its main components. 
Inhibition of activin A and ZOL treatment led to a disturbed microenvironment for the tumor 
to grow and spread. Therefore, their combination might be a particularly effective treatment 
approach, assumed to work via independent pathways, by inducing a disruption of tumor-
associated bone remodeling and by having direct and systemic anti-cancer effects. The exact 
molecular mechanisms of activin A action in osteosarcoma tumor progression still remain 
unknown and need to be further elucidated. 
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Figure 1. Analysis of activing A circulating levels in osteosarcoma patients and healthy 
individuals. (A) Serum levels of activin A (pg/ml) in osteosarcoma (OS) patients and healthy 
individuals (HI) assessed by ELISA. Results are presented as scatter dot plot. (B) Clinical 
characteristics of osteosarcoma patients and healthy individuals. 
Figure 2. The activin A system and its inhibition. (A) Activin A secretion by different OS cell 
lines determined in the supernatant by ELISA (results are presented as mean ± SEM). (B) 
Binding assay in HEK/CAGA/luc cells with activin A (0.2 nM) and FST315, FST315∆HBS-hFc 
and ActRIIA-mFc. Luciferase activity was measured and IC50s of the three activin A 
inhibitory compounds indicated in pM. (C) Blockage of the activin induced Smad2 
phosphorylation in 143B osteosarcoma cells using FST315 (100 nM), FST315∆HBS-hFc 
(100 nM) or ActRІІA-mFc (100 nM). Protein expression of phosphorylated Smad2 and total 
Smad2 (upper black arrow) and 3 (lower black arrow) and GAPDH was assessed by Western 
blot. (D) Cell viability of 143B/lacZ/mCherry cells treated with either activin A, FST315, 
FST315∆HBS-hFC, ActRIIA-mFC, or ZOL at indicated concentrations (results are presented 
as mean ± SEM). (E) Effects of activin A on 143B/lacZ/mCherry cell migration at indicated 
concentrations (results are presented as mean ± SEM). 
Figure 3. Activin inhibitors impede osteoclast differentiation and induce intracellular Smad 
phosphorylation. (A) CD14-positive PBMC were differentiated into TRAP-positive huge 
(approx. 100-200 µm) multinucleated osteoclasts in the presence of m-CSF (25 ng/ml), 
RANKL (30-60 ng/ml), activin A (0.5 nM) and with either FST315, FST315∆HBS-hFc (100 
nM), ActRІІA-mFc (100 nM) or ZOL (0.5 µM) or their combination FST315∆HBS-hFc and 
ZOL, ActRІІA-mFc and ZOL. Numbers of TRAP-positive huge multinucleated osteoclasts 
were counted after 14 days of culture. Results represent mean ± SEM, *** P < 0.01 all groups 
vs. activin A treated group, ++ P < 0.01, + P < 0.05 combination groups vs. control group (1-
way ANOVA, Dunnett post test). (B) Representative images of TRAP-positive huge 
multinucleated osteoclasts with indicated treatment, scale bar 100 µm. (C) Blockage of the 
activin induced Smad2 phosphorylation in pre-osteoclasts using FST315 (100 nM), 
FST315∆HBS-hFc (100 nM) or ActRІІA-mFc (100 nM). Protein expression of phosphorylated 
Smad2 and total Smad2 (upper black arrow) and 3 (lower black arrow) and GAPDH was 
assessed by Western blot. (D) Osteoclast resorption activity. Differentiated osteoclasts 
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cultured on a europium-conjugated collagen matrix were incubated with activin A (0.5 nM), 
FST315 (100 nM), FST315-hFc∆HBS (100 nM), ActRІІA-mFc (100 nM) or ZOL (50 nM) or 
their combinations. Resorption activity was measured based on the released europium-
conjugated collagen in the supernatant. RFU: relative fluorescence unit. Results are presented 
as mean ± SEM, *** P < 0.01, ** P < 0.01, * P < 0.05 vs. activin A treated group (1-way 
ANOVA, Bonferroni post test). 
Figure 4. Activin inhibition and ZOL treatment reduces tumor growth in the orthotopic 143B 
osteosarcoma mouse model. (A) X-Ray image of the intratibial injection of metastatic 
143/lacZ/mCherry cells into SCID mice (left panel) and a representative picture of a viable 
tumor by IVIS imaging of the mCherry fluorescence (right panel). (B) Intratibial tumor 
growth over time measured with caliper. Mice were treated with vehicle (KPO4), 
FST315∆HBS-hFc, ActRIIA-mFc, ZOL or the combinations FST315∆HBS-hFc and ZOL, or 
ActRIIA-mFc and ZOL. Results represent the mean ± SEM, *** P < 0.001 treated group vs. 
KPO4 group, oo P < 0.01 FST315∆HBS-hFc/ZOL, ActRIIA-mFc/ZOL, ZOL vs. KPO4, ++ P < 
0.01 ActRIIA-mFc /ZOL vs. single compounds ActRIIA-mFc or ZOL (2-way ANOVA, 
Bonferroni post-test). (C) Ex vivo quantification of X-Gal stained 143B/lacZ/mCherry derived 
metastatic nodules on the lung surface. Scatter dot blot with mean ± SEM, ** P < 0.01, * P < 
0.05 treated group vs. KPO4 group. (D) Representative images of whole mounts of lungs of 
SCID mice in indicated treatment groups. Arrows indicate metastases. Scale bar, 200 µm. 
Figure 5. ZOL treatment alone or in combination with activin A inhibition induces higher 
amounts of tumor necrosis in the orthotopic 143B osteosarcoma mouse model. (A) 
Representative images of 143B cell line-derived tumors sections stained for H&E. 
Proportions of tumor necrosis are indicated with arrowheads in the designated treatment 
groups. Scale bar 250 µm. (B) Summary incidence table indicating the average severity 
(scores 0 to 5) of necrosis in the different groups. 
Figure 6. Activin A inhibition and ZOL treatment interrupted tumor associated bone 
remodeling in the intratibial 143B osteosarcoma mouse model. (A) Representative µCT 
images of tumor bearing hind limbs of SCID mice treated with KPO4 (1), FST315∆HBS-hFc 
(2), ActRIIA-mFc (3), ZOL (4) or their combination FST315∆HBS-hFc and ZOL (5), 
ActRIIA-mFc and ZOL (6) after four weeks of treatment. Arrows indicate areas of tumor 
associated osteolysis of the bone. White circle indicates ROI for µCT analysis. (B) Bone 
volume before and after treatment with activin A inhibitors with or without addition of ZOL. 
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Results represent the mean ± SEM, ***P < 0.001, *P < 0.05 treated group vs. KPO4 group; 
2-way ANOVA, Bonferroni post-test. (C) H&E-stained sections indicating periosteal (black 
arrowhead) and endosteal (white arrowhead) new bone formation in all groups, except in the 
vehicle-controls. BM: bone marrow cavity, scale bar 500 µm. (D) Alkaline phosphatase 
activity shown as 4-MU generation per mg of protein in tumor tissue extracts. Results are 
presented as mean ± SEM. **P < 0.01 treated group vs. KPO4 group. (E) Molecular 
investigation of relative gene expression of cathepsin K in tumor tissue extracts. Results 
presented as mean ± SEM, ***P < 0.001, **P < 0.01, *P < 0.05 treated group vs. KPO4 


































































Supplementary Materials & Methods 
Activin induced Smad phosphorylation in pre-osteoclasts 
CD14-positive PBMC were differentiated with m-CSF (25 ng/ml) and RANKL (60 
ng/ml RANKL) for 7 days. On day 7 the emerged pre-osteoclasts were serum starved for 6 
hours and stimulated with or without activin A (2 nM) in a time-dependent manner. Protein 
expression of phosphorylated Smad 2 and total Smad2 (upper black arrow) and 3 (lower black 
arrow) and GAPDH was assessed by Western Blot. 
Quantification of serum levels of FST315∆HBS-hFc and ActRIIA-mFc  
Mice i.p. were injected with FST315∆HBS-hFc or ActRIIA-mFc (10 mg/kg) and serum 
was collected from the tail vein 24 hours later. FST315∆HBS-hFc serum levels were quantified 
using a Human Follistatin ELISA Development Kit (Peprotech, 900-K299) according to the 
manufacturer’s protocol. As an adaptation we used corresponding standard curves using 
purified FST315∆HBS-hFc. ActRIIA-mFc was quantified by ELISA using anti-human activin 
receptor type 2A antibody as a capture antibody (1:150; #NB120-10595, Novus Biologicals, 
cat) and biotinylated anti-human activin receptor type 2A antibody as a detection antibody 
(1:150; # R1265, Leinco Technologies) in combination with HRP-conjugated streptavidin 
(DAKO, P0397). 
Splenic extramedullary hematopoiesis EMH  
EMH was evaluated histologically and scored as follows: 0, absent; 1, minimal (only 
scattered hematopoietic cells, mainly megakaryocytic precursors, observed in the red pulp); 2, 
mild (numerous erythroid and megakaryocytic precursors observed in the red pulp, 
occasionally forming small groups); 3, moderate (numerous erythropoietic cells forming small 
to large clusters in the red pulp); 4, marked (the red pulp is filled with hematopoietic 
precursors, with moderate enlargement of the organ); 5, severe (the red pulp is expanded by 
hematopoietic cells, with distortion of the white pulp and marked enlargement of the organ). 
Supplementary Figure Legends 
Supplementary Figure S1: Cell viability of human SaOS-2 (A) and murine K7M2L2 (B) 
osteosarcoma cells treated with either activin A, FST315, FST315∆HBS-hFC, ActRIIA-mFC, or 
ZOL at indicated concentrations for 48 hours. Cell viability was determined by WST-1 assay 
as described in the Materials and Methods (results as ± SEM). 
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Supplementary Figure S2: Activin A induces time-dependent phosphorylation of Smad2 in 
pre-osteoclasts, which were stimulated with m-CSF (25 ng/ml) and RANKL (60 ng/ml 
RANKL) for 7 days. Upon time dependent stimulation with or without activin A (2 nM) 
protein expression of phosphorylated Smad2, total Smad2 (upper black arrow) and Smad3 
(lower black arrow) and GAPDH was assessed by Western Blot. 
Supplementary Figure S3. FST315∆HBS-hFc and ActR‖A-mFc serum levels in an orthotopic 
143B/SCID osteosarcoma mouse model 24 hours after i.p. injections of either FST315∆HBS-
hFc or ActRIIA-mFc at indicated treatment days.  
Supplementary Figure S4. Activin A treatment increased body weight and extramedullary 
haematopoiesis (EMH) in an orthotopic 143B osteosarcoma mouse model. (A) Statistical 
differences in body weight of all treated groups compared to the KPO4 group (*** P < 0.001, 
**P < 0.01, *P < 0.05 vs. FST315∆HBS-hFc, +++ P < 0.001 vs. FST315∆HBS-hFc/ZOL) (1-way 
ANOVA, Bonferroni post-tests). (B) Splenic EMH was determined on histological paraffin 
sections (H&E stained) and scored for their amount of EMH (score 1 - 5, with 5 having the 
highest grade of EMH) (*** P < 0.001, 1way ANOVA, Bonferroni post-test). (C) Images of 
spleen sections stained for H&E from representative SCID mice treated with KPO4, ActRIIA-
mFc or ActRIIA-mFc/ZOL treated groups. Arrows indicate EMH, represented by 
megakaryocytes and expanded red pulp, scale bar 500 µm. 
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In recent years, there has been the difficulty in finding more effective therapies against 
cancer with less systemic side effects. Therefore Photodynamic Therapy is a novel approach 
for a more tumor selective treatment. 
Photodynamic Therapy (PDT) that makes use of a non-toxic photosensitizer (PS), 
which, upon activation with light of a specific wavelength in the presence of oxygen, 
generates oxygen radicals that elicit a cytotoxic response1. Despite its approval almost twenty 
years ago by the FDA, PDT is nowadays only used to treat a limited number of cancer types 
(skin, bladder) and non-oncological diseases (psoriasis, actinic keratosis)2 . 
The major advantage of the use of PDT is the ability to perform a local treatment, 
which prevents systemic side effects. Moreover, it allows the treatment of tumors at delicate 
sites (e.g. around nerves or blood vessels). Here, an intraoperative application of PDT is 
considered in osteosarcoma (OS), a tumor of the bone, to target primary tumor satellites left 
behind in tumor surrounding tissue after surgical tumor resection. The treatment aims at 
decreasing the number of recurrences and at reducing the risk for (postoperative) metastasis. 
In the present study, we present in vitro PDT procedures to establish the optimal PDT 
settings for effective treatment of widely-used OS cell lines that are used to reproduce the 
human disease in well-established intratibial OS mouse models. The uptake of the PS mTHPC 
was examined with a spectrophotometer and phototoxicity was provoked with laser-light 
excitation of mTHPC at 652 nm to induce cell death assessed with a WST-1 assay and by the 
counting of surviving cells. The established techniques enable us to define the optimal PDT 
settings for future studies in animal models. They are an easy and quick tool for the evaluation 




Today’s state of the art treatment of osteosarcoma (OS), a primary bone tumor, 
encompasses a combination of neo-adjuvant chemotherapy and surgery. This treatment 
regimen revealed an increase in the survival rate of patients with localized disease from 
approximately 20% before the use of chemotherapy, to currently between 60-70%3,4. 
However, in the last two decades, the overall survival of OS patients with local disease has 
plateaued4,5. Moreover, 30-40% of these patients relapse within 3 years after diagnosis and 
83 
 
patients with metastatic disease continue to have a poor survival of 20-30%4,6,7. To improve 
the outcome of these patients, new therapeutic strategies need to be developed. 
Photodynamic Therapy (PDT), a rather novel anticancer therapy, uses light of a 
specific wavelength for excitation of a photosensitizer (PS), which accumulates in the tumor 
cells after its injection into the bloodstream. Laser-light excitation of the PS generates oxygen 
radicals in the presence of oxygen, which induce cytotoxic reaction in tumor cells and cell 
death. Besides this primary mechanism, two additional PDT-evoked biological processes 
contribute to reduced tumor growth: PDT causes vasoconstriction and thrombus formation of 
the tumor microvasculature and, consequently local hypoxia and anoxia inside the tumor, 
leading to tumor infarction. Finally, PDT-injured and dying tumor cells trigger a local 
immune response, a rather unique feature of PDT. This involves the complement system and 
the activation of antigen-presenting dendritic cells8. Thus, conditions are created for the 
presentation of tumor antigens with subsequent activation of lymphoid cells, leading to tumor-
specific immunity. 
So far, PDT has been used to treat several types of soft tissue tumors and 
hyperplasia’s, such as actinic keratosis, Barrett’s esophagus, endobronchial tumors, bladder 
cancer, basal cell carcinomas and palliative treatment of head and neck cancer2. The treatment 
is known to induce local, large-scale necrosis with only little side effects, and thus has the 
potential to selectively eradicate tumor tissue. Despite these advantages, the application of 
PDT remains technically more demanding than the administration of chemotherapeutic drugs. 
In order to achieve maximal efficacy, the PS concentration, light exposure time and total light 
energy transfer need to be optimized. This can be done in in vivo experiments, but, because of 
the relative large number of parameters that need to be optimized, it is more efficient to 
initially determine optimal conditions in vitro. 
In the experiments described below, we tested the in vitro efficacy of PDT using the 
PS 5,10,15,20-tetrakis(meta-hydroxyphenyl)chlorin, abbreviated mTHPC (Figure 1A). 
mTHPC is the active substance in the medicinal product Foscan, which is currently used in 
the clinic for palliative treatment of head and neck cancer. It is one of the most potent PS, 
inducing massive cell damage already at low concentrations, and it was demonstrated to be 
superior to other PS in terms of tissue penetration9,10. Its light absorption spectrum (Figure 
1B) shows two prominent peaks, one at 417 nm and a second at 652 nm, which are used for 
tissue localization of accumulating PS and for PDT induction, respectively. 
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Currently, a liposomal formulation for mTHPC is under development. Here, we 
describe the procedures to quantify the uptake of this liposomal formulation, and to perform 
PDT in two human OS cell lines; the low-metastatic HOS and the high-metastatic 143B cells. 
Some of the data presented here have been reported earlier11. The approach described here 
enables us to study the effect of a metastatic phenotype on PDT efficacy. 143B cells, 
orthotopically injected into the hind limbs of immune-deficient SCID mice cause intratibial 
metastasizing primary tumors, a model closely mimicking the human metastasizing disease. 
Thus, the proposed in vitro experiments are perfectly suitable to assess the optimal PDT 
settings to be later used in in vivo experiments. 
 
Protocol 
1. Comparison of the Uptake of mTHPC in the Respective Low and Highly Metastatic 
HOS and 143B OS Cell Lines 
1. Prepare cell culture medium containing DMEM, Ham F12, and heat inactivated fetal calf 
serum in a ratio 4.5:4.5:1. 
Note: The liposomal formulation of the PS mTHPC was dissolved in water at a final 
concentration of 1.5 mg/ml mTHPC. 
2. Plate 0.2 x 106 HOS and 143B cells/well in 6-well plates (triplicates for each condition) 
and let the cells adhere overnight. 
Note: the number has to be adjusted to individual cell lines. A confluency of 80-90% is 
most suitable at the time of the experiment. 
3. On the following day, incubate the cells with a fixed concentration of mTHPC for different 
time periods (time dependent uptake), or with increasing concentrations of mTHPC 
during a fixed time period (dose dependent uptake). 
4. Incubate the cells with mTHPC for specific time points or concentrations of mTHPC. 
Note: In this study, both the HOS and 143B cell lines were incubated with 0.6 μg/ml 
mTHPC for 0, 2.5, 5, or 10 hr, or with 0, 0.6, 2.5, and 10 μg/ml mTHPC for 5 hr. The 
applied time periods and dosages may vary depending on the cell line that is used. 
5. Remember to always work in the dark or in dimmed light conditions to prevent direct light 
exposure of the cells. 
6. After incubation of the cells at the indicated conditions, aspirate the medium and wash the 




7. After detachment, centrifuge the cells at 400 x g for 5 min, aspirate the medium and 
resuspend the cells in PBS to a final density of 200,000 cells/ml. 
8. Pipette 100 μl of the obtained cell suspension (i.e. 20,000 cells) in a 96-well plate and 
measure the fluorescence of these cells in a fluorescence spectrophotometer. The settings 
for mTHPC fluorescence measurements are: 417 nm for the excitation and 652 nm for the 
emission. 
9. In order to calculate the amount of internalized mTHPC per cell, normalize the relative 
fluorescence unit (RFU) for the cell number and cell volume as follows: 
10. Prepare a standard curve using different concentrations of mTHPC in PBS from 0-4 μg/ml 
(use triplicate measurements). Pipette 100 μl of each dilution in a 96-well plate and 
measure the fluorescence of the wells using the settings described under step 1.6. 
11. Divide the RFU (obtained for 20,000 cells) by the slope of the linear standard curve of 
mTHPC, which gives the concentration of mTHPC (in μg/ml) in the well. 
12. Divide this mTHPC concentration by 10 to get the total amount of mTHPC in one well (in 
μg, representing 100 μl of cell suspension) and divide this value by the volume of 20,000 
cells. 
13. Calculate the volume with the formula for a sphere: (4/3 x π) x r3. Obtain the radius r by 
measuring the diameter of 20 trypsinized cells under a microscope, and dividing this 
value by 2. 
14. Finally, normalize all the values to those obtained for HOS cells after 10 hr of incubation 
(dose dependent uptake) or treated with 10 μg/ml mTHPC (time dependent uptake), 
which were set to 100%.  
 
2. Measurement of Phototoxicity of PS In Vitro 
1. Seed 3,000 cells/well in a 96-well plate (triplicates for each concentration of mTHPC used) 
and let them adhere overnight. Similarly prepare an additional 96-well plate and treat the 
cells as described below, but then put them aside for phase contrast imaging. 
Note: the number has to be adjusted for each individual cell line. A confluency of 50-
60% at the time of the experiment is ideal. 
1. Keep in mind to add the corresponding dark toxicity control of cells for each of the 
mTHPC concentrations. These are cells that will be incubated in the absence or presence 
of selected concentrations of mTHPC, but will not be illuminated. 
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2. On the following day, incubate the cells with different concentrations of mTHPC (0, 
0.0001, 0.001, 0.01, 0.03, 0.075, 0.15, 0.3, 0.6, 1.25, 2.5, 5, and 10 μg/ml) depending on 
the cell lines and keep them in the dark for 5 hr. 
1. Refer to Section 1.3.2 
Note: The incubation time before illumination depends on the cell line and on the PS 
used, therefore it is advisable to test different concentrations and different time points in 
separate experiments. 
3. Following incubation for the indicated time period, wash the cells twice with PBS and add 
new fresh medium without mTHPC. 
4. Illuminate the cells with a 652 nm diode laser, specific for the mTHPC absorption spectrum 
(see Figure 1). 
1. Set the laser to 21.88 mW/cm2 power at a height of 13.5 cm distance from the cells, 
in order to get an energy dose of 5 J/cm2. Illuminate the cells for 230 sec. Do not 
illuminate the dark toxicity control cells (with and without mTHPC). 
Note: Always wear glasses to protect the eyes from the laser light used for excitation 
of the PS. 
5. After illumination, keep the cells in the dark at 37 ºC for 24 hr. Subsequently, add water 
soluble tetrazolium (WST-1) reagent (10 μl/100 μl of medium). 
6. Three hours after the addition of the WST-1 reagent, measure the absorbance of individual 
wells of the 96-well plate at 415 nm. 
7. In order to calculate the percentage of surviving cells, set the mean of the values obtained 
for the non mTHPC treated cells for each condition to 100% (i.e. illuminated, without 
mTHPC and nonilluminated, without mTHPC). 
 
3. Estimation of Cell Number by Cell Counting 
1. Seed 20,000 cells/well in a 24-well plate and let them adhere overnight. 
2. Incubate the cells for 5 hr with mTHPC (0.001, 0.003, 0.15, 0.6, and 1.25 μg/ml) and 
illuminate them as described above. 
3. Collect the medium, wash the cells once with PBS, trypsinize them and collect them by 
centrifugation at 400 x g for 5 min. 
4. After centrifugation, aspirate the medium and resuspend the cells in 200 μl of fresh 
medium. 




Representative Results  
With the here reported techniques, we investigated mTHPC-based PDT in human OS 
cells. First, the time- and dose-dependent uptake of mTHPC was investigated in the low 
metastatic HOS and in the highly metastatic 143B OS cell lines. mTHPC uptake can be 
assessed by measuring the fluorescence of mTHPC with a fluorescence spectrophotometer 
(Figure 2, reproduced with permission from Reidy et al.11). Figure 2 A illustrates the uptake 
of mTHPC in a time-dependent manner. The fluorescence intensity of the cell suspension 
represents the intracellular levels of mTHPC. Figure 2 B illustrates the dose-dependent 
mTHPC uptake in HOS and 143B cells after 5 hr incubation. The uptake in the high-
metastatic cell line 143B tended to be higher than in the low- metastatic parental HOS cell 
line. 
Dark- and photo-toxicity of mTHPC in 143B cells was assessed by determining the 
cell metabolic activity (with a WST-1 assay) and by counting the number of residual cells 
after 5 hr of incubation with mTHPC, subsequent incubation in the dark or treatment with 
laser light for 230 sec and further incubation for 24 hr in the dark.  
Dose-dependent dark-toxicity is shown in Figure 3 (reproduced with permission from 
Reidy et al.11). In Figure 3A, 143B cells were treated with different mTHPC dosages and 
compared to untreated cells. A dose-dependent decrease of cell number and metabolic activity 
was observed. Decreased cell viability was recognized at an mTHPC concentration equal and 
higher than 2.5 µg/ml. Dose-dependent phototoxicity of mTHPC is illustrated in Figure 3B. 
Cells were treated with different mTHPC doses and with subsequent illumination (5 J/cm2).  
A consequential decrease in cell metabolic activity (measured with the WST assay), as well as 
a decrease in cell number was observed. The resulting decrease in cell number after applying 
PDT is visualized in Figure 4.  
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Figure 1: Chemical structure of mTHPC (A) and light absorption spectrum (B). Figures were provided by 
biolitec research GmbH. 
 
Figure 2: Time- and dose-dependent uptake of mTHPC by the human OS cell lines HOS and 143B. A. 
HOS (in grey) and 143B (in black) were seeded in 6-well plates (0.2 x 206 cells per well). After overnight 
culturing, the cells were incubated with 0.6 µg/ml mTHPC for 0, 2.5, 5, 7.5 and 10 hr (A), or for 5 hr with 0, 0.6, 
2.5 and 10 µg/ml mTHPC (B). Fluorescence intensity was determined by measuring the fluorescence of 20.000 
cells at 652 nm upon excitation at 417 nm. Values were normalized to the calculated cell volume and the 
mTHPC uptake of HOS cells at 10 hr (A) or after incubation with 10 µg/ml (B) was set to 100%. Values are the 




Figure 3: Dark and phototoxicity of mTHPC in 143B cells. Cells were seeded and grown overnight before 
treatment. To determine mTHPC dose-dependent dark toxicity, 143B cells were incubated for 5 hr in the dark in 
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the absence or presence of indicated mTHPC concentrations (A). To determine mTHPC dose-dependent photo-
toxicity, 143B cells were incubated with or without mTHPC for 5 hr at indicated concentrations and then 
illuminated with 5 J/cm2 with a power of 21.88 mW/cm2 for 230 sec (B). For measurements of the metabolic 
activity (●) with the WST-1 assay, 143B cells were seeded in 96-well plates at a density of 3.000 cells per well. 
Cell numbers (○) were counted from cells seeded at 20.000 cells per well in 24-well plates. Values are the mean 
± SEM of three independent experiments. Adapted from Reidy, K., et al. (Reidy, Campanile et al. 2012). 
 
Figure 4: Phase- contrast images of 143B cells before and after PDT. Cells were seeded and left to adhere 
overnight as described in the protocol. To visualize dose-dependent, mTHPC mediated light toxicity, 143B cells 
were incubated for 5 hr in the dark with 0, 0.6, 2.5 and 10 µg/ml mTHPC (panels A-D, respectively). The cells 
were then illuminated with 5 J/cm2 light of 652 nm wavelength for 230 seconds, and photographed after 24 hr. 
Scale bar: 100 µm. 
 
Discussion 
To achieve optimal cytotoxicity in response to PDT, it is crucial to choose the right 
laser light settings and incubation times. The here described procedures are consistent and 
efficient to determine PS uptake and to quantify PDT-induced cytotoxicity in vitro. Using the 
specific absorption wavelengths of the PS mTHPC, the cellular PS uptake can be determined 
in a direct manner, and the PS can be activated to generate cytotoxic reactive oxygen species. 
Using this in vitro setup, all parameters such as PS concentration, drug-light interval 
and laser light intensity can be easily adjusted to the characteristics of the PS and the cell lines 
used. Cell count gives a direct read out of surviving attached cells, which together with the 
WST-1 assay (monitoring metabolic activity) gives a good estimate for cell survival. 
However, the presented method can only model the “first hit”, i.e. the cell toxicity of reactive 
oxygen species immediately after activation of the PS. The in vivo observed subsequent 
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vasoconstriction and the activation of the immune system, necessary for full tumor 
eradication, can only be investigated in animals. 
Figure 2 demonstrated a time- and dose-dependent uptake of mTHPC to a higher level 
in the highly metastatic 143B than in its parental low metastatic HOS cell line. Dark-toxicity 
of mTHPC in 143B OS cells was observed after incubation for 5 hr only at high 
concentrations (Figure 3). 143B cells show a high sensitivity to PDT, shown by the mTHPC 
and light-dose dependent phototoxic effect. A phototoxic effect was observed already at an 
mTHPC concentration as low as 0.075 µg/ml, and a half-maximal lethal concentration of 
0.022 ± 0.006 µg/ml was observed (Figure 3).  
Although PDT is minimally invasive and efficient against many tumor types, minor 
side effects can occur when applying the technique in patients (e.g. swelling, erythema). This 
indicates that the PS is not only taken up by tumor cells, as shown here, but also by non-tumor 
cells, causing toxicity after PDT also in these cells. Triesscheijn et al. was able to show an 
increased photosensitivity of tumor cells compared to human fibroblasts. In contrast, human 
microvascular endothelial cells showed a higher uptake of mTHPC than the other tested cell 
lines, which led to a high photosensitivity12. These findings also correlate with PDT 
associated anti-vascular effects, which are frequently observed2.  
The described methods can also be applied for other PS. Incubation time and laser 
light intensity need to be adapted to the characteristics of the PS. Additionally, PDT can also 
be induced in other than OS cells, since only the settings are cell line dependent but not the 
method itself. As additional read-outs, cell death mechanisms can be analyzed, e.g. by 
Western Blot analysis of proteins involved in apoptosis, necrosis or autophagy. Also the 
subcellular localization of PS can be visualized e.g. by confocal laser scanning microscopy. 
The different steps that have been described for PDT in vitro, i.e. incubation of the 
cells with the PS and induction of PDT with laser light, closely resemble the clinical situation. 
Patients receive (i.v. or s.c. applied) the PS, and after a distinct drug light interval, the area of 
interest (e.g. tumor tissue) is illuminated with laser light12. Although not yet applied in OS, its 
potential advantages are obvious; PDT is considered to be particularly attractive for the 
intraoperative treatment of tumor satellites, which frequently grow as primary tumor cell 
clusters close to the main rim of the primary tumor and may initiate a recurrence when missed 
during surgical resection of the primary tumor. Even large osseous tumors may be treated 
with this technique. This has been shown by a promising study in dogs14. In addition, 
eradication of tumor cells that cannot be resected by surgery (e.g. multiple metastases mostly 
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occurring in the lungs), may also represent a possible future application of PDT in patients 
with OS metastatic disease.  
It is important to note that, while performing the experiments, care should be taken 
that all working steps are performed under minimal light exposure after adding the PS to the 
cells, as normal daylight also contains the wavelength necessary to activate mTHPC. 
Likewise, for in vivo application in preclinical models, care needs to be taken to shield the 
animals from direct light after injecting mTHPC. It also needs to be noted that the WST-1 
assay only assesses the metabolic activity of tumor cells, which is an indirect indicator of cell 
death. Therefore, a combination with a total cell count, as presented here, is recommended. 
In conclusion, the combination of the described methods (PS-uptake and PDT-induced 
cell toxicity) provides a fast and cost effective procedure to characterize toxicity properties of 
a PS in vitro. With these in vitro results, the range of the optimal light intensity and the drug 
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Current osteosarcoma therapies cause severe treatment-related side effects and 
chemoresistance, and have low success rates. Consequently, alternative treatment options are 
urgently needed. Photodynamic therapy (PDT) is a minimally invasive, local therapy with 
proven clinical efficacy for a variety of tumor types. PDT is cytotoxic, provokes anti-vascular 
effects and stimulates tumor cell targeting mechanisms of the immune system and, 
consequently, has potential as a novel therapy for osteosarcoma patients. This study 
investigated first the uptake and the dark- and phototoxicity and cytotoxic mechanisms of the 
photosensitizer (PS) 5,10,15,20-tetrakis(meta-hydroxyphenyl) chlorine (mTHPC, Foscan) and 
a liposomal mTHPC formulation (Foslip) in the human 143B and a mouse K7M2-derived cell 
line (K7M2L2) in vitro. Secondly the tumor- and metastasis-suppressive efficacies of mTHPC 
formulations based PDT and associated mechanisms in intratibial, metastasizing osteosarcoma 
mouse models (143B/SCID and syngeneic K7M2L2/BALB/c) derived from the two cell lines 
were studied. The uptake of Foscan and Foslip in vitro was time- and dose-dependent and 
resulted in mTHPC and light dose-dependent phototoxicity associated with apoptosis. In vivo, 
the uptake of both i.v. administered mTHPC formulations was higher in tumor than in healthy 
control tissue. PDT caused significant (Foscan P < 0.05, Foslip P < 0.001) tumor growth 
inhibition in both models, and significant (Foscan P < 0.001, Foslip P < 0.001) immunsystem-
dependent suppression of lung metastasis in the K7M2L2/BALB/c model.  
In conclusion, mTHPC-based PDT is effective in clinically relevant experimental 
osteosarcoma and suppresses lung metastasis in immunocompetent mice with beneficial 
effects of the liposomal mTHPC formulation Foslip. 
  
Introduction 
Osteosarcoma is the most common primary high-grade bone neoplasm and one of the 
deadliest cancer types in children and adolescents1, 2. Since the introduction of new treatment 
protocols in the 70ies, including neoadjuvant and adjuvant chemotherapy, the 5-year survival 
rate (5-ysr) of patients with localized disease increased significantly to approximately 60% but 
plateaued ever since3,4. However, patients with metastatic disease, with lesions most frequently 
developing in the lungs and other bones, continue to have a poor 5-ysr of approximately 30%5. 
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Current therapy combines primary tumor surgery with chemotherapy using high-dose 
methotrexate, cisplatin, and doxorubicin. Unfortunately this multi-drug therapy is associated 
with a variety of severe side effects ranging from gastrointestinal problems, neutropenia, 
cardiac toxicity, neurological dysfunction, second malignant neoplasms to even death6, 7. 
Although multi-agent chemotherapy increased the survival of patients, it plateaued over the 
last three decades, most probably owing to the high tumor heterogeneity of osteosarcoma and 
to chemoresistance8,9. The lack of novel, more effective therapeutic strategies for 
metastasizing osteosarcoma has become an increasing problem. 
During the last four decades, photodynamic therapy (PDT) evolved into a novel 
attractive treatment option for a variety of cancer types10. PDT is a multi-step process making 
use of three components; photosensitizer (PS), light and oxygen11. In a first step of the therapy, 
PS are injected into the blood stream and are taken up by tumor and also by healthy cells. 
Next, tumor-selective PDT is achieved by local illumination of the tumor site with light, which 
activates the light-sensitive PS to a higher energy state and results in the direct or indirect 
transfer of excess energy to neighboring oxygen molecules or tissue molecules, producing cell-
toxic reactive oxygen. Finally, in addition to eliciting direct cytotoxicity, PDT provokes a 
variety of additional beneficial anti-tumor effects such as an acute inflammatory response, 
anti-vascular effects and an activation of the immune system11. PDT has commonly been 
employed for the treatment of solid tumors at superficial anatomical locations, however, its 
application in other tumors at more inaccessible sites has become an aim of clinical 
investigations12, 13. Additionally to the advantage of PDT as a local application, also a systemic 
immune response against tumors have been reported14-16, therefore PDT is potentially not only 
effective against local tumor growth but also against distant metastases.  
PDT has proven clinical value, due to good functional and aesthetic outcomes and 
clinical studies reported it as a good treatment option for patients unsuitable for other 
treatments in head and neck cancers17, 18, but studies investigating potential therapeutic 
applications in osteosarcoma are scarce. In vitro investigations demonstrated strong cytotoxic 
effects of PDT in different osteosarcoma cells lines19-22. Preclinical studies in osteosarcoma 
mouse models showed an inhibition of local tumor growth23, 24, but these studies were either 
performed in subcutaneous osteosarcoma mouse models, which do not reproduce the clinical 
situation, or in immune suppressed mice, where the impact on distant metastases cannot be 
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evaluated. Nevertheless, a preclinical study by Burch et al., who applied PDT in dogs that 
spontaneously developed osteosarcoma, demonstrated substantial tumor necrosis, indicating 
the potential of PDT for effective treatment of osteosarcoma, long-term effects or treatment 
impact on metastases were not reported25. 
One of the most powerful and commonly used PS is 5,10,15,20-tetrakis(meta-
hydroxyphenyl)chlorine (mTHPC), traded under the name Foscan®. In Europe, Foscan has 
been licensed for clinical use in 2001 for the treatment of head and neck cancer and of prostate 
and pancreatic tumors26. In addition to being one of the most potent PS on the market, mTHPC 
has advantageous physical properties compared to other PS, which made it attractive for this 
study. The right shift of the excitation wavelength (652 nm) compared to other clinically 
approved PS such as Photofrin (635 nm) results in deeper tissue penetration of the applied 
laser light than light of shorter wavelength. Although mTHPC is a potent PS, its high 
hydrophobicity restricts the routes of administration. Encapsulation of mTHPC into liposomal 
structures, however, achieved with the formulation Foslip used in the present study, makes it 
water soluble, which potentially increases PDT efficacy27-29.  
In this study, we investigated the uptake and the dark- and phototoxicity of Foscan and 
Foslip in the human 143B and in a derivative (K7M2L2) of the mouse K7M2 osteosarcoma 
cell line. In addition, we studied the efficacies of Foscan- and Foslip-based PDT in a 143B cell 
line-dependent intratibial xenograft osteosarcoma model in SCID mice and in an intratibial 
K7M2L2 cell line-derived model in syngeneic, immune competent BALB/c mice. Tumors in 
both models metastasize to the lung. Thus, these models allowed us to compare the tumor- and 
metastasis-suppressive potential of Foscan-and Foslip-based PDT in the absence and in the 
presence of a functional immune system. The results demonstrated promising tumor and 
immune system-dependent metastasis suppressive effects and anti-vascular activity of the here 
applied PDT in a clinically relevant experimental osteosarcoma model. 
 
Materials and Methods 
Photosensitizer and OS cell lines 
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Foscan and Foslip were kindly provided by Biolitec research GmbH (Jena, Germany). 
Foscan was reconstituted and diluted in ethanol (40% w/w) and propylene glycol (60% w/w). 
Foslip, a liposomal formulation of mTHPC, is a 9:1 mixture of dipalmitoylphosphatidylcholine 
(DPPC) and dipalmitoylphosphatidylglycerol (DPPG; >99% purity). Foslip (freeze-dried 
product) was reconstituted with water to 1.5 mg mTHPC/ml and further diluted in 5% glucose. 
Cells were cultured in DMEM (4.5 g/l glucose)/HamF12 (1:1) medium (Invitrogen, 
Carlsbad, CA), supplemented with 10% heat-inactivated FCS (GIBCO, Basel, Switzerland), at 
37°C in a humidified atmosphere of 5% CO2 air. 
Human 143B osteosarcoma cells were purchased from ECACC (Salisbury, UK) and 
murine K7M2 osteosarcoma cells (CRL-2836) were kindly provided by Dr. Chand Khanna 
(Center for Cancer Research National Institute, Bethesda, MD, USA). Both cell lines were 
transduced with a lacZ reporter gene30. 10 µl PBS/0.05% EDTA containing 3 x 105 of 
K7M2/lacZ cells were intratibially (i.t.) injected into female, 8 week old BALB/c mice as 
described before31. The K7M2L2/lacZ cell line was obtained after two rounds of in vivo 
selection according to Fidler’s method32. Briefly, approximately three weeks after i.t. injection 
of K7M2/lacZ cells, mice developed large primary tumors and were sacrificed. The lungs of 
these mice were collected and metastatic lacZ-expressing cells (K7M2L1/lacZ) were isolated 
by digestion of the lung tissues in a collagenase B solution (Roche, Switzerland) and 
subsequent selection in cell culture medium containing 800 µg/ml G418 (Invitrogen, Life 
Technologies, Carlsbad, CA, USA). Selected K7M2L1/lacZ cells were then reinjected i.t. into 
BALB/c mice in order to obtain K7M2L2/lacZ cells in the same manner.  
Uptake of mTHPC in vitro 
143B/lacZ and K7M2L2/lacZ (referred to as 143B and K7M2L2) cells were seeded in 
six well plates (2000 cells/well for dose dependent uptake and 800 cells/well for time-
dependent uptake) and allowed to adhere overnight. In time-course experiments, cells were 
incubated under tissue culture conditions with Foscan or Foslip equivalent to 0.6 µg/ml 
mTHPC for 0 - 48 h. For dose-dependent uptake, the cells were incubated for 5 h in the dark in 
tissue culture medium containing PS formulations equivalent to 0 - 10µg/ml mTHPC. 
Subsequently, the cells were washed two times with 100 µl PBS before the fluorescence of the 
cells in 100 µl PBS was measured at 652 nm with excitation at 417 nm in a Spectramax 
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Gemini XS plate reader (Molecular Devices, Sunnyvale, CA). Results were obtained as 
relative fluorescence unit (RFU). 
Subcellular localization of mTHPC (Foscan and Foslip) was visualized by confocal 
laser scanning microscopy as previously described19. Cells were stained with Hoechst (Life 
Technologies, Carlsbad, USA). 
Cytotoxicity assay 
143B and K7M2L2 cells (2500 cells / well) were incubated under tissue culture 
conditions for 5 h at different concentrations of Foslip or Foscan (0 - 200 µg/ml mTHPC) and 
left untreated in the dark or illuminated with 652 nm laser light at an energy dose of 1 J/cm2 or 
5 J/cm2 (21.88 mW/cm2) as described previously19. 24 hours later, the cell viability was 
measured with the water-soluble tetrazolium (WST-1) assay (Roche, Basel, Switzerland) 
according to the manufacturer’s protocol. 
Western Blot analysis of apoptosis 
106 143B or K7M2L2 cells were seeded in 6 cm cell culture dishes. After overnight 
adherence, cells were incubated under tissue culture conditions for 5 h with Foscan or Foslip 
(0.6 µg/ml mTHPC) and pre-incubated for 1 h with or without the pan-caspase inhibitor Z-
VAD-FMK (100 µM) or its solvent control (1% DMSO) (BD Pharmingen AG, Allschwil, 
Switzerland). Cells were illuminated with 5 J/cm2 (21.88 mW/cm2) 652 nm laser light or kept 
in the dark, and cell lysates were collected 90 min after illumination as previously described19. 
Protein extracts were analyzed for PARP and cleaved PARP (1:1000, Cell Signaling 
Technology) and GAPDH (1:3000, Santa Cruz Biotechnologies, Texas, USA) as a protein 
loading control as previously described19. 
Intratibial human xenograft and syngeneic osteosarcoma mouse models 
All studies were conducted with the approval of the Veterinary Office Kanton Zurich, 
Switzerland (animal application license 167/2012) and in accordance with the guidelines of the 
Swiss Federal Veterinary Office. Eight-week-old female SCID and BALB/c mice were 
obtained from Charles River Laboratories and kept in the mouse facility for one week of 
adaptation before tumor cell injection. 105 143B/lacZ cells in 10 µl PBS/0.05% EDTA were 
injected i.t. into SCID mice (143B/SCID) (human xenograft mouse model) and 105 
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K7M2L2/lacZ cells in 10 µl PBS/0.05% EDTA i.t. into BALB/c mice (K7M2L2/BALB/c) 
(syngeneic mouse model) as previously described31.  
In vivo uptake of Foscan and Foslip by intratibial tumors 
Upon formation of a tumor (>50 mm3), Foscan or Foslip at doses equivalent to 1.5 
mg/kg mTHPC were administered to the mice (143B/SCID n=10, K7M2L2/BALB/c n=14) 
with a slow (4-6 min) intravenous (i.v.) injection in the tail vein. The mice were then kept in a 
darkened environment for the rest of the experiment. The area of the leg where the tumor was 
localized was shaved and the mTHPC uptake by the tumor was measured with a PDT 
fluorometer (JETI Technische Instrumente GmbH, Jena, Germany) in three different locations 
on the surface of the skin covering the tumor (excitation 405 nm, emission 550-800 nm). 
Background fluorescence of intratibial tumor tissue was measured (integration time 7500 ms) 
in a mouse without PS injection and was subtracted from each measurement resulting in RFU. 
The mean RFU of the tumor in individual PS-injected mice was calculated from all three 
emission peak values detected at 652 nm. Upon sacrifice, tumors were cut longitudinally into 
halves and mTHPC fluorescence was measured inside the tumor tissue in three different 
locations as described above. 
PDT protocol 
In both, the xenograft and the syngeneic osteosarcoma model, the mice were randomly 
assigned to three groups; a control group receiving PS but no illumination (143B/SCID n=10, 
K7M2L2/BALB/c n=15), a group receiving Foscan-based PDT (143B/SCID n=7, 
K7M2L2/BALB/c n=8) and a group that was subjected to Foslip-based PDT (143B/SCID n=7, 
K7M2L2/BALB/c n=9). Foscan or Foslip control mice revealed no difference in any 
experimental analyses and were therefore merged and presented as one control group (data not 
shown). A control group of mice that were only illuminated without PS injection was not 
included in the study to reduce the number of animals. Results of preliminary studies 
conducted at our facility showed that laser light treatment of tumors in the absence of mTHPC 
did not affect tumor development (data not shown). Treatment was started after the formation 
of a tumor (>50 mm3). Both legs were shaved and the mice were injected with Temgesic (i.p., 
0.1 mg/kg). Foscan or Foslip (mTHPC 0.15 mg/kg) were administered by i.v. injection (4-6 
min). The mice were kept in a darkened environment for the rest of the experiment. 24 h after 
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mTHPC injection, the mice were anaesthetized (1-5% isoflurane/O2) and covered with 
aluminum foil and black paper such that only the primary tumor within the left hind leg was 
exposed. The tumors in the PDT groups were illuminated at an energy dose of 10 J/cm2 
(26.817 mW/cm2, 720 sec) with a 652 nm diode laser (Applied Optronics Corp., South 
Plainfield, NJ), equipped with a fiber-based frontal light distributor (Medlight SA, Ecublens, 
Switzerland). Primary tumor growth over time after PDT was monitored by caliper ruler 
measurements at indicated time points and the data are presented as tumor volume fold-
change, comparing the tumor volume in individual mice with the respective volume on the day 
of PDT. 
In the xenograft model (143B/SCID), the mice were sacrificed 14 days after PDT. In 
the syngeneic model (K7M2L2/BALB/c), three mice per group were sacrificed 2 days after 
illumination for histological analyses of tumor tissue; all other mice were sacrificed 10 days 
after PDT.  
Pulmonary metastases 
After sacrifice of the mice in situ, lung perfusion was performed. The lungs were 
dissected and stained with X-gal for lacZ-transduced tumor cells as previously described33. 
Histological analyses 
mTHPC fluorescence in primary tumor tissue: Pieces of primary tumor tissue were 
embedded in mounting medium (Dako, Denmark) and snap frozen in liquid nitrogen. mTHPC 
in 10 µm sections of primary tumor tissue was visualized with an AxioCam MRm camera 
connected to a Zeiss Observer.Z1 inverted microscope (Carl Zeiss MicroImaging GmbH) set 
to 4x magnification and equipped with a fluorescent filter for excitation at 488 nm and 
detection of emission at 600-700 nm. 
Histological stainings: Tumor tissue dissected from the hind-limb at sacrifice was fixed 
in 4% paraformaldehyde and subsequently decalcified in Osteosoft (Merck Millipore, 
Germany). The tumors were trimmed, dehydrated in graded alcohol and embedded in paraffin 
according to standard protocols. Sections of 3-5 µm were mounted on glass slides, 




Tumor necrosis was assessed in the HE-stained sections as follows: Grade 0: no 
necrosis; Grade 1: necrosis below 20%; Grade 2: necrosis higher than 20% but lower than 
40%; Grade 3: necrosis higher than 40% but lower than 60%; Grade 4: necrosis higher than 
60% but lower than 80%; and Grade 5: necrosis higher than 80%. Apoptosis was assessed by 
immunostaining with an antibody to cleaved caspase 3 (Cell Signaling) and tumor 
vascularization by staining with an antibody to CD31 (Santa Cruz Biotechnologies), a cell 
surface marker of endothelial cells34. The number of apoptotic cells present in tumor sections 
was normalized to the total number of cells (apoptotic index35). The apoptotic index was 
determined by counting at least 2500 cells in randomly selected areas of tumor tissue sections 
free of necrotic regions using Visiomorph software (Visiopharm, Denmark). 
Assessment of hind limb blood vessel perfusion 
Mice were anesthetized (1-5% isoflurane) and placed in supine position under the laser 
Doppler perfusion imager (LDI-2, Moor instruments Ltd., UK). A window (5.5 x 2.3 cm), 
comprising both hind limbs, was set and tissue perfusion was measured before PDT and 2, 7 
and 10 days after illumination at a speed of 4 ms/pixel using moorLDI Measurement v6.0 
software (Moor instruments Ltd., UK). The results were analyzed by drawing a region of 
interest (ROI) around areas of tumor growth and the corresponding contralateral region in the 
control limb (normal tissue) using moorLDI Review v6.0. The branching of the epigastric vein 
from the femoral vein and the branching of the caudal femoral vein were used as anatomical 
landmarks to define the ROI. The percent difference in perfusion of tumor compared to normal 
tissue was calculated using the following formula: (1- (fluxnormal / fluxtumor)) x 100. 
Statistical analysis 
In vitro experiments show results of three independent experiments. The results are 
presented as the mean ± standard error of the mean (SEM) if not described otherwise. 
Statistical significance of differences between groups was determined using one-way ANOVA 
with Bonferroni post hoc test. Two-way repeated measures ANOVA with Bonferroni’s post-
test analysis was used to compare mTHPC uptake in vitro and in vivo and treatment efficacy 
(tumor volume, blood vessel perfusion). Statistical analyses were performed using GraphPad 
Prism Version 5.01 software (GraphPad Software, Inc.). A P value below 0.05 was considered 




Cellular uptake of Foscan and Foslip in osteosarcoma cell lines 
In both human 143B and murine K7M2L2 osteosarcoma cells, Foscan and Foslip were 
taken up in a dose- and time-dependent manner (Figs. 1a, b). No differences in cellular uptake 
of Foscan and Foslip were observed at mTHPC concentrations up to 10 µg/ml (Fig 1a). In 
time course experiments, both the 143B and K7M2L2 cell lines exhibited a slightly delayed 
uptake of Foslip compared to Foscan, but the difference was no longer significant after 48 h of 
incubation (Fig. 1b). Confocal laser scanning microscopy of 143B and K7M2L2 cells 
incubated with Foscan and Foslip showed a cytoplasmic localization of mTHPC, but no 
mTHPC in the nucleus (Fig. 1c).  
Cytotoxicity of Foscan and Foslip  
To investigate differences in photo- and dark-toxicity of Foscan and Foslip in 143B 
and K7M2L2 osteosarcoma cells, the cells were incubated with the mTHPC formulations at 
indicated mTHPC concentrations. Foscan exhibited a dose-dependent dark-toxicity in 143B 
and K7M2L2 cells with half-maximal inhibitory doses (IC50) equivalent to 11.74 µg/ml and 
10.4 µg/ml mTHPC, respectively (Fig. 2a). In contrast, Foslip showed no detectable dark-
toxicity in both cell lines. Both, Foscan and Foslip showed mTHPC and a laser light dose-
dependent phototoxicity (Fig 2b). IC50 of Foscan and Foslip in 143B and K7M2L2 cells 
illuminated with 1 J/cm2 or 5 J/cm2 laser light are summarized in Supporting Information 
Table 1. The data shows that the sensitivity of 143B and K7M2L2 cells to Foscan- and Foslip-
based PDT was laser light energy dose-dependent and overall comparable, but, interestingly, 
K7M2L2 cells were slightly more sensitive to Foscan than to Foslip when illuminated with the 
higher energy dose. 
Both Foscan and Foslip-based treatment induced apoptotic cell death, shown by the 
presence of cleaved PARP in extracts of cells subjected to PDT in both 143B (Fig. 2c) and 
K7M2L2 cells (Fig. 2d). In both cell lines, PARP cleavage was suppressed by pretreatment of 
the cells with the pan-caspase inhibitor Z-VAD-FMK prior to PDT, indicating a caspase 
dependent apoptosis pathway, confirmed by the detection of cleaved of caspase 3, 7 and 9 in 
the cell extracts (Supporting Information Figures 1a, b). 
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In vivo uptake of Foslip and Foscan by primary tumors in the xenograft and syngeneic 
osteosarcoma mouse models 
In order to compare the uptake of the mTHPC formulations Foscan and Foslip by 
intratibial primary tumors in the xenograft 143B/SCID and the syngeneic K7M2L2/BALB/c 
osteosarcoma mouse models, the PS formulations were i.v. injected into respective tumor-
bearing mice. The uptake by tumor tissue was monitored in vivo during 48 h and subsequently 
analyzed ex vivo. In both models, the two mTHPC formulations were taken up by the tumor 
tissue in a time dependent manner (Figs. 3a, b). In 143B cell line derived tumors, Foslip was 
taken up significantly more efficiently than Foscan (Fig. 3a), whereas in the K7M2L2 cell line 
derived tumors, the uptake of Foslip compared to Foscan was only significantly higher at 6 h 
after PS administration (Fig. 3b). Ex vivo measurements of mTHPC fluorescence in dissected 
tumor and healthy control leg tissue revealed a significant 2.4- and 2.7-times higher uptake of 
Foscan and Foslip, respectively, in 143B cell line-derived tumors than in the control tissue 
(Fig. 3c). Similarly, in the K7M2L2/BALB/c model, the uptake of Foscan and Foslip by tumor 
tissue was 3.4-and 4-times higher, respectively, than by control tissue (Fig. 3d). Based on 
these ex vivo measurements, the uptake of the two mTHPC formulations by tumor tissue was 
indistinguishable in both osteosarcoma mouse models.  
Fluorescence microscopy of tumor tissue cryosections showed a rather uniform 
distribution of mTHPC fluorescence of Foscan and Foslip in both osteosarcoma mouse 
models. The fluorescence in adjacent muscle tissue was considerably lower than in tumor 
tissue in both tumor models indicating again more efficient uptake of both mTHPC 
formulations by tumor than by healthy tissue (Fig. 3e).  
Anti-tumor efficacy of Foscan or Foslip–based PDT in the xenograft and syngeneic 
osteosarcoma mouse models 
We next assessed the tumor suppressive potential of Foscan- and Foslip-based PDT in 
the two osteosarcoma mouse models. The growth of i.t. tumors derived from 143B cells in 
SCID mice, lacking functional T and B lymphocytes, was significantly inhibited by Foscan 
and Foslip-based PDT and Foslip was slightly more effective than Foscan (Figs. 4a, c). 
Treatment-induced swelling of the tumor leg 3 days after PDT explained the observed 
transient increase in tumor volume. One week after PDT, the tumor volume of Foslip-treated 
mice was only 1.2-times and that of Foscan-treated animals only 1.8-times larger compared to 
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the non-treated control mice, which had a 2.2-times larger tumors compared to before PDT. 
Two weeks after PDT, the tumor volume of the control mice was 4-times larger than before 
treatment start, whereas mice subjected to Foscan and Foslip-based treatment had only a 2.6-
time and 1.8-times, respectively, larger tumors compared to before PDT. The difference in 
tumor volume in both groups of PDT treated mice was not statistically significant. 
In BALB/c mice with an intact immune system, the inhibition of tumor growth by 
Foscan- and Foslip-mediated PDT was even more pronounced than in SCID mice (Figs. 4b, 
d). One week after PDT, the tumors in Foscan- or Foslip-based PDT treated mice was 
indistinguishable and  only 2.4 times larger than before treatment compared to the non-treated 
control mice, which had a 7.8 times larger tumors compared to before PDT. At sacrifice of the 
mice, K7M2L2 cell line-derived tumors in non-treated mice were 14.3-times larger than at the 
beginning of the experiment. The tumors of Foscan/PDT treated animals were still only 2.7 
times larger and those of Foslip/PDT treated mice only 4.7 times larger than before treatment. 
In contrast, two days after laser light illumination of the tumor, a swelling and edema 
formation in the leg where the tumor was localized was observed in all mice subjected to PDT. 
In the PDT study performed in the KM2L2/BALB/c osteosarcoma model, three mice 
per group were sacrificed 48 h after PDT to assess the extent of necrosis and apoptosis in the 
tumor tissue of treated and non-treated animals (Fig. 4e). Overall, the level of necrosis and 
apoptosis was remarkably higher in the PDT-treated than in control tumors, which only 
showed negligible areas of necrosis and cleaved-caspase 3 staining (average necrosis 
histological score: 0.3; average apoptotic index: 0.02%). Despite substantial variability among 
the PDT-treated tumors, Foscan/PDT treated tumors exhibited on average higher necrosis 
(average necrosis histological score: 4.5) and apoptosis (average apoptotic index: 7.5%) scores 
than those subjected to Foslip- based PDT (average necrosis histological score: 2.7; average 
apoptotic index: 2.6%). 
The effect of Foscan and Foslip - based PDT on pulmonary metastases 
To study the impact of the immune system on a putative systemic anti-tumor effect of 
PDT in experimental osteosarcoma, lungs were dissected at sacrifice from 143B/SCID and 
from K7M2L2/BALB/c mice 14 and 10 days after Foscan- or Foslip- based PDT. The number 
of micro- and macrometastases was assessed on the surface of lung whole mounts (Fig. 5). 
PDT with either Foscan or Foslip had no effect on pulmonary metastasis in SCID mice with 
105 
 
intratibial 143B cell line derived tumors (Figs. 5a, b). In contrast, in immunocompetent 
BALB/c mice with intratibial tumors derived from the syngeneic K7M2L2 cell line, Foscan- 
and Foslip-based PDT significantly inhibited the formation of lung micro- and macro-
metastases to a comparable extent (Figs. 5c, d). Thus, in experimental osteosarcoma 
investigated here, PDT requires an intact immune system to provoke a systemic anti-tumor 
effect.  
PDT inhibits tumor perfusion in the syngeneic K7M2L2/BALB/c osteosarcoma mouse 
model 
Blood perfusion of the tumor-bearing and the healthy control hind limb was measured 
prior to and after Foscan- and Foslip-based PDT. The perfusion of the tumor-bearing hind limb 
area before PDT was on average 45.5% higher than in the corresponding hind limb area of the 
control leg in all experimental groups of mice (Fig. 6a). Two days after PDT, a striking 
reduction of tumor perfusion was observed in the Foscan- and Foslip-based PDT treated mice 
(P < 0.001). Remarkably, on experimental day 7, the perfusion in the tumors in both treatment 
groups recovered to levels prior to PDT (Figs. 6.a, b).  
The effects of PDT on tumor vascularization were also investigated by histology and 
immunohistochemistry (Fig. 6c). CD31-immunostained endothelial cells were virtually absent 
in predominantly necrotic PDT-treated tumor areas, indicating disruption of vessels. In non-
necrotic areas of PDT-treated tumors CD31 immunostaining remained detectable, but at 
overall less density than that observed in tumor tissue not subjected to PDT, which showed 
moderate to high numbers of CD31-stained blood vessels.  
Discussion 
This study investigated the potential use of PDT in two clinically relevant models of 
experimental osteosarcoma as a novel approach for effective treatment of metastasizing 
osteosarcoma. The study compared the uptake and dark- and phototoxicity in vitro and the 
efficacy of PDT in vivo with mTHPC in the free formulation Foscan and the liposomal 
formulation Foslip. It took advantage of the orthotopic human 143B and the mouse K7M2L2 
cell line, which form primary intratibial tumors and lung metastases within two weeks after 
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inoculation in immune-defective SCID and in syngeneic immune-competent BALB/c mice, 
respectively. 
The results of the experiments carried out in vitro, demonstrating comparable time- and 
dose-dependent uptake of both Foscan and Foslip in the two osteosarcoma cell lines, are in 
line with the results of previous studies performed in human biliary cancer cell lines36. Despite 
a slightly less efficient uptake of Foslip compared to Foscan by the two osteosarcoma cell lines 
over time, both compounds showed a comparable phototoxicity triggering apoptosis, but 
importantly, Foslip, unlike Foscan, showed hardly any dark-toxicity at the concentrations used 
in the present study. This later finding was again in good agreement with those of the study 
with the human biliary cancer cell lines36 due to the considerable toxicity of 
ethanol/propandiol (data not shown), which is used as a solvent for Foscan in place of water 
for Foslip.  
Crucial for the success of PDT in cancer therapy is a predominant uptake of PS by 
tumor compared to healthy tissue. This was indeed observed in vivo and ex vivo for i.v. 
administered Foscan and Foslip in both osteosarcoma mouse models investigated in the 
present study. These results confirmed a previously reported higher content of both 
formulations in tumor than in adjacent muscle tissue28, 37. Two mechanisms have been 
proposed to account for these findings. Both Foscan and Foslip bind to serum proteins such as 
albumin and high and low density lipoproteins (HDL/LDL) that facilitate their cellular uptake, 
which is apparently accelerated in fast proliferating cancer cells that are dependent on a high 
transport rate of lipoproteins38, 39. Increased PS uptake in tumor compared to healthy tissue is 
also caused by anatomical changes within the tumor, characterized by an enhanced leakiness 
of tumor blood vessels, and a slower lymphatic drainage, causing an accumulation of the PS in 
the tumor tissue, called the enhanced permeability and retention (EPR) effect40, 41.  
The results of the here reported experiments, analyzing the time-dependent uptake of 
mTHPC by tumor tissue, showed a significantly higher uptake of Foslip than of Foscan at all 
time points investigated in the 143B/SCID model and at 6 hours after mTHPC administration 
in the K7M2L2/BALB/c model. These observations are consistent with the findings of De 
Visscher et al., who reported a significantly higher increase of Foslip than of Foscan 
fluorescence intensities upon i.v. PS administration in a subcutaneous adenocarcinoma mouse 
model42. Thus, Foslip appears to enhance the bioavailability of mTHPC in tumor tissue. Along 
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these lines, it is assumed that liposomal carriers enhance the EPR effect due to the formation 
of larger macromolecules upon binding to plasma proteins43, 44.  
Already 20 years ago, pioneering studies performed by Korbelik et al., demonstrated 
the importance of an intact immune system for the efficacy of PDT45. A comparison of the 
efficacy of PDT in immune-compromised and in immune-competent mice in the present study 
confirmed the important findings of Korbelik et al. PDT with Foscan and Foslip only 
transiently inhibited the growth of intratibial 143B cell line-derived tumors in SCID mice and 
had no significant effect on lung metastasis. In immune-competent BALB/c mice, however, 
the growth of K7M2L2 cell line-derived primary tumors was persistently suppressed and the 
formation of both micro- and macro-metastases significantly inhibited by PDT with the two PS 
formulations. Altogether, the findings confirmed the important impact of an intact immune 
system on PDT efficacy reported by Korbelik et al. and may need to be further explored. 
Analysis of tumor vascularization and perfusion in the K7M2L2/BALB/c model 
demonstrated a pronounced, however mainly transient inhibitory effect of the here applied 
PDT on the blood supply of the primary tumor. These observations are consistent with 
reported toxic and inhibitory effects of PDT on endothelial cells and platelet formation, 
respectively, leading to vascular leakage and collapse11, 46, 47. Since angiogenesis plays a major 
role in tumor progression, targeting tumor vascularization by PDT has an additional beneficial 
tumor suppressive effect48.  
Interestingly, in the 143B/SCID model, Foslip was more effective than Foscan, 
presumably due to the observed higher amounts of mTHPC accumulating in tumors of Foslip 
than of Foscan-treated mice and to previously reported higher concentrations of monomeric 
mTHPC achieved with liposomal formulations, as hydrophobic PS (Foscan) strongly 
aggregate in aqueous media weakening their photosensitizing efficacy38, 43.  
Differences in efficacy between Foscan- based and Foslip-based PDT was only 
observed in the xenograft mouse model, further studies are needed to evaluate additional 
treatment setting for both mTHPC formulations. The relation of the liposomal carrier system 
and their pharmacokinetics to PDT efficacy is still under debate. Previous studies in preclinical 
mammary carcinoma and fibrosarcoma models showed no correlation of the PS concentrations 
in the tumor and PDT efficacy, indicating a correlation between PDT efficacy and PS 
concentration in endothelial cells 49, 50. On the other side, d`Hallewin et al. demonstrated the 
108 
 
importance of Foslip accumulation in the tumor tissue, giving rise to the highest amount of 
tumor necrosis with the highest PS concentration in the tumor51. Our results provide a first 
hint that in osteosarcoma, Foslip is equally potent compared to Foscan, but to truly compare 
the PDT efficiency between both compounds, further studies are needed. 
In summary, this study demonstrates potent primary tumor and, even more important in 
osteosarcoma, lung metastasis suppressive action of mTHPC-mediated PDT in animals in two 
clinically relevant intratibial mouse models of osteosarcoma with an intact immune system. 
Considering that PDT has a relatively low systemic toxicity, repetitive application is possible. 
Consequently, it is an interesting novel option for the treatment of osteosarcoma, even in 
combination with current standards of care neoadjuvant chemotherapy. 
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Figure 1. Dose- and time-dependent uptake of Foscan and Foslip in 143B and K7M2L2 
osteosarcoma cells. Cells were incubated in the dark with either Foscan (■) or Foslip (●) with 
the indicated concentrations of mTHPC for 5 h (a) or with 0.6 µg/ml mTHPC for indicated 
time periods (b). After washing with PBS, mTHPC fluorescence intensity (indicated as 
relative fluorescence unit (RFU)) was measured at 652 nm after excitation at 452 nm. * P < 
0.05, ** P < 0.01, Foscan compared with Foslip. (c) Representative images of cellular 
localization of mTHPC by confocal laser scanning microscopy in 143B and K7M2L2 cells. 
mTHPC fluorescence appeared red and nuclei stained with Hoechst appeared blue, 20-fold 
magnification, scale bar, 100 µm.  
Figure 2. Dark- and photo-toxicity of Foscan and Foslip in 143B and K7M2L2 osteosarcoma 
cells, and PDT induced apoptosis. (a) Dose-dependent dark-toxicity. 143B (left panel) and 
K7M2L2 (right panel) cells (2000 cells/ well) were incubated in the dark in the absence 
(control, set to 100%) or in the presence of indicated concentrations of mTHPC (Foscan ■, 
Foslip ●) for 5 h. Cell viability was assessed in a WST-1 assay. (b) Dose-dependent photo-
toxicity. 143B (left panel) and K7M2L2 (right panel) cells (800 cells/ well) were incubated in 
the dark in the absence (control, set to 100%) or in the presence of indicated concentrations of 
mTHPC for 5 h and subsequently illuminated with doses of 1 J/cm2 (Foscan □, Foslip ○) or 5 
J/cm2 (Foscan ■, Foslip ●) of 652 nm laser light. The cell viability was determined as in (a). 
(c) Inhibition of PDT-induced PARP cleavage by Z-VAD-FMK in 143B cells. The cells were 
pre-incubated in the absence or presence of Z-VAD-FMK or DMSO and treated with Foscan 
(left panel) or Foslip (right panel) at indicated concentrations and subjected to PDT as 
described in Materials and Methods. (d) Inhibition of PARP cleavage by Z-VAD-FMK in 
K7M2L2 subjected to PDT as described in (c). GAPDH was used as protein loading controls. 
 Figure 3. Uptake of Foscan or Foslip by intratibial human xenograft 143B cell line-derived 
tumors in SCID mice and by intratibial mouse K7M2L2 cell line-derived tumors in syngeneic 
BALB/c mice. SCID and BALB/c mice with tumors > 50 mm3 were i.v. injected with Foscan 
or Foslip equivalent to 1.5 mg/kg mTHPC and the uptake of the mTHPC formulations by 
tumor tissue over time was assessed with a fluorimeter as described in Materials and Methods. 
Fluorescence measurements were corrected for background fluorescence of tumor tissue, 
assessed in non-injected mice (no mTHPC). (a) Mean (± SEM) uptake (indicated as RFU) in 
vivo of listed mTHPC formulations at indicated time points by 143B cell line-derived tumors 
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(n=10) and (b) by K7M2L2 cell line-derived tumors (n=14). .* P < 0.05, ** P < 0.01, *** P < 
0.001 Foslip compared to Foscan (2-way ANOVA, Bonferroni post-test). (c) Mean (± SEM) 
uptake (RFU) of indicated formulations assessed ex vivo 48 h after PS injection in 143B cell 
line-derived tumors (n=10) and in corresponding healthy leg tissue (control leg) and (d) in 
K7M2L2 cell line-derived tumors (n=14) and in control legs. * P < 0.05, ** P < 0.01, *** P < 
0.001 tumor leg compared to control leg, n.s.: not significant (1-way ANOVA, Bonferroni 
post-test). (e) Ex vivo visualization of mTHPC (red) in cryosections (fluorescence filter 
~620nm) of indicated primary tumor tissue of Foscan- or Foslip- and non-injected mice. 
White arrows point to muscle tissue. Scale bar, 200 µm. 
Figure 4. Inhibition of osteosarcoma primary tumor growth in two intratibial osteosarcoma 
mouse models in response to Foscan or Foslip based PDT (i.v. PS administration equivalent 
to 0.15 mg/kg mTHPC, 20 J/cm2). (a) Mean (± SEM) fold change in size of intratibial human 
143B cell line-derived tumors in SCID mice (10 control, 7 Foscan and 7 Foslip-treated mice) 
and (b) of intratibial mouse K7M2L2 cell line-derived tumors in syngeneic BALB/c mice (15 
control, 8 Foscan and 9 Foslip-treated mice) assessed on indicated days after PDT by caliper 
measurements and normalized to the tumor size in individual mice measured on the day of 
PDT treatment. The control groups of mice received PS but no laser light illumination 
(control). (c) Photographs taken on indicated days from representative SCID mice with 
intratibial 143B cell line-derived tumors and (d) from representative BALB/c mice with 
intratibial K7M2L2 cell line-derived tumors in the right hind limb. The mice were treated as 
indicated. + P < 0.05, +++ P < 0.001 Foscan PDT vs. control, *** P < 0.001 Foslip PDT vs. 
control. (e) Representative images of 10 µm sections of K7M2L2 cell line-derived intratibial 
tumors collected two days after PDT from BALB/c mice treated as indicated. The sections 
were stained with hematoxylin and eosin (HE) for histological examination and 
immunostained for cleaved caspase 3 (CC3) indicating apoptotic tissue areas. N: necrosis, V: 
viable tumor, black arrows indicate apoptotic cells. Scale bars: top panel, 1 mm, bottom panel, 
100 µm.  
Figure 5. Effect of intratibial primary tumor treatment by PDT on pulmonary metastases in 
the human xenograft 143B/SCID and the syngeneic K7M2L2/BALB/c osteosarcoma mouse 
models. (a) Ex vivo quantification of X-Gal stained 143B/LacZ cell-derived metastases on the 
surface of whole mounts of lungs collected from SCID mice at sacrifice 14 days after PDT. 
The data indicate the numbers of pulmonary micrometastases per lung (diameter < 0.1mm, 
left panel) and of pulmonary macrometastases (diameter > 0.1mm, right panel) in individual 
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mice of the indicated treatment groups. The numbers of lungs analyzed in the different 
experimental groups are shown by the number of corresponding symbols in the figures. (b) 
Representative images of blue X-gal–stained metastatic nodules on whole mounts of lungs of 
SCID mice analyzed as described in (a). Scale bar, 200 µm. (c) Ex vivo quantification of X-
Gal stained K7M2L2/LacZ cells on whole mounts of lungs collected from BALB/c mice at 
sacrifice 10 days after treatment. The mice of the indicated treatment groups were analyzed 
and the data are presented as described in (a), ** P < 0.01, *** P < 0.001, PDT-treated groups 
vs. control, n.s.: not significant. (d) Representative images of blue X-Gal–stained metastases 
on whole mounts of lungs of BALB/c mice analyzed as described in (c). Scale bar, 200 µm. 
Black arrows point to pulmonary micrometastases and the open black arrow to a 
macrometastasis. 
Figure 6. Effect of primary tumor treatment by Foscan or Foslip-based PDT on hind limb 
blood flow in the syngeneic K7M2L2/BALB/c osteosarcoma mouse model. (a) Blood flow in 
control and tumor-bearing hind limbs was measured with a laser Doppler perfusion imager in 
the regions of interest (ROI) (as indicated in b), and the data collected from 12 mice per 
treatment group on indicated experimental days are presented as percent change in perfusion 
(flux) of tumor compared to normal tissue, *** P < 0.001 PDT- treated vs. control. (b) Images 
of hind limb perfusion taken on indicated experimental days from representative mice of the 
different experimental groups. White circles indicate ROI for laser Doppler image analysis. 
(c) Representative images of CD31 immunostained 10 µm sections of intratibial tumors 
collected from representative mice of the indicated treatment groups on day 2 after PDT. 
Black arrows point to CD31-stained endothelial cells, scale bar 250 µm. 
Supporting Information Table 1. Half-maximal cell viability inhibitory doses (IC50) of 
Foscan and Foslip in 143B and K7M2L2 osteosarcoma cells subjected to PDT with light 
energy doses of 1J/cm2 or 5 J/cm2 as indicated. 
Supporting Information Figure 1. 106 143B (a) or K7M2L2 (b) cells were incubated for 5 h 
with Foscan or Foslip at indicated mTHPC concentrations. Osteosarcoma cells were 
illuminated (as described in Material and Methods) or kept in the dark. Cell lysates were 
analyzed with antibodies to cleaved caspase 3 (1:1000, Cell Signaling Technology, Danvers, 
MA), to cleaved caspase 7 (1:1000, Cell Signaling Technology), to caspase 9 and cleaved 
caspase 9 (1:1000, Cell Signaling Technology), to PARP and cleaved PARP (1:1000, Cell 
Signaling Technology), to GAPDH (1:3000 Santa Cruz Biotechnologies) and to Actin 
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6.4 Additional Study: lipid nanoparticles as novel carriers for 
mTHPC 
 Results 6.4.1
In addition to Foscan and the liposomal formulation of mTHPC, Foslip, also lipid 
nanoparticles (LNP) loaded with mTHPC were investigated and the data are presented here. 
LNP (or lipidots®) consist of a lipid core loaded with mTHPC, surrounded by phospholipids 
and pegylated surfactants. LNP were tested for their PDT efficacy in vitro and in vivo in the 
human 143B OS cell line and in a 143B cell line-derived intratibial metastasizing OS model 
in SCID mice (143B/SCID), respectively. 
Cellular uptake and cytotoxicity of Foscan and LNP (mTHPC) 
The uptake of mTHPC in the Foscan formulation and its lipid nanoparticle formulation 
LNP was determined in the 143B cell line. A significantly higher time-dependent uptake was 
observed for Foscan than for LNP (mTHPC) at 24 h and 48 h of incubation. Conversely after 
72 h of incubation, uptake of the LNP was significantly higher than that of Foscan (Fig. A1 
A). 
Dark-toxicity, examined in 143B cells was not observed at the indicated 
concentrations up to 20 µg/ml of mTHPC. Photo-toxicity, however, occurred in the 143B cell 






Figure A1: Cellular uptake and cytotoxicity of mTHPC containing lipid nanoparticles (LNP). (A) 
Time dependent uptake of Foscan and LNP (mTHPC) by 143B OS cells. Cells were incubated in the dark with 
either Foscan (blue) or LNP (violet) with 2.5 µg/ml mTHPC for indicated time periods. After replacing the 
medium, mTHPC fluorescence intensity was measured at 652 nm after excitation at 417 nm. ** P < 0.01, *** P 
< 0.001 Foscan treated vs. LNP (mTHPC) treated. (B) Photo- and dark-toxicity of LNP (mTHPC) in 143B cells. 
Cells were incubated in the dark in the absence (control) or in the presence of LNP (mTHPC) at indicated 
concentrations of mTHPC for 5 h and illuminated with laser light of 652 nm wavelength at doses of 5 J/cm2. To 
determine dark-toxicity, the cells were kept in the dark until harvested. Metabolic activity was assessed after 24 
h. Results are the mean ± SEM of three independent experiments. 
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LNP uptake in vivo in the 143B/SCID model 
Uptake of the mTHPC formulations Foscan, Foslip and LNP (mTHPC) was 
investigated in an orthotopic 143B osteosarcoma mouse model and the data are illustrated in 
Figure A2. All mTHPC formulations were taken up by the tumor tissue in a time-dependent 
manner. Since the results of the Foslip uptake were already evaluated and discussed in the 
third manuscript (Chapter 6.3), the focus in this section of the thesis is on the uptake of LNP 
in relation to Foscan and Foslip. 
Although the injection of Foslip resulted in the highest mTHPC signal in the tumor 
bearing leg, the injection of LNP with mTHPC in the lipid core revealed also a statistically 
significant higher mTHPC uptake than that observed with `naked` mTHPC in the Foscan 
formulation (Fig. A2 A). Ex vivo measurements of mTHPC fluorescence in tumor and control 
tissue in mice that received LNP loaded with mTHPC showed a 2.5-fold higher accumulation 
of mTHPC in the tumor tissue than in corresponding healthy control tissue dissected form 
contralateral hind limb (Fig. A2 B).  
In order to investigate in more detail the in vivo uptake and tissue distribution of LNP 
in the 143B/SCID model, LNP were loaded with a near-infrared fluorescent dye (NIR) and 
their distribution in tumor and healthy tissue analyzed in 3D in a fluorescence molecular 
tomograph (FMT). Results are presented as the concentration of mTHPC (pmol) within the 
tumor tissue and in the corresponding ROI in the control leg at the indicated time points (Fig. 
A2 C). The results confirmed the ex vivo measured significant difference in LNP (mTHPC) 
uptake between the tumor-bearing and the healthy contralateral leg. A significant higher 
uptake in the tumor than in the control leg was observed during the entire experimental period 
of 48 h. Figure A2 D shows representative FMT pictures of the LNP (NIR) uptake in the ROI 






















Figure A2: Uptake of Foscan, Foslip and LNP in the 143B/SCID model. Mice with intratibial 
tumors > 50 mm3 were injected with or without indicated photosensitizer formulations equivalent to 1.5 mg/kg 
mTHPC. (A) In vivo photosensitizer uptake in the 143B tumor leg was assessed with a fluorimeter over time as 
described in Materials and Methods. (B) mTHPC fluorescence 48 h after injection was measured ex vivo within 
the primary tumor tissue with the fluorimeter. * P < 0.05, ** P < 0.01, *** P < 0.001 Foslip vs. Foscan, + P < 
0.05 LNP vs. Foscan, ^ P < 0.05 Foslip vs. LNP (mTHPC). (C) In vivo uptake of LNP containing a near-infrared 
fluorescent dye (LNP (NIR)) measured with a FMT (FMT 2500, Perkin Elmer), *** < 0.001 tumor leg vs. 
control leg. Results are the mean ± SEM of three independent experiments. 
Tumor-suppressive efficacy of LNP (mTHPC) based photodynamic therapy in the 
143B/SCID model 
The change in tumor volume in mice subjected to LNP (mTHPC) mediated PDT was 
not significantly different compared to that in control animals (Fig A3 A, B). There was 
however a tendency for larger tumors in treated than in control mice two weeks after 
illumination; at that time point, the treated mice had on average a 9.4-fold larger volume than 
on the day of treatment whereas the tumors in the control group were only 4.1-fold larger. No 
difference in the fold change of tumor volume was observed between the Foscan and LNP 
(mTHPC) injected control (no illumination) mice (Fig. A3, A, B). It is important to note that 
1 out of 6 control mice (17%) compared to 4 out of 8 LNP (mTHPC)-based PDT treated mice 
had to be sacrificed before the end the treatment study. 
The counting of pulmonary metastases on the lung surface revealed no significant 
 difference in the number of macrometastases in treated and non-treated mice (Fig A4 A), but 
a significant increase in the number of micrometastases in the PDT treated compared to non-
treated mice (Fig. A4 B).  
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Figure A3: Osteosarcoma primary tumor growth in the 143B/SCID model upon LNP (mTHPC) 
based PDT (0.15 mg/kg mTHPC, 20 J/cm
2
). (A) Intratibial tumor growth in 143B/SCID mice on the day of 
laser light illumination and 3, 7 and 14 days after illumination. Tumor volume was measured with a caliper ruler 
and is shown as the fold change compared to the tumor volume measured on the day of laser light illumination. 
The control group received i.v. Foscan and LNP (mTHPC) but no laser light illumination. (B) Representative 
photographs of the hind limbs of control and PDT treated 143B/SCID mice. Results are the mean ± SEM of 











Figure A4: Effect of LNP (mTHPC) - based PDT on pulmonary metastases in the 
143B/SCID model. (A, B) Ex vivo quantification of X-Gal stained 143B/LacZ cells on the surface of the entire 
lung. (A) Number of pulmonary macrometastases (diameter > 0.1mm) (left panel) and representative images of 
blue X-gal–stained macrometastases on the lung surface (right panel). (B) Number of pulmonary 
micrometastases (diameter < 0.1mm) (left panel) and representative images of blue X-Gal–stained 
micrometastases in the lungs observed at 4-fold magnification under the microscope, scale bar, 200 µm (right 
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This study shows the in vitro and in vivo efficacy of PDT with mTHPC incorporated 
into LNP. The in vitro results demonstrated an effective uptake and cytotoxicity in 
osteosarcoma cell lines. All components of the LNP are biocompatible, biodegradable and are 
FDA approved, which makes them an interesting novel carrier for mTHPC (Delmas, Couffin 
et al. 2011). Navarro et al., already demonstrated that the encapsulation of mTHPC into solid 
LNP does not affect the generation of oxygen radical and the LNP showed good colloidal 
stability and increased significantly the solubility of the photosensitizer compared to the 
hydrophobic Foscan formulation of mTHPC (Navarro, Creusat et al. 2014).  
Cellular uptake of LNP (mTHPC) was shown to be slightly delayed when compared to 
Foscan in the first hours, probably due to a delay in the release from the inner oil core of the 
LNP. The LNP provoked also striking cytotoxicity at low mTHPC doses, which is 
comparable to previously published data (Reidy, Campanile et al. 2012) and results shown in 
the third manuscript (Chapter 6.3, Results). Similar to Foslip, a reduction in dark-toxicity was 
also demonstrated and the findings are in line with previous observations in breast cancer 
cells (Navarro, Creusat et al. 2014). 
Based on these promising in vitro results, the LNP were further tested in an intratibial 
xenograft osteosarcoma mouse model, which largely reproduces the clinical situation in 
patients, including metastatic spread to the lungs. Comparable to the already described data in 
the results part of the third manuscript (Chapter 6.3, Results), the LNP showed an efficient 
uptake by the tumor tissue compared to healthy tissue. These data were also confirmed by 
FMT imaging using LNP that contained a near-infrared fluorescent dye, which allowed not 
only an epifluorescence measurement but a three-dimensional measurement of the mTHPC 
uptake in the tumor tissue (Ntziachristos, Tung et al. 2002; Jacquart, Keramidas et al. 2013). 
The LNP mediated uptake of mTHPC in the tumor tissue was higher than that of Foscan. 
Likely explanations for the higher LNP uptake are an enhanced permeability and retention 
(ERP) effect (Fang, Nakamura et al. 2011), but also the PEGylated shell of the LNP, which 
reduces the recognition by the mononuclear phagocyte system and thereby enhances the half-
life in the circulation (Caliceti and Veronese 2003; Jokerst, Lobovkina et al. 2011; Perry, 
Reuter et al. 2012). 
Despite the proof of uptake and cytotoxic activity in vitro and LNP uptake by primary 
tumor tissue in vivo, the present study showed no effect of the LNP (mTHPC)-based PDT in 
the osteosarcoma mouse model. Both, primary tumor growth and metastatic spread were not 
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inhibited, and there was even a tendency for more aggressive tumor progression and 
metastasis in treated than in non-treated mice. The components of mTHPC loaded LNP 
unlikely induced tumor progression because tumors in mice that received LNP (mTHPC) or 
Foscan without illumination showed no difference in progression. Therefore, further studies 
are needed to investigate unknown processes that lead to the failure of LNP (mTHPC)-based 
PDT in the osteosarcoma mouse used in this study.  
 Material and Methods 6.4.3
Lipid nanoparticles 
Lipid nanoparticles (LNP) also called Lipidots® were prepared as reported (Delmas, 
Couffin et al. 2011). LNP consist of a lipid core (soybean oil and suppocire NB), which is 
surrounded by a lecithin layer (lipoid s75) decorated with pegylated surfactants and are kept 
in suspension in an aqueous buffer such as PBS. 50 nm sized LNP were designed due to their 
suitable weight ratios of core/shell excipients. The LNP were then loaded with mTHPC PS 
accodring to Navarro et al. (Navarro, Creusat et al. 2014) aiming at a content of 920  
molecules of mTHPC per LNP. 
For in vivo fluorescence imaging, the lipid core of LNP was loaded with the near-
infrared fluorescent dye IRO-780-Oleyl (LNP-NIR) as previously described (Jacquart, 
Keramidas et al. 2013). 
In vitro photosensitizer uptake 
143B cells were seeded in six well plates (800 cells / well) and allowed to adhere 
overnight. Either Foscan or LNP (mTHPC) were added (25 µl/well; 0.6 µg/ml mTHPC) in a 
time dependent manner (0 - 48 h) and the cells kept in the dark. PS uptake was stopped by 
washing the cells twice with 100 µl PBS. The fluorescence of the cells in 100 µl PBS was 
measured at 652 nm after excitation at 417 nm with a Spectramax Gemini XS plate reader 
(Molecular Devices, Sunnyvale, CA).  
Dark- and phototoxicity of LNP (mTHPC) 
143B were incubated with indicated concentrations of LNP, equivalent to 0 - 200 
µg/ml mTHPC, for 5 h, and subsequently illuminated with an energy dose of 5 J/cm2 at 652 
nm (21.88 mW/cm2, 230sec) as described previously (Reidy, Campanile et al. 2012). The 
remaining cell metabolic activity was then measured with the water-soluble tetrazolium 
(WST-1) assay according to the manufacturer’s protocol. 
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Intratibial human xenograft OS mouse model 
All studies were conducted with the approval of the Veterinary Office Kanton Zurich, 
Switzerland (animal application license 167/2012), in accordance with the guidelines of the 
Swiss Federal Veterinary Office. A highly metastatic 143B cell line derived intratibial 
xenograft model in SCID mice (143B/SCID) was used as described in previously (Sabile, Arlt 
et al. 2011). 
In vivo uptake of different mTHPC formulations 
Upon formation of a tumor larger than > 50 mm3, Foscan (10 mice), Foslip (10 mice) or 
LNP (mTHPC) (11 mice) (mTHPC 1.5 mg/kg) was i.v. administered. mTHPC uptake was 
measured using a PDT fluorometer as described in the Materials and Methods of the third 
manuscript (Chapter 6.3). 
LNP containing the near-infrared fluorescent dye LNP (NIR) were used for 3D 
biodistribution imaging of LNP in a fluorescence molecular tomograph (FMT2500, Perkin 
Elmer Inc., Boston, USA). The FMT was calibrated for the LNP (NIR), following the 
guidelines of the TrueQuant™ Operator Manual 2011. 
SCID mice were i.v. injected with 200µl of LNP (10 µM NIR) and imaged 0, 1, 6, 12, 
24 and 48 h after injection. Before imaging, mice were shaved and anesthetized with 1-5% 
isoflurane. The anesthetized mice were placed in the imaging cassette to restrain the mouse 
and adjust the position. The imaging cassette with the mouse was inserted into the heated 
docking system in the FMT machine. A trans-illumination laser using an excitation filter at 
790 nm and an emission filter above 805 nm were used for signal detection. The fluorescence 
data were reconstructed using the TrueQuant 3.1 PerkinElmer Software. Three-dimensional 
regions of interest (ROI) were marked around the hind limbs. The mTHPC uptake in the 
tumor tissue was calculated as the concentration of mTHPC in the ROI and in the 
corresponding ROI in the non-tumor bearing leg (control leg).  
In vivo PDT protocol with LNP (mTHPC) 
The PDT treatment using LNP (mTHPC) and measurements of tumor growth and 
pulmonary metastases were performed in the same study as described in the Materials and 
Methods of the third manuscript (Chapter 6.3). Mice were randomly assigned into three 
groups; control (with LNP (mTHPC) or Foscan, without illumination, n= 6) and LNP 
(mTHPC) (n=8) PDT treated mice. 
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7 Conclusion and Outlook 
 
Current protocols for the treatment of OS, developed in recent decades and combining 
neoadjuvant chemotherapy and refined tumor surgical techniques, no longer improve the 
outcome of the patients and their quality of life. Many patients suffer from severe side effects 
of multimodal drug therapy and the development of chemoresistance during treatment. Thus, 
novel drugs that strictly and specifically target local OS specific pathophysiological processes 
with minimal side effects are needed to complement or even replace current therapies. 
Consequently, aim 1 of the thesis presented here focused on targeting, in clinically 
relevant experimental OS mouse models, key mechanisms in the “vicious cycle” of the 
interaction between the primary tumor in the bone and its microenvironment that causes 
pathological, abnormal regulation of local bone remodeling in favor of the tumor. Similarly, 
in aim 2, we investigated in experimental metastasizing OS in immunocompromised and 
immunocompetent mice, the potential of minimally toxic PDT, shown to be effective in many 
other tumor types, for supplementary treatment of metastasizing OS with minimal side 
effects.  
The data of the studies carried out under aim 1 provide solid evidence for aberrant 
regulation of local bone remodeling in favor of tumor development, considered as the 
“vicious cycle”, as an essential pathophysiological mechanism in OS progression. The studies 
identified activin A as an important regulator in this cycle. The inhibition of activin A lead to 
a disruption of tumor-promoted osteoclast-mediated bone resorption and osteoblast-mediated 
bone formation and a marked suppression of OS primary tumor progression. Our results 
highlight activin A inhibitors also in combination with the gold-standard in the inhibition of 
bone remodeling, zoledronic acid, as a promising therapeutic intervention in OS.  
Future studies that further investigate the biological relevance of activin A in the 
osteosarcoma bone microenvironment are of great interest. These studies need to address the 
communication between the osteosarcoma cells and the different cell types in the bone 
microenvironment such as the osteoclasts, osteoblasts, mesenchymal stem cells or endothelial 
cells and they need to further elucidate the role of activin A in these interactions. 
The studies carried out under aim 2 proofed the principle of PDT, being effective in 
clinically relevant metastasizing OS with minimal side effects as reported for a variety of 
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other tumor types. These findings, including low toxicity of PDT, are particularly important 
for the treatment of rapidly growing pediatric patients. These patients are most sensitive to 
treatment-associated side effects, which affect their normal development. We consider PDT as 
an intraoperative approach with the aim to save vital local anatomical structures and to 
suppress metastasis by inducing an anti-tumor immune response, the main cause of death in 
OS patients. The results of the in vitro experiments demonstrate high sensitivity of OS cells to 
PDT with Foscan and indicate a considerable efficacy-enhancing potential of liposomal and 
lipid nanoparticle formulations. Importantly, the findings were confirmed in vivo in the two 
clinically relevant OS mouse models for Foscan and Foslip, whereas the treatment with the 
LNP formulation of Foscan failed for, at the moment, unknown reasons. The results also 
highlight the importance of an intact immune system for PDT potency and a therapeutic 
immune response-dependent effect on lung metastasis.  
To further improve PDT efficacy, a targeted approach is of great interest. Our results 
confirm a passive targeting of the tumor tissue, probably mainly due to the EPR effect, but its 
limitations are obvious. Changes in permeability and retention of PS within the tumor or 
limited PS uptake by smaller tumors that might not exhibit a leaky vasculature likely can 
hamper PS efficacy. Accordingly, current research investigates novel PS carriers with 
targeting moieties, such as PEGylated liposomes decorated with receptor-ligands, antibodies 
or other tumor targeting proteins (Goutayer, Dufort et al. 2010; Pereira, Korsak et al. 2015). 
Although OS is missing a common marker, potential targets in OS include EGFRs, playing an 
important role in tumor proliferation of different sarcomas (Wen, Koeppen et al. 2007), the 
CXCR4 chemokine receptor, involved in chemotaxis, invasion, angiogenesis and proliferation 
and associated with poor survival when upregulated in OS (Brennecke, Arlt et al. 2013; Zhao, 
Guo et al. 2015), VEGF, playing an important role in tumor angiogenesis; avβ3, an integrin 
receptor expressed in osteosarcoma tumor tissue (Gvozdenovic A., et al. submitted to 
Oncotarget, May 2016). Of great therapeutic interest is also the combination of PDT with 
established chemotherapeutics with the aim to potentiate treatment efficacy while reducing 
the doses of currently used toxic drugs. Preclinical studies already revealed additive tumor-
suppressive effects of cisplatin and doxorubicin administered at low non-therapeutic doses in 
combination with PDT (Canti, Nicolin et al. 1998; Kirveliene, Grazeliene et al. 2006). Co-
delivery of both, chemotherapeutics and PS within nanoparticles has already been 
investigated (Wang, Ma et al. 2015). 
Altogether, based on the results presented in thesis and those reported by Akens MK et 
al., even a combination of activin A inhibitors and photodynamic therapy can be considered 
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for the treatment of metastasizing OS. The recent study performed by Akens MK et al. 
reported a combination of ZOL with Verteporfin-based PDT as a safe treatment for 
experimental bone-metastatic breast cancer (Akens, Wise-Milestone et al. 2014). In 
conclusion, this thesis shows novel routes for effective treatment of metastatic OS that target 
the primary tumor together with its microenvironment, which supports tumor progression. 
Moreover, applications of these novel treatment modalities in combination with currently 
used drugs can be envisaged. 
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